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Cancer cachexia (involuntary wasting syndrome) is an under-researched 
cause of major patient morbidity and mortality, which has no efficacious 
treatment or generally accepted strategy for management. Skeletal muscle 
and fat loss are the two markers in the diagnosis and classification of cachexia. 
This thesis aimed to assess molecular mediators involved in muscle and fat 
wasting through a variety of ways, including taking samples of muscle, fat and 
blood from patients with and without cancer cachexia. 
 
Firstly, a review of tools used to diagnose unintentional weight loss was 
undertaken and found that no single tool was currently able to synchronously 
diagnose cachexia, age-related muscle loss, and simple malnutrition. 
Components to make up a new tool which have since been used as the subject 
of an editorial to inform a consensus on the definition and management of 
malnutrition were therefore suggested. Secondly, CT was used to investigate 
the effect of chemotherapy on muscle and fat wasting. All patients lost muscle 
mass during chemotherapy, but those who were older lost more fat, and that 
the type of fat that was lost was different between men and women. Thirdly, 
the main investigation of muscle in this study was looking at the interface 
between muscle and nerves. This was found to be the same between healthy 
individuals and patients with cancer who did and did not have cachexia, 
suggesting that cachexia is  primarily a muscular disorder. Forthly, fat samples 
from patients were analysed. There was found to be large differences in 
 26 
expression of genes between fat from under the skin and inside the abdomen, 
suggesting that fat from inside the abdomen may play a role in the cachexia 
process. “Intelectin-1” was identified as a possible marker of this wasting. 
Finally, breakdown products (metabolites) of fat wasting were identified from 
the blood of patients with weight loss, suggesting this may be of use as a test 
to monitor the effects of future anti-cachexia treatments.  
 
It is hoped that results from this study will identify potential therapeutic targets 























Cancer cachexia has been defined as a multifactorial syndrome characterised 
by an ongoing loss of skeletal muscle that cannot be fully reversed by 
conventional nutritional support. Cachexia affects most patients with advanced 
cancer and is associated with reductions in treatment tolerance, response to 
therapy, quality of life, and survival. Thus, amelioration of cachexia would 
improve both quality of life and clinical outcome. However, the aetiology of 
cachexia is poorly understood, and there are no agreed diagnostic biomarkers 
or management strategy for patients with cancer cachexia.  
Recent advances in the field of cachexia research include the development of 
diagnostic criteria for cachexia, as well as computed tomography (CT) body 
composition analysis software, making the ability to detect clinically significant 
muscle wasting in obese patients in particular more accurate. Although muscle 
loss appears to be the most important and physiologically relevant event in 
cachexia, the importance of fat wasting is less understood. During cachexia, 
different adipose depots around the body demonstrate differential rates of 
wasting. Furthermore, recent studies from animal models have suggested that 
adipose tissue may be a key driver of muscle wasting through fat-muscle 
crosstalk. However, human studies in this area are lacking. The molecular 
mechanisms driving muscle loss in humans are also poorly understood, and 
the relationships between muscle and fat wasting, functional impairment and 
reduced survival are largely unknown. The prognostic significance of adipose 
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wasting and investigations in tissue cross-talk therefore are now becoming 
more important whilst the quest for a cachexia related biomarker remains at 
the fore.  
The main aim of this thesis was to investigate specific mediators, mechanisms 
and biomarkers of cachexia in robustly phenotyped patients with upper 
gastrointestinal cancer (UGI) in whom cachexia is known to be prevalent.  
 
This thesis is comprised of several projects designed to investigate various 
areas of cachexia pathophysiology, diagnosis and staging. In order to recruit 
patients to clinical trials, drive cachexia research and identify those who would 
benefit from early intervention, it is important to understand how to screen and 
diagnose patients with cachexia. Many patients present to clinicians with 
unintentional weight loss (UWL). This can occur in patients with cachexia, 
sarcopenia and malnutrition.  With increasing rates of obesity worldwide, as 
well as an ageing population, differentiating causes of UWL is difficult. Firstly 
therefore, in order to investigate the feasibility of screening for UWL a 
systematic review was undertaken in chapter 3 to determine which screening 
tools were able to assess cachexia, sarcopenia and malnutrition according to 
the consensus definitions for each. Each tool was judged against a reference 
method and psychometric evaluation carried out. No one tool was able to 
assess all three conditions simultaneously, and out of the 22 tools assessed, 
only 3 had been validated against the gold standard of CT cross-sectional 
imaging. Thus, the development of a novel tool that encompasses the 
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consensus definition criteria and directs clinicians towards the underlying 
diagnosis would likely improve detection and outcomes.  
 
Secondly, building upon screening and methods for diagnosing low 
muscularity, chapter 4 uses CT body composition analysis to determine any 
age and sex-related variations in patients with UGI cancer. CT-based cut-offs 
for determining low skeletal muscle volume are sex and body mass index 
(BMI) specific and have been driven in order to predict mortality in these 
patients. As discussed above, the prevalence of obesity is increasing and the 
population is ageing therefore, many patients may be sarcopenic at diagnosis, 
making the assessment of clinically significant muscle wasting difficult. A 
retrospective, observational study was carried out on patients who had 
undergone potentially curative oncological and surgical treatment for 
oesophageal cancer. Analysis of both staging and post neoadjuvant 
chemotherapy (NAC) CT was performed in order to assess baseline 
characteristics and dynamic changes in body composition. Males had higher 
baseline muscle and visceral fat volume whereas females had higher 
subcutaneous fat volume. Patients of all ages and both sexes lost muscle 
volume though there was no difference in rates of wasting between groups. 
Older patients and females lost significantly more total fat during 
chemotherapy. This chapter therefore highlights the need for further 
investigation to define differences in adipose depots during cancer progression 
and their prognostic value.  
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Chapter 5 showcases the main biological assessment of cancer associated 
muscle wasting in this thesis. As shown in chapter 4 all patients demonstrated 
some evidence of muscle wasting. A potential mechanism of this was therefore 
investigated further by looking at the role of the neuromuscular junction (NMJ). 
The NMJ provides the link between myelinated motor nerves and skeletal 
muscle. Very little is known about the structure of the NMJ in human health or 
in disease. Experimental denervation is a recognised model for studying 
muscle wasting in vivo, and as a result experimental evidence for the role of 
the NMJ in cachexia is dependent upon animal models. Recent data, however 
have shown that rodent and human NMJs are markedly different. NMJ morph, 
an imageJ-based package was used for morphometric analysis of the NMJ in 
UGI cancer patients with or without cachexia and non-cancer controls. No 
significant differences were found between groups in any of the major pre- or 
post-synaptic variables measured suggesting that the NMJ remains 
structurally intact in cancer cachexia, and thus, the denervation of skeletal 
muscle is not a major driver of the disease.  
 
Whilst it is recognised that muscle mass plays a significant role in the 
syndrome of cancer cachexia, as shown in chapter 4 through body 
composition analysis the importance of fat wasting and the effect of metabolic 
mediators on fat volume requires attention. In murine tumour models, loss of 
fat volume may predate the loss of muscle volume. Fatty acids, leptines, 
cytokines and other adipokines may cause lipotoxic effects in skeletal muscle. 
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Adipokines have been reported to induce insulin resistance, impair muscle 
development, alter muscle lipid amino acid metabolism and modify signalling 
thus affecting skeletal muscle volume. Clinical studies have shown that 
adipokines from murine models are also measurable in patients with cancer 
cachexia. In chapter 6 through the use of transcriptomics, subcutaneous (SAT) 
and visceral adipose tissue (VAT) depots were analysed from UGI cancer 
patients with and without cachexia and healthy controls to elucidate the 
biochemistry of fat wasting in cancer cachexia. Over 2000 genes differed 
between cachexia VAT and SAT. The gene that showed the largest difference 
in expression between cancer VAT and control was Intelectin-1 (ITLN1), a 
novel adipocytokine. Genes involving inflammation were upregulated in cancer 
whereas genes involved in energy metabolism and fat browning were down 
regulated. VAT, therefore, may be a target for therapeutic manipulation in 
cancer. Further investigation is required in to the role of Intelectin-1 as a 
biomarker in cachexia.  
 
Finally, in previous searches for biomarkers of cancer, likely responsiveness 
to treatment and the presence of cachexia, plasma has been used as a readily 
available biofluid for investigation. However, no robust cachexia biomarker has 
been found. Although as work continues it seems that individual biomarker 
targets should be replaced by an array of markers. Chapter 7 used liquid 
chromatography mass spectrometry (LC/MS)-based metabolomics to 
investigate the metabolic profile of weight loss from plasma samples taken at 
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the time of anaesthesia from patients under-going UGI resectional surgery. 
This showed two distinct profiles based on percentage weight loss in 
accordance with the consensus definition. There were 40 metabolites 
associated with cachexia with six of those being highly discriminative of weight 
loss. Specifically, a combination profile of LysoPC 18.2, Hexadecanoic acid, 
Octadecanoic acid, Phenylalanine and LysoPC 16.1 showed close correlation 
for eight weight-losing samples (≥5% weight loss) and nine weight stable 
samples (<5% weight loss). In particular ,many of the metabolites discovered 
were involved in lipid metabolism, lending credence again to the importance 
of understanding adipose wasting in cachexia.  
 
In summary, the role of adipose wasting as investigated through imaging and 
biochemical results has been shown to be important in the aetiology of cancer 
cachexia. It has been demonstrated that there is currently no adequate way to 
screen for conditions which present with UWL and that the adaptation of a tool 
in order to do this would drive further research and the content of complex 
interventions. Previously published CT-derived cut points are BMI and sex 
specific, however, it has been shown that there is a growing need to develop 
these in order to define patients by age also. In doing so this would define 
stricter criteria for clinical trials and lead to improved end points. Potential novel 
biomarkers of lipid wasting have been discovered in this thesis. ITLN1 which 
has corresponded with weight loss previously in other groups warrants further 
investigation as it may be a target for future therapeutic manipulation. Those 
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biomarkers discovered in the metabolomics study show that it is possible to 
separate patients based on weight loss alone. Although this was a pilot study 
after further investigation and development, biomarkers of lipid wasting may 
be useful as inclusion criteria or outcome measures in clinical trials. The 
discoveries of the lack of fat browning and the stability of the NMJ in cachectic 



















This thesis represents a comprehensive, and importantly human, approach to 
the unmet clinical need afforded by cancer cachexia. By performing body 
composition analysis and biochemical studies on plasma, muscle and adipose 
tissue, the project aims to provide a broad and wide-reaching analysis of 
cachectic markers in robustly phenotyped patients. The development of 
successful treatments for cancer cachexia would be a major advancement in 
the treatment of virtually all tumour types as almost all patients with advanced 
disease demonstrate weight loss. Treatments to decelerate or reverse muscle 
loss would improve both quantity and quality of life. The following introductory 
chapter provides an overview of cancer cachexia with a particular focus on 
novel mediators that have been shown to be of relevance in human disease. 
Previously trialled therapies are discussed alongside those that offer promise 
for the future. 
 
Cachexia comes from two Greek words: “Kakos” meaning bad and “hexis” 
meaning condition (1). It has long been recognised as a side effect of many 
chronic conditions such as renal, heart and liver failure, and chronic lung 
disease; however, it is most prevalent in patients suffering from cancer (2). It 
is estimated that half of all cancer patients experience weight loss, and one 
third lose more than 5% of their body weight, with this value increasing to 86% 
in the last 1 to 2 weeks of life (3,4). This weight loss is due to depletion of both 
 36 
adipose tissue and skeletal muscle mass (5). Symptoms of cachexia include 
unintentional weight loss (UWL), anorexia, inflammation and muscle wasting 
resulting in a decreased quality of life (6). This muscle wasting can involve the 
chest, diaphragm and cardiac muscle, and therefore many patients die of 
cardiac or respiratory failure (7,8). Cachexia has adverse effects on treatment 
and outcomes and is considered the immediate cause of death in a large 
proportion of cancer patients (6) (figure 1). It is therefore essential to apply a 
systemic approach to its investigation and management. It is also important to 
recognise the effect the tumour has on the disease, and thus the complex 
interaction between it and the host.  
Cachexia is particularly prevalent in patients with UGI cancer (>80% patients 
affected), including oesophageal and pancreatic cancer (6,9), two tumour 
types highlighted by the research strategy of Cancer Research UK (CRUK) 
(10). Cancer cachexia remains an unmet clinical need, because even in the 
current era of multimodal therapies (including surgical resection with 
neoadjuvant/adjuvant oncological treatments), patients with UGI cancer are 
still likely to develop disease recurrence and die, with median survival times of 
approximately 2 years (5-year survival rates for oesophageal and pancreatic 
cancer are 15% and 5%, respectively) (11). Therefore, holistic treatment 
strategies for patients with unresectable or recurrent disease are a priority. 
Muscle wasting in cancer is multifactorial and complex. It is underpinned by 
hypercatabolism, a net loss of energy, and systemic inflammation (12) (figure 
 37 
2). Classical understanding of muscle atrophy has focused on the imbalance 
between protein synthesis and degradation; however, new evidence has also 
raised the issues of contribution of apoptosis and impaired renewal. Signalling 
pathways that have been investigated previously include those involved in 
systemic inflammation, TGF-family signalling and autophagy (13). Many 
possible mediators continue to be discovered, and those that lend themselves 
as therapeutic targets are discussed in more detail later in this introduction. 
Although loss of muscle mass is a common feature of cancer cachexia, 
differences in the underlying mechanisms have been reported between 
different experimental models and human tumour types (14,15). This diversity 
leads to challenges in the development of effective therapeutic management 















Figure 1 Clinical features of cancer cachexia 
Cancer cachexia leads to a range of symptoms including changes in body 










































Figure 2 Host-tumour interactions in cancer 
cachexia  
Different mediators and oncological treatments 
contribute to host-tumour interaction 
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The previous section has offered a basic overview of cancer cachexia and has 
very simply described some of the underlying mechanisms. In order to 
understand the clinical relevance of cachexia we must firstly consider the 
importance of normal muscle structure and function to then understand why 
abnormalities in it are important in the disease process. 
1.2 Muscle structure and function 
 
Skeletal muscle has a complex structure and function. The healthy human 
body is composed of approximately 40% muscle tissue, which accounts for 
30-45% of whole body protein turnover (16). Skeletal muscle is highly 
adaptable, being able to undergo hypertrophy or wasting in response to 
various stimuli. Skeletal muscle differentiation is complete by the time of birth 
meaning that differentiated myofibres are unable to divide or grow new muscle 
tissue. Muscle tissue instead contains undifferentiated stem cells called 
satellite cells. These cells are able to respond to stimuli and produce daughter 
cells that differentiate into myoblasts which can then fuse together or with 
existing myofibres to enlarge or repair them (17). The opposite can also occur 
meaning muscle can atrophy in response to opposing stimuli or an increase in 
protein degradation signaling (18). As well as its primary role in movement of 
the body, muscle also serves as an amino acid store. It can be broken down 
to provide glutamine and amino acids as energy stores during the acute phase 
response to injury. It also plays a role in thermoregulation, insulin resistance, 
and glucose metabolism (19).  
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All muscle types in animals and humans have a common basic structure 
including actin and myosin protein filaments that make up the thick and thin 
muscle filaments. Myosin is the larger filament and is the force-generating 
form. It consists of two large polypeptide heavy chains and 4 small light chains. 
Actin is a 42kDa globular protein found in all eukaryotic cells and is a major 
component of the cytoskeleton. In muscle it makes up the thin filament along 
with troponin and tropomyosin. In skeletal muscle the thick and thin filaments 
are arranged into bundles called myofibrils, that in turn are grouped together 
into muscle fibres or cells.  
 
Myofibrils are an aggregation of filaments that run parallel to the long axis of 
the muscle fibre. Each fibre contains several hundred myofibrils, making up 
the largest part of the muscle fibre volume. Myofibrils are surrounded by 
sarcoplasmic reticulum which acts to release Ca2+ in response to the muscle 
action potential – the excitation contraction coupling process. The whole 
myofibre is bound by the sarcolemma which contains myofibrils, endoplasmic 
reticulum, nuclei and mitochondria (20). Mitochondria in the I band (figure 3), 
in particular, have a highly convoluted structure in order to fit into the restricted 
space available between myofibrils. The number of mitochondria varies 
between muscle fibres. Those relying on aerobic glycolysis (slow twitch or type 
1 fibres) are rich in mitochondria, whereas those who have a higher utilization 
of anaerobic energy (fast twitch or type 2 fibres) have fewer (21).  
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Muscle contraction occurs when the myosin heads interact with the actin of 
thin filaments. The movement of muscle occurs as the fibre and their myofibril 
subunits shorten. When the skeletal muscle shortens, thick and thin fibres of 
the sarcomere move past each other in a sliding filament mechanism (22). This 
mechanism involves the formation of a cross bridge between thick and thin 
filaments. The myosin head binds to actin, the cross bridge moves and is then 
dissociated, allowing the process to be repeated. The energy is provided by 
Adenosine triphosphate (ATP) hydrolysis at the ATPase on the myosin heavy 
chain. Tropomyosin regulates this process by blocking the myosin binding 
sites on actin. Calcium (Ca2+) acts on troponin, thus moving the tropomyosin 


















Figure 3 Muscle structure (24) 
The structure of the myofibril is made up of repeating sarcomeres, the centre 
of which is called the M line. This is a protein disc to which parallel thick 
filaments are attached known as the A band. Inter-linking with the thick 
filaments are overlapping thin filaments. The area of no overlap is known as 
the I band, and their attachment at either end of the sarcomere to a protein 





1.3 What is cachexia? 
So why are abnormalities in the normal structure and function of muscle 
relevant to patients with cachexia? In order to understand the answer to this 
question we must first define what cachexia is and appreciate the scale of the 
problem. 
 
1.3.1 Definition of cancer cachexia 
 
Historically, cachexia was defined as loss of weight (involuntary weight loss 
>10%) (25). More recent, definitions, however recognise that weight loss may 
be underestimated in overweight or obese patients or in patients who have 
gained weight because of oedema or a growing tumour mass (26). The 
previous image of the “wasted cachectic patient” is not usually seen due to the 
growing obesity epidemic. Therefore, many cachectic patients may have a 
normal or raised body mass index (BMI) (27). Due to this increasing complexity 
in diagnosis, a panel of experts agreed on a consensus definition. The 
international consensus definition states “Cancer cachexia is a multifactorial 
syndrome defined by an ongoing loss of skeletal muscle mass (with or without 
loss of fat mass) that cannot be fully reversed by conventional nutritional 
support and leads to progressive functional impairment” (28). The agreed 
diagnostic criterion for cachexia were: 
• Weight loss >5% over the past 6 months (in absence of simple 
starvation); or 
• BMI <20 and any degree of weight loss >2%; or 
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• Appendicular skeletal muscle index consistent with sarcopenia (males 
<7.26 kg/m2; females <5.45 kg/m2) and any degree of weight loss >2% 
(28) 
 
The diagnosis of cancer cachexia requires the fulfilment of one of the three 
criteria. The consensus definition has previously been validated showing that 
those patients who full fill the cachexia criteria have shorter survival times than 
those who are not defined as being cachectic. However, it does not aid in 
estimating the prognosis of the cachectic patient (29). Factors such as quality 
of life (QoL) and physical function are also important to consider. Previous 
studies have compared this current definition with existing definitions, most 
notably that by Evans et al in 2008 (30). The Evans et al. definition included 
defining decreased muscle strength, anorexia, symptoms of fatigue or 
biochemical abnormalities. It was found that the Evans criteria did in fact show 
greater discrimination with regards to overall survival (31). The current 
consensus definition also uses Dual x-ray absorptiometry (DXA) cut points 
which although still in existence have now been superseded by CT imaging 
and BMI-stratified criteria (32). Perhaps therefore the 2011 definition requires 
revision incorporating more biochemical and functional measures, as well as 





1.3.2 Staging of cachexia 
The assessment of severity of cachexia is complex. The consensus group also 
suggested a method for staging severity (28). Cachexia can be seen on a 








Figure 4 Staging of cachexia [adapted from (28)] 
Progression of cachexia throughout the disease process. Patients who are 
pre-cachectic would benefit the most from intervention but they pose the 




Five domains were suggested to be assessed including food intake, 
biochemical derangements, functional implications and assessment of 
adipose and muscle mass (28). These stages of cachexia were suggested to 
be of use for prognostication and for discussion with patients, but their use in 
diagnosis remains difficult due to the subtlety of observable differences 
between pre-cachexia and cachexia, in particular. At the severe end of the 
scale, the accurate diagnosis of refractory cachexia is reliant on monitoring the 
patient’s overall clinical condition, and the specific response of their tumour to 
treatment. A study in cancer patients investigated this three level staging 
system with respect to QoL, morbidity and mortality. It found that those in the 
pre-cachectic and cachectic group behaved in the same way (33). A further 
study assessing weight loss at diagnosis suggested a survival benefit to those 
who were pre-cachectic, but this was only apparent one year after diagnosis 
(34). More recent developments have seen the introduction of “The Cachexia 
SCOre” also known as the CASCO (35). This screening tool incorporates five 
components including weight loss and body composition, metabolic 
derangements, physical performance, QoL and anorexia. It was developed to 
aid in staging cachexia and is discussed in more detail later on.  
 
In order to help clinicians with recognising and diagnosing cachexia earlier and 
to facilitate research, a single universal definition would be helpful. In 2017 the 
European Society of Clinical Nutrition and Metabolism (ESPEN) 
recommended that all patients with cancer should be screened for nutritional 
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risk and that this should include an assessment of body composition and 
inflammatory markers (36). The best way in which to do this risk assessment 
remains up for debate. Multimodal interventions should then be instigated, 
focusing on increasing nutritional intake and exercise and decreasing 
inflammation.  
 
The main aim of all of these definitions and screening tools is to identify 
patients with pre-cachexia in order to instigate prophylactic interventions. The 
lack of strict diagnostic criteria also hinders clinical trials and leads to 
difficulties in comparison between studies due to the use of multiple different 
inclusion criteria. Previous cachexia trials have seen high attrition rates, and 
therefore use of the staging criteria would avoid the recruitment of patients with 
refractory cachexia into clinical trials and aid biomarker development (37). 
Much of this thesis therefore is targeted at patients early on in their disease 
process to identify and investigate those who may benefit from future 
therapeutic interventions.  
 
1.4 Epidemiology of cancer cachexia and impact of 
tumour type  
As discussed above, definitions of cachexia used in research vary by research 
group, and this variability leads to an impact on reported prevalence. One of 
the most well-known studies to investigate the various definitions reported that 
the proportion of palliative care cancer patients suffering from cachexia ranged 
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from 12 to 85% depending on the definition used (38). The incidence of weight 
loss upon diagnosis has been shown to vary greatly depending upon the site 
of the tumour. Arguably the biggest study to investigate this was the Eastern 
Cooperative Oncology Group (ECOG) chemotherapy trial (6). This study 
involved over 3000 patients and concluded that the greatest incidence of 
weight loss could be found in patients who had solid tumours i.e. Pancreatic, 
gastric, lung, colorectal, and head and neck. Cachexia was most prevalent in 
those with pancreatic and gastric cancer with around 85% of them showing 
signs of weight loss compared to approximately 30% of patients with breast 
cancer or leukaemia (Table 1). One third had more than 10% weight loss, 
although evidence of any weight loss, no matter how minor, was associated 
with poorer prognosis. Patients with weight loss who were considered to have 
a better performance status or an early tumour stage had better outcomes 















Cancer type Weight loss in the previous 









0-5 5-10 >10 
Gastric 20 29 38 87 13 




25 21 15 61 39 
Small cell 
lung cancer 
23 20 14 57 43 
Prostate 
cancer 
28 18 10 56 44 









27 8 4 39 61 





14 8 10 32 68 
 
Table 1 Cancer types with the highest rates of cachexia (6). Patients with 
solid tumour types in particular demonstrated a higher prevalence of cachexia 
as defined by percentage weight loss. 
 51 
 
Despite the use of different definitions there is thought to be an overall 
prevalence of cachexia in advanced cancer ranging from 60 to 80%, with that 
rising to 86% in the last few weeks of life (3,4). Cancer cachexia is thought to 
contribute to 30% of cancer deaths (3). Furthermore, the true percentage of 
cachexia related deaths may be being masked by the presence of obesity with 
sarcopenic obesity (discussed in more detail later), being shown to be an 
independent adverse prognosticator (27). 
 
Of particular note is the aggressive nature of pancreatic and gastric cancers. 
The prevalence of cachexia has been investigated in 8451 cancer patients 
using four different definitions (39). Namely 1: The International Classification 
of Diseases (ICD) definition, 2: ICD definition, anorexia, abnormal weight loss 
or feeding difficulties, 3: Prescription for the use of ‘anti-cachectic’ drugs such 
as megestrol, acetate, oxandrolone, somatropin or dronabinol and 4: ³5% 
weight loss. There were varying prevalence rates according to the different 
definitions (2.5, 5.5, 6.4 and 14.7% respectively) (39). Although this was a 
large study, it highlighted problems with the ICD definition as only 3.9% of 
patients with pancreatic cancer were defined as being cachectic, which is in 
contrast to most other studies. Even when comparing the consensus definition 
against two other classifications of cachexia - the SCRINIO definition (based 
on >10% weight loss and either anorexia, fatigue or early satiation) and the 
three factor definition (weight loss >10%, low food intake and raised C-reactive 
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protein [CRP]) - there was again wide variation in prevalence rates from 12 to 
85% (39). 
 
Aside from UGI malignancy, lung, and head and neck cancer patients are also 
well known to suffer drastic weight loss. Between 59 to 76% of patients with 
lung cancer are reported to have weight loss at presentation compared with 
>30% of head and neck cancer patients (40,41), although the latter group are 
likely to have difficulties with dysphagia and therefore maybe suffering from 
malnutrition rather than cachexia.  
 
The reasons why some cancers are more strongly associated with cachexia 
than others are not clear. It has been hypothesised that some cancers are 
more likely to present earlier in the disease process than others and therefore 
are diagnosed before any weight loss occurs (42). Alternative suggestions 
have involved the acute phase response and hypermetabolism being more 
common in certain cancers, therefore leading to a more rapid loss of skeletal 
muscle (43). There is also variation of the presentation of cachexia between 
patients with the same type of cancer e.g. up to 85% of patients with pancreatic 
cancer will present with cachexia but 15% will not, possibly due to a differing 
phenotype or genotype (44). Candidate gene studies have shown that single 
nucleotide polymorphisms (SNPs) in the P-selectin, ACVR2B, ACE, LEPR and 
TNF genes were associated with low muscle mass in patients with cancer (45). 
What is clear is the need for a widely agreed upon definition in cachexia 
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research. With some studies published after the consensus definition in 2011 
still using different diagnostic criteria or cut-off values, it makes the comparison 
of cancer types and patient groups very difficult. Body composition analysis 
techniques offer the ability to standardise the diagnosis of cachexia, allowing 
for accurate quantification of muscle and adipose tissue even in obese 
patients.  
 
1.5 Mechanisms underlying muscle wasting in cachexia 
 
Now we have an understanding of normal muscle function and why cachexia 
poses an important problem to cancer patients. Next the mechanisms 
underlying its pathophysiology will be discussed before going onto describe 
why this is relevant for clinicians.  
 
1.5.1 The neuromuscular junction 
 
The main focus of muscle-specific work in this thesis relates to the role of the 
neuromuscular junction (NMJ) in cachexia, and so this will be discussed in 
more detail. Skeletal muscle innervation culminates in the formation of the 
NMJ. It is the point where the peripheral nervous system and skeletal muscle 
fibres interact, and is therefore of great functional importance in locomotion 
and respiration.  
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Neuromuscular transmission is complex, and deficits in neurotransmission can 
lead to muscle weakness, wasting and paralysis. The structure and function of 
the NMJ has been well characterized in animal models, but less so in humans. 
Although many concepts derived from rodent NMJs have been validated by 
the identification of the same genes in humans, research performed in animals 
does not necessarily translate to patients with neuromuscular disorders. 
Indeed, a recent study characterizing the human NMJ it was shown to be 
inherently different from the mouse NMJ. The previous assumption that human 
NMJs are larger and more unstable than those of the rodent has been shown 
to be inaccurate (46). Therefore, there is a requirement for completely human-
based studies to investigate the molecular mechanisms and therapeutic 
possibilities for treating NMJ-related disease. 
 
1.5.1.1 NMJ structure and function 
Lower motor neurones are organised functionally into motor units. The motor 
unit consists of a single alpha motor neuron and all of the muscle fibres it 
innervates, and it is the smallest functional component of the neuromuscular 
system. The lower motor neuron cell body is located in the ventral horn of the 
spinal cord, whilst the terminal part of its axon branches to form the pre-
synaptic component of the NMJ. All of the muscle fibres within a single motor 
unit have the same characteristics and are all activated together (47). Motor 
units have a spatial distribution of several centimetres in length and 5-10mm 
in depth in larger limb muscles. The pattern of motor unit organisation is initially 
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fluid during polyneural innervation of muscle fibres. During the process of 
synapse elimination, there is a gradual reduction in the number of axonal 
inputs onto each muscle fibre (47). This process continues until each muscle 


























Figure 5  Overview of the neuromuscular system  
One motor unit innervates several muscle fibres. Each motor unit terminates in  
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NMJs develop at specific locations in muscles. They are located together in a 
narrow, central region of the muscle termed the ‘endplate band’. Each NMJ 
connects a single motor axon to a single multinucleated muscle fibre. The 
distal ramifications of each axon are known as nerve terminals or synaptic 
boutons. These boutons synapse with the motor endplate on the surface of the 



































Figure 6 Events involved in the transmission of an action potential at the 
neuromuscular junction. Tens of millions of ligand-gated acetylcholine 
receptors (AChRs) and voltage-gated sodium channels are densely organised 
in the post synaptic junctional folds of the motor endplate. Effective synaptic 
transmission results in large endplate potentials in muscle fibres, evoked by 
nerve excitation. This is mediated by calcium-dependent exocytosis of 
synaptic vesicles from motor nerve terminals.  As an action potential reaches 
the axon terminal, it induces the opening of voltage-gated Ca2+ channels on 
the presynaptic nerve membrane. This allows an influx of Ca2+, which causes 
synaptic vesicles to fuse with the presynaptic membrane, releasing the 
neurotransmitter acetylcholine (ACh) into the synaptic cleft. ACh then diffuses 
and binds to AChRs on the postsynaptic muscle fibre membrane. In doing so 
the AChRs become permeable to Sodium (Na+) and Potassium (K+) which 
opens the associated voltage-gated Na+ channels on the muscle membrane. 
This initiates an action potential causing Ca2+ to be released from the 
sarcoplasmic reticulum into the cytosol, and in doing so, leads to muscle 
contraction.    







Skeletal muscle fibre 
Nicotinic receptors 
Motor end plate 
Acetylcholinesterase 
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About three times as much neurotransmitter is released over the amount 
required to trigger an action potential into a muscle twitch. The action of ACh 
is stopped by the enzyme acetylcholinesterase (AChE), which is found in the 
synaptic basal lamina between the presynaptic terminal and the postsynaptic 
muscle fibre. Acetylcholinesterase that encases muscle fibres rapidly 
inactivates ACh released from the presynaptic membrane. Therefore, the 
concentration of ACh in the synaptic cleft falls rapidly, stopping 
neurotransmission (48).  
 
1.5.1.2 Evidence for the role of the NMJ in cachexia 
A previous study has shown abnormalities in both the sarcolemma and the 
associated basal lamina of muscles isolated from colon carcinoma C26-
bearing mice (a recognised model of cachexia) and cancer patients. 
Sarcolemma; abnormalities observed in cachectic muscles were associated 
with myofibre damage that was similar to that observed in Duchenne Muscular 
Dystrophy (DMD) patients, although less severe. The muscle analysis of C26-
bearing mice also identified common DGC alterations between Muscular 
Dystrophies (MDs) and cancer cachexia, including reduced dystrophin levels, 
compensatory up regulation of utrophin, and hyperglycosylation of b-
dystroglycan and b-sarcoglycan. These changes were also observed in mice 
bearing Lewis lung carcinoma (LLC), gastrointestinal and gastro-oesophageal 
adenocarcinomas (49).  
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Central nuclei are considered to be a sign of skeletal muscle fibre regeneration 
and therefore a sign of myopathy. Central myonuclei have previously been 
observed in both pre-cachectic patients and animal models of cancer, in 
contrast with the reduced regenerative potential of cachectic muscles. 
Mononuclei have recently been further characterised in pre-cachectic and 
cachectic cancer patients, as well as in C26 tumour-bearing mice (50). Rectus 
abdominis and Tibialis Anterior were examined. Non-peripheral myonuclei 
were observed in two different populations – central nuclei, and nuclei that 
were not central nor subsarcolemmal and therefore “displaced”. Both these 
types of nuclei were identified in all types of muscle fibres; however, displaced 
nuclei were the only ones that varied between cachectic and control muscles. 
They were also observed in the absence of muscle regeneration markers e.g. 
embryonic or fetal myosin. Longitudinal sections revealed clustering of 
displaced myonuclei upon denervation, and that these clusters were increased 
in cachectic patients. The increase in clusters was also associated with the 
upregulation of N-CAM, another marker of denervation (50). This suggests that 
the presence of displaced nuclei is consistent with motor neuron loss, 
indicating that change in NMJ state may be a cause of cachexia. Therefore, 
this could imply that further investigation of denervation, rather than myofibre 
damage and regeneration in cachexia, might be of relevance. 
 
The role of the NMJ in cardiac cachexia has been studied in rats induced with 
heart failure by monocrotaline. The soleus muscle was harvested and used for 
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analysis. Ultrastructural and morphological analysis revealed no difference 
between cases and controls. Confocal microscope analysis showed 
disaggregation of the nAChRs. Aggregates of nAChRs were distributed as 
continuous branches that were elongated, smooth and fluorescent, forming 
continuous channels along the muscle fibre. In the heart failure group, nAChRs 
presented a spot or island pattern characterised by discontinuous fluorescent 
areas in the NMJs, suggesting that they had undergone potential remodelling. 
Investigation of nAChR subunit gene expression showed upregulation of the 
alpha1 and epsilon subunits of nicotinic AChR in the heart failure group (51). 
 
Oxidative stress is thought to play a role in the development of cancer cachexia 
by inducing a greater expression of the ubiquitin-proteosome pathway (UPP) 
in skeletal muscle, thus contributing to protein degradation. Mitochondrial 
dysfunction may lead to altered calcium buffering, less ATP and more reactive 
oxygen species production (ROS). The impaired buffering of Ca2+ leads to an 
increased concentration of cytosolic Ca2+, which may activate calpains. These 
interact with rapysn to disrupt AChR clusters (52). A direct correlation between 
increased oxidative stress and neuromuscular function was found in mice 
lacking the antioxidant enzyme Cu/Zn/superoxide dismutase (CuZnSOD). 
These mice showed high oxidative damage and rapid onset of muscle wasting. 
NMJ morphology was altered in 18-month-old Sod1-/- mice and was 
comparable to older (30-month) wild type mice. Denervated NMJs and 
fragmented AChRs were observed in young Sod1-/- mice, and they had 
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noticeably reduced muscular contractile force (52). This suggests that NMJ 
degeneration may be due to oxidative stress, produced by mitochondrial 
dysfunction. 
 
1.5.2 Muscle specific mediators of cachexia 
 
There are many mediators of pathways leading to muscle wasting. Most of 
these pathways are involved in protein degradation. Some act directly within 
or on muscle cells whilst others act as local paracrine mediators.  
 
1.5.2.1 Protein metabolism 
 
As discussed, skeletal muscle is a highly adaptive tissue, capable of altering 
its size, capacity and function in response to various stimuli. Proteolysis is 
controlled by two important cellular degradation systems namely the Ubiquitin 
Proteasome Pathway (UPP) and autophagy-lysosomal pathway. These 
pathways are carefully regulated by various signalling molecules that 
ultimately determine protein turnover rates. They are discussed in more detail 
below. 
 
1.5.2.2 Ubiquitin Proteasome Pathway and Autophagy 
 
Muscle mass in healthy individuals remains constant due to a balance between 
synthesis and degradation. Specific regulating molecules may be upregulated 
in response to certain stimuli. Forkhead box O (FoxO) transcription factors are 
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phosphorylated and inactivated by phosphatidylinositol 3-kinase (PI3K)-
Akt/PKB and translocated into the cell nucleus, where they induce the 
transcription of E3 ubiquitin ligases, MURF-1 and atrogin-1/muscle atrophy F-
box (MAFbx), as well as autophagy-related genes LC3 and Bnip3 (53). This 
large intracellular system regulates muscle mass in response to tumour factors 
and circulating cytokines. The ubiquitin specific protease 19 is the 
deubiquitinating enzyme that has been most studied in muscle wasting. It is 
upregulated in muscle in catabolic conditions and its inactivation leads to 
protection from muscle loss (54). Ubiquitin specific 19 regulates protein 
synthesis and degradation, as well as myogenesis, thereby controlling key 
processes involved in muscle mass maintenance. RNA and protein analysis 
on muscle biopsies suggests that components of the UPP are associated with 
weight loss in cancer patients (55) but global gene expression analysis has 
been unable to replicate those findings which have been widely described in 
animal models.  Inhibition of proteolytic pathways have been investigated in 
clinical trials. The drug Bortezomib, a proteasome inhibitor, has not shown any 
effect on muscle wasting and weight loss (56). MG132, a different proteasome 
inhibitor, improved muscle mass in animal models, possibly due to a different 
mechanism of action to that observed in human muscle (57). Evidence for 
upregulation of markers of the UPP in humans is not as robust as those seen 
in animals, which is perhaps why these drugs have failed in clinical trials. 
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Autophagy is a homeostatic mechanism involving lysosomal-dependent 
degradation of cellular products including damaged organelles, proteins and 
intracellular pathogens. It works in all eukaryotic cells as a quality control 
mechanism, preventing accumulation of degenerated proteins. Conditions of 
stress or starvation induce its upregulation to replace damaged cellular 
products and mobilise energy stores. It regulates muscle mass and muscle-
specific deletions of autophagy genes (e.g. Atg7) in mice have been shown to 
lead to muscle wasting (55). Markers of increased autophagy have been 
demonstrated in patients with oesophageal, lung, UGI and pancreatic cancers 
(55). The pathophysiological role of autophagy in cachexia is not fully 
understood due to difficulties in assessing the autophagic flux in the clinical 
setting. 
 
1.5.2.3 Myostatin and Activin A 
 
A recent factor that has been the subject of much research is a member of the 
TGFb family – Myostatin. Animals and humans who have non-functional 
copies of the myostatin gene demonstrate dramatic muscle hypertrophy (58). 
Secretion from skeletal muscle is the main source of Myostatin. It activates 
Smad2/3 transcription factor complexes through ActRIIB. Enhanced 
production of myostatin in mice leads to muscle atrophy, whereas genetic 
inhibition leads to enhanced muscle mass and fibre size (58). The exact 
mechanisms via which myostatin leads to muscle loss are unclear, but it may 
be due to its ability to inhibit Akt and TORC1 pathways. These pathways 
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enhance protein synthesis as well as the ability of myostatin to inhibit 
myosatellite cell proliferation (58). Other TGFb family members, such as 
Activin A, are upregulated in skeletal muscle during cachexia (59). Activin A is 
increased following activation of the TNFa/TAK-1 signaling pathway. Many 
cancers induce altered expression of Activin A in muscle (60). Due to the 
complex interactions within these pathways, the blocking of one target alone 
may not be sufficient enough to prevent muscle wasting. The ActRIIB receptor 
is common to both myostatin and the Activins and its blockade in the rodent 
C26 model of cancer cachexia was effective in reversing muscle wasting and 
prolonging survival (61).   
 
Attention has been given to therapeutic agents that target myostatin and the 
ActRIIB pathway in humans. The human derivative of the myostatin 
neutralising mouse IgG1 monoclonal antibody Landogrozumab (LY2495655) 
was investigated in a phase 2 trial in palliative pancreatic cancer patients (62). 
There was a trend towards decreased overall survival in the treatment groups 
possibly due to differing chemotherapy regimens between groups. Although 
there was no significant difference in performance status on treatment, 
patients with <5% weight loss had better performance-related results. This 
may be indicative of the fact that LY2495655 prevents muscle loss rather than 
fully reversing the cachectic process, or that patients with end stage disease 
and refractory cachexia were selectively recruited. These findings are in 
contrast to a randomised trial involving elderly patients who had fallen, where 
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LY2495655 treatment increased lean body mass and improved functional 
measures of muscle power although the results were not statistically significant 
(63). Initially thought to be more promising was Bimagrumab (BYM338), a 
human monoclonal anti-ActRII antibody. It prevents the binding of these 
ligands to their receptor, promoting muscle hypertrophy, and accelerating 
recovery from muscle wasting conditions in animals. Results from clinical trials 
have been mixed, with increases in muscle volume seen in patients with 
inclusion body myositis, sarcopenia and disuse atrophy following fracture (64–
66). However, co-primary endpoints of increasing functionality were again not 
reached.  
1.5.2.4 TWEAK and Fn14 
Tumour Necrosis Factor-Related weak inducer of Apoptosis (TWEAK) and its 
related receptor, fibroblast growth factor-inducible 14 (Fn14), are members of 
the TNF/TNFR superfamily. They are upregulated in tumours and lead to 
potent skeletal muscle wasting (67). TWEAK causes myotube atrophy through 
coordinated activation of the UPP, autophagy and caspases. Animal models 
have shown antibodies to Fn14 can extend lifespan by inhibiting tumour-
induced weight loss (67). Fn14 signalling arises from the tumour itself, as 
tumours in Fn14 and TWEAK-deficient hosts still developed cachexia that was 
comparable to wild type mice (67). These animal model results suggest Fn14 
antibodies may be a promising approach for the future.  
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Healthy individuals were investigated following resistance training and 
cardiovascular exercise. Serial muscle biopsies were taken, and TWEAK and 
Fn14 protein and mRNA levels were found to be elevated in the recovery 




The metal ion transporter ZRT and IRT like protein 14 (ZIP14) is a newly 
identified critical mediator of cachexia in mouse models of various types of 
metastatic cancer. It is a member of the SLC39A zinc transporter family. 
Induced by TNF-a and TGF-b, it is expressed in the liver, and it aids zinc 
uptake by cells (69). Its muscle-specific deletion reduces muscle wasting in 
animal models of cancer cachexia. It does this by reducing the expression of 
MyoD and Mef2c therefore blocking muscle cell differentiation. ZIP14 
mediated Zinc accumulation in well-differentiated muscle cells has been 
shown to lead to the loss of myosin heavy chains. Muscle-specific deletion 
reduced muscle wasting in animal models of cancer cachexia (70). Drugs that 
inhibit ZIP14 offer future promise.  
 
1.5.2.6 Mitochondria and exercise 
 
Targeting mitochondrial dysfunction is a therapeutic opportunity to normalise 
energy metabolism in catabolic conditions. Exercise is an important regulator 
of mitochondrial function and skeletal muscle metabolism, but compliance with 
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exercise regimens in patients with advanced cancer is difficult due to chronic 
fatigue and co-morbidities (71). The benefits of increased exercise include 
reduced adiposity, increased muscularity, lower chronic inflammation, 
increased muscle mitochondrial content and function through PGC-
1a expression, and improved insulin sensitivity (72). The exercise mimetic 5-
aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR), an 
adenosine monophosphate-activated protein kinase (AMPK) activator, was 
investigated in C26 mice (73). Activation of AMPK is associated with a pro-
atrophic signal in muscle and demonstrates anti-inflammatory effects. AMPK 
activation in cachexia – an inflammatory driven muscle condition could 
therefore be useful. AICAR, the AMPK agonist, suppresses IFNγ/TNFα‐
induced atrophy. IFNγ/TNFα impair mitochondrial oxidative respiration in 
myotubes and promote a metabolic shift to aerobic glycolysis. AICAR partially 
restored metabolic function and prevented muscle wasting in mouse models 
of cancer (73). 
 
Mitochondrial dysfunction can also be due to disruption of fission and fusion 
processes. The latter is regulated by mitofusin 1 and 2 (MFN-1/2) and optic 
atrophy protein 1 (OPA1). MFN-1 and 2 have differing functions in GTP 
tethering and formation of fusion complexes. OPA1 regulates these 
processes. The loss of mitochondrial fusion has been shown to lead to muscle 
wasting in MFN1-and 2 knockout mice (74). 
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1.5.3 Circulating mediators 
 
Many circulating mediators have systemic effects in the pathogenesis of 
cachexia. Their mechanisms of action, and controversies surrounding the 
drugs used to target them, are discussed below. 
1.5.3.1 Angiotensin II  
 
Patients with advanced cardiac and renal failure often suffer from cachexia. 
They also display increased levels of angiotensin II. Injection of angiotensin II 
into rodents has been shown to cause marked weight loss via the angiotensin 
II type 1 receptor (AT1R), and this loss was reduced in those given Lorsartan 
(75). Angiotensin II type 2 receptor (AT2R) has also been shown to be 
increased in mouse skeletal muscle myoblasts during differentiation, 
suggesting it plays a role in muscle regeneration (76). In humans, reduced 
weight loss has also been noted in those patients with heart/renal failure and 
cachexia who took enalapril (77). Causal network analysis techniques (CAN) 
have identified angiotensin II as an upstream regulator of cachexia, and raised 
levels have been associated with poorer patient survival (78). Genetic 
polymorphisms, and single nucleotide polymorphisms (SNPS) coding for 
angiotensin converting enzyme (ACE) have been identified in patients with 









Macrophage inhibitory cytokine-1/growth differentiation factor 15 (MIC-
1/GDF15) is associated with metabolic disease processes including obesity 
and anorexia, and has consistently been shown to induce cachexia in animal 
models (79). The link between MIC-1/GDF15 in humans was first suggested 
after increased levels were associated with weight loss in prostate cancer 
patients (80). MIC-1/GDF15 has been shown to act on the hypothalamus and 
brainstem to cause anorexia, leading to drastic weight loss and cachexia in 
mice. Ablation of MIC-1/GDF15 in animal models resulted in increased body 
weight, whereas overexpression led to lower body weight and fat mass (79). 
The mechanisms by which MIC-1/GDF15 acts on the hypothalamus are 
unclear. Studies have identified GFRAL, a member of the glial derived 
neurotrophic factor (GDNF) receptor a family, as the receptor by which MIC-
1/GDF15 binds. It is also impacted by GDF11, which is closely related to 
myostatin and is a more potent ligand for the ActRII/Alk complex than 
myostatin (81,82). Raised levels of GDF11 cause cachexia in mice, and raise 
levels of Activin A leading to further muscle wasting. Increased levels of 
GDF11 cause upregulation of GDF15 and recruitment of SMAD2/3. Inhibition 
of GDF15 was shown to improve appetite but did not reverse the GDF11 
induced muscle wasting. This was reversed by antibodies to the activin type II 




1.5.3.3 Proteolysis-inducing factor 
 
A much-debated mediator of increased muscle loss in cancer cachexia is the 
tumour derived proteolysis-inducing factor (PIF). In animal models it has been 
shown to induce muscle loss via activation of the UPP (84). It was initially 
isolated from MAC16 rodents and the urine of patients with cancer cachexia. 
It acts to increase expression of proteasomes via NFkB thus inhibiting protein 
synthesis (85). Its existence in humans, however, has proved controversial. 
Several studies have shown a link between PIF and weight loss in patients 
with cancer. It is specifically expressed by the tumour and has been found in 
patients urine. The only longitudinal study on the presence of PIF in 36 patients 
with gastrointestinal cancer showed that those with PIF present in their urine 
experienced greater weight loss over time. (86) There was concern, however, 
that the antibody measured in the urine was not specific to PIF (87). The 
human cachexia-associated protein (HCAP), which is based on the sequence 
of PIF, has been identified in the cell lines, metastatic tumours and urine of 
patients with cachexia. It has also been associated with progression of disease 
and weight loss in patients with prostate cancer (88). Other groups have, 
however, failed to demonstrate its presence or link it with markers of weight 
loss, tumour burden or survival in cancer patients (89). 
1.5.3.4 Ghrelin 
Ghrelin is an orexigenic gut hormone primarily secreted by the endocrine cells 
of the gastric mucosa. It is a 28 amino acid peptide that is an endogenous 
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ligand for the growth hormone (GH) secretagogue receptor. Serum levels have 
been found to be elevated in cachectic cancer patients (90). Ghrelin increases 
body weight by increasing appetite, GH secretion and prevention of muscle 
catabolism (91). It has anti-inflammatory actions through its ability to inhibit 
TNF-a,  CRP, IL-1b, and IL-6 in mouse models. Ghrelin is able to initiate its 
orexigenic effect by stimulation of the hypothalamus and brain stem neurons, 
and can increase the expression of cannabinoid-1 and MCH-1 receptors on 
vagal afferents (92). Ghrelin stimulates GH to spare protein stores at the 
expense of fats therefore demonstrating GH-dependent and independent anti-
cachectic effects (93). The drug developed to target it - Anamorelin - is 










1.6 Immune regulation of cancer cachexia 
Tumour and host derived factors lead to a chronic inflammatory and impaired 
immune state. The dysfunction of the immune system is complex and involves 
multiple mechanisms characterised by a reduction in monocyte, macrophage, 
dendritic and natural killer (NK) cell function, ultimately leading to susceptibility 
to infections and poor clinical outcome.  
 
1.6.1 Immune regulation in the host circulation 
 
1.6.1.1 Pro-Cachectic cytokines 
 
1.6.1.1.1 TNF-α  
 
TNF-a [previously known as “cachectin”) (94) was initially held responsible 
for causing most of the metabolic derangements and clinical features seen 
in cachexia (figure 7). TNF-a is released by many types of cell including 
activated macrophages, CD4+, neutrophils, mast cells, eosinophils and 
neurons. In particular, it can be produced by tumour, immune and stromal cells 
to induce growth and survival advantage in the tumour microenvironment (95). 
Its expression can ultimately lead to anorexia, muscle and adipose wasting, 
loss of appetite, increased energy expenditure and insulin resistance in both 
patients with various types of cancer, and the Colon-26 carcinoma mouse 
model of cancer cachexia (C26) (96). Many of TNF-a’s effects come about 
through activation of NFkB, which in turn leads to activation of the UPP and 
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inhibition of myogenesis in vitro (97). It also acts to induce oxidative stress and 
nitric oxide species (NOS). Experimental evidence suggests TNF-a can induce 
adipose wasting in white adipose tissue (WAT) through inhibition of lipoprotein 
lipase (LPL), suppression of transcription and increasing lipolysis as well as 
stimulating thermogenesis through increased expression of UCP2 and UCP3 
in skeletal muscle (98,99). 
 
The role of TNF-a in mediating many of the effects of cancer cachexia was 
initially supported by evidence that intraperitoneal injection of soluble 
recombinant human TNF-receptor antagonist was able to improve food intake 
and thus lead to weight gain in tumour-bearing rats (100). Lewis lung 
carcinoma (LLC) mice deficient in TNF-a receptor protein type 1 showed a 
reduction in muscle wasting compared with LLC wild-type mice despite similar 
levels of TNF-a being detected in the serum (101). Treatment with antioxidants 
or NOS inhibitors was shown to increase body weight and prevent muscle 
wasting in mice (102). Despite this, TNF inhibition alone in animals has not 
been shown to be sufficient to stop or reverse the cachectic process indicating 
that, although it is involved in the pathogenesis of cancer cachexia, it is not 
solely responsible (103). 
 
Studies in patients with cancer, however, have not confirmed these effects; in 
particular, adipocytes taken from cancer patients, showed no decrease in LPL 
messenger RNA (mRNA) or LPL enzyme activity (104). Some studies have 
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shown raised TNF-a levels in the serum of patients with pancreatic cancer 
associated with weight loss, whereas other studies in patients with terminal 
cancer showed no association between TNF-a and weight loss (105,106). 
Others have shown that TNF-a correlates with stage of disease or tumour size 
rather than degree of weight loss (107). These discrepancies between studies 
may be due to differences in measuring techniques, possible auto or paracrine 
roles for TNF-a in adipose tissue, or heterogeneity between patients, sexes 
and tumours. 
Although many animal models of cancer cachexia have been shown to 
synthesise and secrete TNF-a, the actual primary source in humans remains 
unknown. It is secreted from activated macrophages which have been located 
in adipocytes in cancer patients. However, subcutaneous adipose tissue 
biopsies have not shown any changes in inflammatory genes during 
microarray studies in patients with gastrointestinal cancer (98,108). The 
presence of innate immune cells in skeletal muscle has not been described as 
so it is unlikely to be the source. In summary, TNF-a is involved in systemic 
inflammation but as cachexia is likely to be multifactorial it is difficult to 
implicate TNF-a as the sole cause. More clinical studies are required to fully 
identify its effects in patients. 
1.6.1.1.1.1 TNFa inhibitors 
There are currently many TNF inhibitors in use for the management of other 
diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel 
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disease, namely Etanercept, Infliximab and Adalimumab (109). These drugs 
have revolutionised the treatment of rheumatoid but have also offered insights 
into the role that TNF-a plays in cachexia. In rheumatoid patients, they 
attenuate the hepatic acute phase response and importantly improve patient’s 
QoL (109,110). They have also been shown recently to prevent worsening of 
the disease and restore fat free mass (111). These drugs are now used to treat 
many thousands of patients and have been shown to be effective at blocking 
TNF-a but are not effective in treating cancer-induced cachexia. The feature 
common to all of these diseases is chronic inflammation due to exaggerated 
production of pro-inflammatory cytokines. The causes of cancer cachexia are 
complex and do not appear to be dependent upon a single cytokine or 
inflammatory mediator. Etanercept has showed some promising results in 
improving fatigue in a small cohort of cancer patients (112). A phase I/II study 
was conducted on pancreatic cancer patients comparing etanercept and 
gemcitabine with gemcitabine alone. A small increase in progression free 
survival was seen and associated with higher plasma IL-10 levels but did not 
show any significant improvement in 6 month progression free survival 
compared with gemcitabine alone (112). A placebo-controlled double blind trial 
was undertaken in 63 patients with incurable malignancy and weight loss of 
>2.27 kg over 2 months or daily intake of <20 calories/kg body weight. Weight 
gain was found to be minimal in both arms with comparable survival times. 
Etanercept was associated with higher neurotoxicity (113). In this trial 
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therefore it appeared to not be effective in the treatment of cachexia in patients 
with advanced disease. 
Infliximab has been used in a phase II placebo controlled randomised study in 
patients with stage II-IV pancreatic cancer (114). Patients were given either 
3mg/kg or 5mg/kg infliximab and gemcitabine or placebo and gemcitabine. The 
mean change in lean body mass was +0.4 kg for those on placebo, +0.3kg for 
those receiving 3mg/kg of infliximab, and +1.7kg for those receiving 5mg/kg of 
infliximab. No statistically significant differences were seen (114). 
Another agent with anti-inflammatory activity is OHR/AVR118, a broad-
spectrum peptide-nucleic acid immune modulator that targets both TNF-α and 
IL-6 (115). A phase II study involving patients with advanced cancer and 
cachexia showed an improvement in anorexia, dyspepsia, strength, and 
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Interferons are multifunctional cytokines that block viral infections and affect 
cell proliferation and differentiation (116). Interferon gamma (IFNg) is produced 
by activated T and natural killer cells, and is arguably the most potent 
monocyte-macrophage activating factor (117). In the context of cancer, 
tumour‐infiltrating lymphocytes (TILs), which have shown to be of particular 
importance in tumour immunosurveillance, are the main source of IFNγ (118). 
There is an overwhelming body of evidence for both beneficial and detrimental 
roles of IFNg in a range of diseases, including cancer. However, its role in 
patients with cachexia is a relatively underexplored area.  
 
Several animal studies have indicated a central role for IFNg in the 
pathogenesis of cachexia. Central administration of rat interferon resulted in 
decreased food intake whereas peripheral administration failed to do so (119). 
Mice overexpressing IFNg developed loss of body weight, atrophy of adipose 
tissue, and reduced appetite, all of which were then reversed by pre-treatment 
of the mice with anti-IFNg antibodies (120). Mice with LLC also demonstrated 
a reduction in weight loss after treatment with anti-IFNg antibody, significantly 
reducing fat wasting in particular (121). In rats that had received transplants of 
MCG 101 sarcoma, anti-IFNg antibody reduced weight loss but the effect of 
treatment was short-lived (122). Similarly to TNF-a, IFNg has been shown to 
inhibit LPL activity in adipocyte cells in vitro, as well as that of glycerol 
phosphate dehydrogenase in cultures of rat adipocytes (123). 
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1.6.1.1.2.1 Anti-IFNg treatments 
 
Anti IFNg treatments have been effective in reverting cachexia in the LLC 
mouse model (120). It has shown no benefit in improving cachexia due to 
sepsis in humans (124), but there have been no trials undertaken in cancer 
patients, mainly due to the fact that this type of therapy requires a large number 
of antibody molecules to completely block the action of IFNg which at present 
is very expensive.  
 
1.6.1.1.3 IL-1a  
 
Levels of IL-1 have been shown to be increased in animal models of cachexia. 
It is thought to cause similar effects to that of TNF-a (125). IL-1 is a pro-
inflammatory cytokine produced mainly by macrophages and endothelial cells 
and is known for being a trigger of the acute phase response, thus playing a 
role in cancer pathogenesis, as well as shock and autoimmune disorders 
(126). In a similar way to other cytokines discussed, it is also able to inhibit 
LPL activity and stimulate lipolysis in cultured adipocytes (127). The ability of 
IL-1 to induce anorexia is thought to be due to a central effect on appetite 
suppression involving blockade of neuropeptide Y (NPY) (128). It also 
increases plasma concentrations of tryptophan and serotonin leading to early 
satiety and suppression of hunger (129). 
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Again, there is evidence for the role of IL-1 in animal models of cachexia, but 
little in humans. IL-1a can induce cachexia and anorexia in rats. IL-1 treated 
rats showed loss of body weight. Administration of IL-1 receptor antagonist (IL-
1ra) to tumour bearing rats however, did not result in any improvement in body 
weight (130). Following direct tumour injection with IL-1ra, C26 mice 
demonstrated significantly reduced weight loss (without an effect on tumour 
burden) compared with mice who had systemic injection. Cultures of C26 cells 
also demonstrated raised levels of IL-6 after stimulation with IL-1, which were 
suppressed by monoclonal antibody to IL-6 (131). In tumour samples from 
patients undergoing surgical resection for upper gastrointestinal malignancy, 
IL-1b and IL-6 were also significantly overexpressed at both mRNA and protein 
levels in the cancer specimens compared with control mucosa. Protein levels 
were seen to correlate with C-Reactive Protein (CRP), indicating that tumour 




IL-6 signals through the membrane bound receptor gp130 found in most 
tissues in the body (133).  IL-6 can target adipose tissue, skeletal muscle, gut, 
and liver tissue, which can all affect cachectic patient body composition. Once 
bound to its receptor, it activates JAK tyrosine kinase leading to 
phosphorylation of tyrosines and the binding of STAT proteins. STAT proteins 
can translocate to the nucleus and increase the transcription of genes involved 
in immune function, cell proliferation, differentiation and apoptosis (133).  
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Several mouse cancer models have clearly demonstrated that blocking IL-6 
and associated signalling can attenuate cachexia progression. Deletion of the 
IL-6 gene in the APCMin/+ mouse prevented the development of cachexia (134). 
IL-6 when secreted by tumour cells can also increase autophagy in myotubes 
when joined with soluble IL-6 receptor (135). IL-6 trans-signalling through the 
soluble IL-6R has the potential to amplify IL-6 signalling in the cachectic patient 
and has been shown to be involved in cross-talk between tumour, muscle and 
adipose tissue in genetic mouse models of pancreatic cancer cachexia (136). 
Autophagy and increasing IL-6 levels have been associated with poor 
prognosis and weight loss in lung cancer patients (135). IL-6 remains a 
promising therapeutic target in cancer cachexia but a better understanding of 
its direct and indirect effects, as well as tissue specific actions, are required. 
 
1.6.1.1.5 IL-1/6 inhibitors 
 
The IL-1 pathway has been previously targeted with the recombinant human 
IL-1 receptor antagonist Anakinra and the neutralising monoclonal anti-IL-1 
antibody Canakinumab. Anakinra, as previously discussed, has had success 
in rheumatoid patients but has yet to be trialled in patients with cancer (109). 
A more specific IL-1a human monoclonal antibody, MABp1 has also shown 
promising results. An initial dose escalation and expansion study was 
designed using MABp1 (137). The first dose escalation part was performed in 
patients with refractory cancer to assess its safety and tolerability. It identified 
an optimal intravenous dose which was then used in the following phase II 
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study of forty-two patients (137). Median plasma IL-6 concentrations 
decreased from baseline to week 8 (p=0.08). Of those 30 patients who had an 
assessment of body composition lean mass increased significantly by 
1.02 ± 2.24 kg (P = 0.02). It was then compared to megestrol acetate in 
patients with advanced colorectal cancer and >5% weight loss. Those in the 
MABp1 treatment arm showed a trend towards increased survival (138). A 
placebo-controlled, double blind phase III study in 333 patients with advanced 
colorectal cancer was then undertaken which resulted in increased lean body 
mass as well as symptom relief (pain, anorexia, fatigue) (139). 
 
IP1510 is a synthetic peptide IL-1 receptor antagonist. Pre-clinical studies 
suggested it to have low toxicity and be effective for the treatment of cachexia. 
It was then trialled in advanced gynaecological cancer patients where it was 
well tolerated, and it significantly improved patient anorexia, depression and 
physical performance. Weight stabilisation or gain was seen in 17 of the 26 
enrolled patients (140). Interpretation of the current data is limited because the 
study was neither randomised nor controlled. However, further larger trials are 
to be initiated for cachexia associated with COPD, as well as cancer.  
 
The only current treatment which specifically targets IL-1a is Bermekimab; a 
human monoclonal IgG1k antibody. It is cloned from the natural human 
immune response which neutralises IL-1a. It has been shown to block the 
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biological activities of IL-1a in vitro by binding to the IL-1R1. It was first studied 
in patients with a variety of metastatic cancers. It was shown to be tolerable 
and have minimal adverse events as well as being associated with a 1kg 
increase in lean body mass (141).  
 
Studies involving IL-6 antibodies have been undertaken in patients with 
advanced non-small cell lung cancer. The humanised monoclonal IL-6 
antibody Clazakizumab (ALD518) has shown beneficial results in increasing 
haemoglobin levels and preventing loss of lean body mass. Fatigue scores 
were also improved compared with controls (142). There are, however, no 




1.6.2.1 Myeloid derived suppressor cells 
 
Many studies have now suggested that tumour infiltrating immune cells (those 
which are mainly of myeloid origin) are able to differentiate into cells which 
then promote tumour growth and metastasis through their ability to induce 
systemic inflammation (143). Tumours can grow through myelopoiesis and the 
successful evasion of tumour cells from both the innate and adaptive immune 
systems (144). However, the progression of cancers appears dependent on 
tumour-associated myeloid cells through their ability to promote angiogenesis 
and tissue remodelling (145). This apparent immunosuppression has been 
 85 
linked to the development of cachexia in very few studies, despite tumour-
induced immunosuppression being well documented in the literature (146).  
 
Myeloid derived suppressor cells (MDSC) may play a role in tumour related 
immunosuppression. Tumour-induced amplification of the myeloid 
compartment leads to the expansion of MDSC. MDSC are immature myeloid 
cells in various stages of differentiation but are not fully differentiated 
neutrophils, monocytes/macrophages or dendritic cells. They are found in the 
bone marrow, spleen, lymph nodes and tumours (143). Their mechanisms of 
action are not fully understood but they are thought to be immunosuppressive 
and to play a role in the over production of cytokines and inflammatory 
mediators which may contribute to cachexia.  
 
MDSC expansion in 4T1 breast carcinoma-bearing mice is associated with the 
induction of the hepatic acute phase protein response and altered fat 
metabolism (146). This response is also seen in the C26 and LLC mouse 
models. The cachectic response is not seen, however, in 66C4 subclone of 
4TI mice in which MDSC expansion does not occur (146).  Defects in myeloid 
cell-mediated inflammation has also been shown to result in reduced 
expression of pro-inflammatory cytokines in the serum of mice with hepato-
cellular carcinoma (147). Interestingly, this led to enhanced loss of adipose 
tissue and decreased macrophage number in visceral adipose tissue, 
suggesting a possible local role for macrophages in the regulation of cancer-
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induced fat loss (147). These findings imply that myeloid cell-mediated 
inflammation confers a beneficial function in these rodents, and may provide a 
potential explanation for the failure of several anti-inflammatory drugs in 
treating cachexia. Although a direct link between the development of cachexia 
and MDSC’s has not been proven, the above studies have suggested that the 
development of cancer cachexia is partly explained by the expansion of 
immature myeloid populations associated with the tumour.  
 
1.6.3 Immune system biomarkers 
 
The Neutrophil:Lymphocyte ratio is a prognostic indicator in cancer. 
Neutrophils increase the inflammatory reaction to pathogens but also interact 
with cancer cells to produce cytokines and effector molecules e.g. VEGF that 
are able to stimulate angiogenesis and promote tumour growth (148). 
Activated neutrophils can move from the circulation to the tumour site to 
release reactive oxygen species which in turn can lead to further DNA damage. 
They also have anti-tumour roles through antibody-mediated cytotoxicity of 
tumour cells (149). 
 
CRP is an acute phase non-specific inflammatory marker that can be elevated 
in response to infection, surgery or malignancy. It is produced by the liver in 
response to increased levels of IL-6 released by activated macrophages as 
well as IL-1 and TNF-a (150). The Glasgow Prognostic Score utilises raised 
CRP and hypoalbuminaema to predict those patients with cancer cachexia 
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who have a poor outcome. It has been examined in more than 60,000 patients 
and has been shown to have independent prognostic value (151).  
 
1.6.4 The role of immune cells in the tumour mass  
1.6.4.1 Tumour associated macrophages 
Tumour associated macrophages (TAMs) increase tumour progression and 
metastasis and suppress anti-tumour immune functions (152). Monocytes 
from blood infiltrate the tumour and are primed by the tumour 
microenvironment to exert these effects. The immune cells within the tumour’s 
microenvironment consist of myeloid-derived suppressor cells, NK cells, 
dendritic cells, T cells and macrophages (153). It is this infiltrate that 
contributes to tumour growth and the release of cytokines that promote the 
pro-cachectic environment. TAMs are recruited via cytokines and chemokines 
and suppress the activity of cytotoxic T-lymphocytes via programmed cell 
death 1 ligand 1 (PD-L1) or B7-H4 and other receptors (154). Activated 
macrophages also secrete cytokines leading to the activation of several 
complex cascades, thereby increasing inflammatory status and worsening 
cachexia (155). The chemokine monocyte chemotactic protein-1 (MCP-1) is 
possibly responsible for the migration of monocytes to adipose tissue in 
chronic inflammation (156). The mechanisms by which macrophages 
modulate adipocyte function in cachexia are still unclear. 
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1.6.4.2 Tumour infiltrating lymphocytes 
 
Tumour infiltrating lymphocytes (TIL) are often found in tumours and are 
thought to reflect an immune response against the tumour. Many studies report 
a survival benefit associated with the presence of TIL suggesting they may 
delay tumour progression. CD3+ and CD8+ TILs in particular have been 






















Figure 8 The role of the immune system in cachexia 
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1.6.5 Difficulties in immune regulation of cancer cachexia  
 
The cytokines linked to cachexia development in cancer patients appear to be 
dependent not only on the type of tumour but also on the burden of disease 
present, and patient specific factors such as age, sex and genotype. It is still 
not fully understood why one patient with the same tumour type as another 
may become cachectic whereas another may not. Genetic variation in 
immunity suggests one possible reason for this. Single nucleotide 
polymorphisms in the IL-1, IL-6 and IL-10 genes have been associated with 
cachexia in gastrointestinal cancers (158). The 1082G allele in the IL-10 
promoter was validated in an independent cohort. This was shown to be 
increased in Myc/mTOR-driven mouse models of cachexia as well as 
cachectic colorectal cancer patients (158). The C allele of the rs6136 
polymorphism in the P-selectin gene has also been associated with weight 
loss and low CT muscularity in a large group of cancer patients (45). These 
results suggest a role for the immune system in the complex presentation of 
cachexia.  
 
It is also important to consider the complexities involved in the use of anti-
cytokine drugs in patients with cachexia. Given that immunosuppression is a 
key component of cancer pathogenesis and therefore potentially cachexia, 
these treatments may carry theoretical risks of carcinogenesis or disease 
progression. Common side effects often include reduction in neutrophil counts 
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thus making these already sick patients more susceptible to infections and 
further risk of different cancers. 
 
1.7 Tissue cross-talk 
 
The importance of tissue cross-talk in cachexia pathophysiology is gaining 
more attention. In particular, fat-muscle cross-talk and circulating microRNA 
mediators of systemic cross-talk are developing research interests. 
 
1.7.1 Fat-Muscle cross-talk 
 
Animal models have indicated a role for fat-muscle crosstalk in cachexia. In 
particular, inhibition of lipolysis through genetic ablation of adipose triglyceride 
lipase (Atgl) or hormone sensitive lipase (HSL) reduced muscle wasting (figure 
9) (159). The mediators of cross-talk include myokines, adipokines or free fatty 
acids. A previous study has described worsening myosteatosis in association 
with increasing degrees of cachexia. (160,161) The infiltration of adipose 
tissue into muscle during the cachectic process may therefore be another 
contributor to wasting. This supports the loss of visceral fat driven by lipolytic 
mechanisms as an early event in cancer cachexia with a potential effect of 
increasing fat deposits in skeletal muscle. Inhibition of fatty acid oxidation with 
Etoxomir (an inhibitor of carnitine palmitoyltransferase-1) has been shown to 
stop muscle wasting in animal models (162,163). Parathyroid hormone is 
thought to cause adipose tissue browning and increased energy production 
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via uncoupling protein 1 (UCP1) through activation of protein kinase A (PKA). 
It is also contributes to muscle wasting through activation of the UPP (164). 
Treatment with an antibody neutralising the parathyroid hormone related 
protein (PTHR) prevented muscle wasting as well as adipose tissue browning 
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Figure 9 Fat-muscle cross-talk in cancer 
cachexia adapted from 157 Inhibition of 
lipolysis reduces muscle wasting  
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1.7.2 Involvement of other tissues 
Many other organs or tissues are involved in cancer cachexia, and the cross-
talk between such organs may be driven by systemic inflammation. The liver 
is a major responder to systemic inflammation by increasing the production of 
acute phase proteins. Effects on cardiac function lead to wasting and 
decreased innervation, possibly causing death (166). The brain promotes 
changes in neuropeptides that regulate appetite, and activation of the 
hypothalamic pituitary axis leads to the release of glucocorticoids, which act to 
promote muscle wasting. Loss of muscle is associated with increased 
osteoclast function and therefore increased bone resorption, worsening 
function and QoL (167).   
1.7.3 Microvesicles and MicroRNAs 
The study of exosomal micro RNAs (miRNAs) and muscle-specific miRNAs 
(myomiRs) is a promising future field of research for cancer cachexia. Both are 
thought to play a role in the transduction of inflammatory signals and the 
activation of catabolic status in muscles (168). miRNAs are embedded in 
microvesicles, which are small membrane-derived particles that are potentially 
able to communicate with other cells in the body by fusing with their plasma 
membrane, thus allowing the delivery of various molecules including miRNAs, 
mRNA and proteins (169). High levels of tumour-released extracellular Hsp 70 
and 90, in particular, have been detected in the serum of cachectic mice (168). 
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Exosomal-transported miRNAs are of particular interest as they are involved 
in the development and continuation of inflammation in cancer cachexia. 
Exosomes are nanovesicles which promote tissue cross-talk in an autocrine, 
paracrine and endocrine manner. MiRNAs make this communication more 
efficient. They are non-coding RNA molecules that regulate gene expression 
through the degradation of mRNA and have already been shown to modulate 
inflammatory pathways, induce metastasis, mediate cancer aggressiveness, 
and participate in the regulation of protein synthesis and degradation in 
skeletal muscle. 
 
Changes in the profile of miRNAs may indicate the presence or progression of 
muscular disease. Several studies have shown an increase in miR-21 in 
patients with a variety of cancers (colorectal, gastric, prostate and liver)  
(170,171). The upregulation of miR-21 is thought to promote muscle atrophy 
by binding to the transcription factor YY1, as well as the translational initiation 
factor eIF4E3. In binding to these, miRNAs are able to regulate muscle mass 
wasting and interfere with myogenesis (168). By analysing rectus muscle 
biopsies, eight other miRNAs that are upregulated in cancer cachexia patients 
were demonstrated. These include: hsa-let-7d-3p; hsa-miR-345-5p; hsa-miR-
423-5p; hsa-miR-532-5p; hsa-miR-1296-5p; hsa-miR-3184-3p; hsa-miR-423-
3p; and hsa-miR-199a-3p. These miRNAs affect muscle mass in a variety of 
different ways by controlling appetite, interacting with transferrin and insulin-
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like growth receptors, as well as down regulating genes involved in lipid 
biosynthesis, leptin and energy balance (172).  
 
Taken together, these findings demonstrate the role of miRNAs and myomiRs 
in the modulation of atrophic pathways in cancer cachexia. As cachexia is a 
syndrome of systemic effects, in which there is thought to be a large amount 
of tissue cross-talk, these particles are likely to play an important role. 
Improved knowledge about their characterisation and functions, particularly of 
exosomal miRNAs, would aid in the quest for a cachexia-related biomarker, or 
aid in the development of a drug which could diminish the release of tumour- 
induced inflammatory factors. 
 
A summary of some of the novel mediators and mechanisms discussed is 












































Figure 10 Novel mediators of 
cancer cachexia Tumour and 
host derived circulating 
mediators have been shown to 
act on target tissues to 
stimulate excess catabolism or 
promote central anorectic 
effects. Many mediators also 
have autocrine and paracrine 
effects on muscle. 
SYSTEMIC INFLAMMATION 
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1.8 Cross-sectional imaging 
 
The next section will detail current imaging methods used to diagnose or 
screen for the pathophysiological changes described above. 
 
Within both the international consensus definition of cachexia and the 
European Working Group on Sarcopenia in Older People (EWGSOP) 
statement on age-related sarcopenia are defined cut-offs below which the 
patient is considered to have low muscle mass (28,173). DXA was the first 
imaging modality used to investigate this (174). It correlated well with 
measures of total body potassium, a marker of body cell mass, therefore 
validating its use (175). Imaging techniques and body composition analysis 
have since developed. The benefits and limitations of the most popular 
techniques currently in use are discussed below. 
 
1.8.1 Computed Tomography 
 
CT is often used over time to monitor cancer progression or response to 
treatment and can therefore be taken advantage of to investigate body 
composition. CT can differentiate between skeletal muscle, adipose tissue, 
bones and organs based on tissue specific attenuation values using newly 
developed software programmes, including SliceOmatic and ABACS, which 
has been used in this thesis (TomoVision, Canada). This programme is 
designed to be used at the third lumbar vertebra, muscularity at which has 
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been shown to correlate with total body skeletal muscle volume (32). This 
technique gives a measurement of cross-sectional area (CSA), which can then 
be indexed against height to give the skeletal muscle index (SMI) in cm2/m2. 
This was developed in a cohort of 1473 patients with gastrointestinal and 
respiratory cancers (27). The cut points developed were based on those 
patients who had reduced survival time. They were then analysed further to 
produce cut points which accounted for BMI and patient sex. It is important to 
note, however, that these cut points do not take into account any assessment 
of muscle function and therefore questions have been raised about their ability 
to diagnose true sarcopenia (176,177). CT also does not take into account the 
fact that muscle wasting is a dynamic process and it therefore provides an 
assessment of muscle mass at a defined, static time point. CT has, however, 
been widely validated in a range of studies across oncological and surgical 
fields as a method of body composition analysis and continues to be used to 
highlight that low SMI remains an adverse prognostic indicator.  
 
1.8.2 Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) is a highly accurate method to measure 
body composition and is comparable to CT without exposing patients to 
ionizing radiation (173,178). It is often used in other non-cancer patient groups 
to monitor effect of muscular injuries or disease. Measuring body composition 
from MRI is, however, more complex. The MRI scan often uses the quadriceps 
muscles as a marker of total body musculature but also allows the entire 
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volume of muscle to be scanned rather than estimating it from SMI. Each scan 
takes a much longer period of time and interpretation is very labour intensive 
(179). 
 
1.8.3 Dual X-Ray absorptiometry 
 
The most common method for evaluating body composition in cancer cachexia 
clinical trials has been DXA. It is used to measure total appendicular lean 
tissue, including the extremities, and is therefore assumed to be representative 
of muscle mass (180). Its use in assessing body composition in oncological 
clinical practice is restricted as it has several limitations in this setting, including 
the burden of an additional scan and associated costs. Due to this the 
international consensus definition recommends CT or MRI as first choice 
imaging over DXA in cancer patients (28).  
 
1.8.4 Bioelectrical impedance analysis 
 
Bioelectrical impedance analysis (BIA) can be a useful tool for assessing 
skeletal muscle mass and is accepted as an option for doing so by the 
EWGSP, Asian Working Group for Sarcopenia and the International 
Consensus for Cancer Cachexia (28,181). It differs from other body 
composition tools in that it does not measure a specific body component. It 
relies on calibration equations developed from other reference methods e.g. 
CT or DXA. These equations also assume body shape, the relationship 
between trunk and leg lengths, and the level of hydration and fat fraction (182). 
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Earlier BIA systems used fat free mass (FFM) prediction equations developed 
using underwater weighing or total body water. However, new equations have 
been developed to identify body components other than FFM and percentage 
fat. Phase angle is a more up to date part of the BIA test which is used as a 
marker of cell membrane integrity with lower scores being related to cell 
apoptosis. Cancer reduces intracellular water through cachexia such that the 
total body water derived from these equations for normal populations are likely 
to be inaccurate (183).  
 
1.8.5 Contrast Enhanced Ultrasound Scanning 
 
Other imaging techniques are emerging which have been applied to explore 
the effect of cachexia on skeletal muscle morphology, metabolism and micro-
circulation namely Magnetic Resonance Spectroscopy (MRS) and contrast 
enhanced ultrasound (CEUS) (184). CEUS is able to quantify the skeletal 
muscle mircro-circulation by analysing the replenishment kinetics after 
destruction of intravenously injected microbubbles by ultrasonographic 
impulses (185). It is sensitive enough to allow detection of low skeletal muscle 
perfusion (capillary blood flow at rest) and also allows for measurement of 
increased blood flow after exercise or during pathology e.g. inflammatory 
myopathies. MRS allows for non-invasive analysis of the chemical composition 
of tissues (185). It is able to quantify concentrations of several metabolites in 
particular intramyocellular lipids and high energy phosphates which are 
encountered in diseases leading to muscle degeneration (184). A previous 
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study investigating these imaging techniques has been undertaken in 
cachectic patients and healthy volunteers. Lower muscle mass in the cachectic 
group was confirmed by MRI. Capillary density as determined by histology, 
microcirculation measured in vivo by CEUS, and concentrations of metabolites 
analysed in vivo by MRS were the same in both groups. Cancer cachexia was 
therefore associated with a loss of muscle volume but not of functionality. This 
is indicative of sufficient oxidative phosphorylation potential and oxygen 
availability in muscles of patients with cancer cachexia, suggesting therefore 
that cachectic muscles should respond to exercise programmes since they are 
apparently not damaged irreversibly (184). 
 
1.9 Clinical consequences and management of cachexia 
 
The relative clinical implications of the pathophysiology described above will 
now be discussed in more detail. 
 
Cachexia must be considered as a systemic syndrome. Many of the symptoms 
experienced by patients with cachexia may be attributed to muscle wasting 
with decreased muscle mass leading to fatigue and the inability to perform 
simple tasks (186). Patients with cachexia often report altered body image, 
which has a negative impact on their emotional well-being, as well as family, 
work and social lives (187) (figure 11). These patients often also suffer from 
anorexia and fatigue which compounds physical activity problems (186). In a 
study measuring physical activity levels in patients with cachexia using an 
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activity monitor, those with cachexia were shown to have a 40% reduction in 








































Figure 11 Symptoms associated with cachexia The effects of cachexia are multiple, ranging from severe metabolic derangements to 
psychological distress, each of which contributes to poorer outcomes after surgical and oncological treatments, and worsened quality of life.
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1.9.1 Impact of low skeletal muscle mass on chemotherapy toxicity 
and survival 
There are many CT-based body composition studies in existence investigating 
the association between low skeletal muscle mass and survival, with most 
showing reduced survival and poor outcomes. A recent systematic review 
assessed 53 articles on CT based measures of 9138 patients. Most studies 
were aimed at assessing the association between survival rates and CT 
defined body composition (189). Low muscle mass at baseline was a strong 
predictor of survival independent of age, sex, disease site and performance 
status. Although this was noted in all patients, those who were obese and had 
low muscle mass appeared to have the worst survival rates (189). 
These patients with low muscle mass on CT also have an increased risk of 
toxicity to chemotherapy and a reduced time to tumour progression. 
Chemotherapy drugs are measured on the basis of body surface area which 
does not account for muscle and fat loss or water retention. As a result the 
distribution of cancer drugs is impacted and may therefore decrease their 
effectiveness or increase levels of toxicity. Increased toxicity due to changes 
in body composition has been shown in patients with breast, gastric and colon 
cancers (190–192). Patients with metastatic breast cancer had a reduced time 
to tumour progression for capceitabine and 5-fluorouracil based chemotherapy 
(191). In patients who had oesophagogastric cancer low muscle mass was 
found to be present in 57% of patients upon diagnosis. Following neoadjuvant 
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chemotherapy the patients demonstrated a further loss in FFM and the 
proportion of patients with low muscle mass increased (193).  
Muscle wasting over time also seems to be important. In a study including 
patients with advanced non-small cell lung cancer patients who received 
carboplatin-based therapy, skeletal muscle wasting over time but not 
sarcopenia at baseline, independently predicted survival (194). This may have 
been due to chemotherapy toxicity. Skeletal muscle mass therefore may be a 
better predictor of chemotherapy toxicity than body mass and as a result 
changes in body composition following chemotherapy will be investigated in 
more detail in chapter 4. 
1.10 Complexities of body composition analysis 
1.10.1 The relationship between cachexia, sarcopenia and 
malnutrition 
 
Several conditions present with unintentional weight loss (UWL) namely 
cachexia, sarcopenia and malnutrition (figure 12). The term sarcopenia relates 
to loss of muscle mass with aging. Sarcopenia has been defined as 
“appendicular skeletal muscle mass divided by body height squared in meters 
(muscle mass index)” two standard deviations or more below reference values 
from young, healthy individuals measured with DXA (174). Skeletal muscle 
mass assessed by radiological methods also relates to the term “sarcopenia”. 
This can be used to describe low muscle mass on CT scan but requires a 
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reduction in muscle function, as well as mass, to meet the EWGSOP definition 
(173,195). A number of other definitions of sarcopenia can be found in the 
literature but currently no term exists to define the radiological existence of low 
muscle mass; “myopenia” has been previously suggested (196). The theory 
that decline in muscle function is explained by a decline in muscle mass has 
also yet to be fully proven. 
 
Cachexia should not be confused with malnutrition; there is a distinct 
difference. Malnutrition is nutritional depletion following starvation that 
promptly responds to nutritional supplementation, and replacement. Protective 
mechanisms are triggered within the body that minimise energy needs by 
reducing energy expenditure and preserving muscle mass at the expense of 
fat mass. Cachexia causes these protective pathways to not operate, which 
accelerates nutritional depletion and progressive loss of muscle and fat. 
Cachexia is also minimally responsive to nutritional supplementation 





















Figure 12 Differences between cachexia, sarcopenia and  
Malnutrition. All three present with UWL but have distinct differences 
in aetiology and the type of tissue that is wasted which has  
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1.10.2  Sexual dimorphism 
 
There has been considerably more interest of late in the fact that the response 
to muscle loss and function in patients may be sexually dimorphic. Previously, 
in gastrointestinal cancer patients, it has been shown that there is variability in 
lower limb muscle function, mechanical quality, and mass according to both 
the degree of weight loss and patient sex (198). While lower limb muscle mass, 
strength and power were shown to decline in male cancer patients, females 
appeared to experience attenuated loss of muscle mass and power only. 
Mechanical quality was reduced in both male and female cancer patients, but 
only in females did it decline progressively with cachexia (198). These changes 
lead to a significant reduction in patient’s QoL. One proposed mechanism to 
account for sexual dimorphism may be to do with sex hormone production. It 
has been demonstrated that hypogonadism (low total and/or free testosterone 
levels) is prevalent and is associated with poorer survival in male cancer 
patients (199). It is also well established that low testosterone levels impact on 
muscle mass and function. Testosterone concentrations are known to decline 
with age and disease (200). It has a role in the repair of damaged muscle by 
activating myoblasts and increasing satellite cells, therefore leading to 
increased protein synthesis (201). It has anti-inflammatory properties by 
stimulating the release of IL-10 (202) and inhibiting the release of TNF-α, IL-
1β, and IL-6 (203,204). Lowered concentrations of testosterone are also 
associated with raised levels of Leptin, which has anorexic and lipolytic effects 
(174).  Furthermore, testosterone replacement has been shown to prevent loss 
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of muscle in ageing males (205). These findings are consistent with recent 
literature suggesting sexual dimorphism may impact on the effects of systemic 
disease such as cirrhosis and must be considered when treating cachexia in 
clinical practice (206). 
 
A molecular study investigating dimorphism has recently been undertaken. 
(207). Molecular data were obtained from 41 K Agilent microarray analysis of 
rectus abdominus muscle and Liquid Chromatography Mass Spectrometry 
(LC-MS) analysis of urine in patients with cancer. This study was able to 
identify altered pathways in men and women. Increasing muscularity was 
associated with JAK/STAT signalling pathways in men and growth hormone 
(GH) signalling pathways in women and was negatively associated with 
mismatch deoxyribose nucleic acid (DNA) repair in men and with oestrogen 
receptor (ER) mediated phagocytosis in women. The urinary proteome and 
muscle transcriptome suggested altered carbohydrate metabolism in women 
but not in men. Inflammation, however, was associated with low muscle mass 
independent of sex (207). The effect of gender has also been investigated in 
a study of 368 patients with a variety of advanced cancers (pancreas, 
cholangiocarcinoma, lung and colorectal). The authors concluded that male 
pancreatic cancer patients lost more muscle and fat at an accelerated rate 
compared with females (208). These data suggests that future interventions 
and management of cancer cachexia would be best tackled with a sex-specific 
approach.   
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1.10.3 Adipose tissue and cachexia 
1.10.3.1 Obesity 
Individual patients do not have the same body habitus at diagnosis. 
Demographics have changed since the original cachexia definition was 
developed with rates of obesity increasing worldwide (209). Obesity is defined 
as “abnormal or extensive fat accumulation that negatively affects health.” 
According to the World Health Organisation (WHO) it is defined as a “BMI ³30 
kg/m2 and waist circumference as >102 cm for men and >88cm for women” 
(210). Obesity is a well-known risk factor for many types of cancer (211) and 
is usually considered to have a disadvantage on survival (212), however, it has 
been shown to confer a survival advantage in patients with weight loss 
associated with heart and renal failure due to their larger energy reserve (213). 
Diagnostic criteria for cachexia therefore needs to include additional nutritional 
information beyond weight loss.  
 
1.10.3.2 Sarcopenic obesity 
 
Older obese persons with decreased muscle mass or strength are at special 
risk of adverse outcomes. Excess energy intake, low levels of physical activity, 
low grade inflammation, insulin resistance, and changes in hormones may lead 
to the development of sarcopenic obesity (214).  
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Sarcopenic obesity was also first defined by Baumgartner (215). It has since 
been further defined using anthropometrics, BIA and strength which poses its 
own problems given there are no accepted criteria for low muscle strength 
(216). Similarly to prevalence rates in cachexia, rates of sarcopenic obesity 
vary depending upon definitions used, ranging from 4 to 12% (215–217) (table 
2). Many longitudinal studies have shown that fat mass increases with age, 
with muscle declining after age 30 and being more rapidly lost in the elderly 
(218–220). These important differences in body composition parameters 
between age groups will be investigated in chapter 4. 
 
Many patients with pancreatic cancer will be over-weight rather than 
underweight which makes applying conventional risk stratification measures 
difficult. In a study of 2115 patients with cancers of the respiratory and 
gastrointestinal tract sarcopenic obesity was associated with poorer functional 
status compared with obese patients who did not have sarcopenia and 
independently predicted survival. Estimated fat free mass (FFM) showed a 
poor association with body surface area which as discussed above impacts on 
chemotherapy distribution (221). Sarcopenic obesity therefore is an 
independent adverse prognostic indicator that should be considered for 



















mass -2 SD below 
mean of young 
population or < 7.26 
kg/m2 in men and < 
5.45 kg/m2 in 
women. 
- Obesity: 
percentage body fat 
greater than 
median or > 27% in 
men and 38% in 
women. 
 






- Sarcopenia: two 
lower quintiles of 
muscle mass 
(<9.12 kg/m2 in 
men and <6.53 
kg/m2 in women) 
 
- Obesity: two 
highest quintiles of 
fat mass (>37.16% 
in men and > 











Zoico et al 
(217) 
- Sarcopenia: two 
lower quintiles of 
muscle mass (<5.7 
kg/m2) 
- Obesity: two 
highest quintiles of 
fat mass (>42.9%) 
 
F:167 71.7(2.4) F:12.4% 
 
Table 2 Prevalence of sarcopenic obesity by various definitions. There is 
marked variation in prevalence rates dependent on the definition used. 
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1.10.3.3 Effect of changes in adipose tissue on survival 
It is unclear whether it is adipose or muscle wasting or a combination of the 
two which has the most negative impact on survival. A study based on pooled 
recent data (222) (n=8160) evaluated the prognostic significance of weight 
loss in patients who initially had low, intermediate or high BMI. The authors 
showed that the patients with a lower starting BMI had a worse prognosis, with 
BMI and weight loss being independent predictors of survival regardless of 
cancer site and stage. They were therefore able to develop a cancer weight 
loss grading system that incorporated BMI and weight loss in order to predict 
the risk of reduced survival as shown in figure 13. 
 
A further study investigated the independent prognostic significance of 
adipose tissue in predicting mortality in cancer patients (223). Total adipose 
index (TATI), visceral adipose index (VATI) and subcutaneous adipose index 
(SATI) were estimated for 1473 gastrointestinal and respiratory cancer 
patients. Low SATI was independently associated with increased mortality and 
shorter survival. In the presence of sarcopenia, however, the longest survival 
was observed in patients with high subcutaneous adiposity (223).  Other 
studies have suggested that those patients who lose fat mass only have as 
poor a survival as those patients who lose muscle and fat mass (224). The 
relevance of fat wasting in cachexia does however, remain a relatively 
unanswered question and the investigation of this will therefore form a key 







Figure 13 Diagnostic criteria for cancer associated weight loss (222, 
reproduced with permission from JCO) 
 
Risk of reduced survival as a function of BMI and percentage weight loss. 
Panel A represents number of patients, panel B is median survival in months 
and panel C is the unadjusted estimated hazard ratios. Panel D represents the 
staging system. Colours represent grading from 0 to 4. Grade 4 is of value in 
identifying individuals whose expected survival is too short to merit specific 
treatment plans or interventions and should therefore be taken into account 
when risk assessing patients with cancer-associated weight loss.  Finding that 
degree of weight loss affects survival supports the suggestion that cachexia 
has degrees of severity, even within the distinct phases of the syndrome.  
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1.11 Cachexia clinical trials 
 
Many of the previous cachexia trials have been discussed alongside their 
targeted mediators, but there are a few which merit more attention 
(summarised in figures 14 and 15). Over the last few years there have been 
five phase 3 randomised, double blind placebo-controlled trials. Most notably 
the potential of Ghrelin as a treatment for cancer cachexia was investigated in 
the ROMANA I and II trials, and the ROMANA 3 safety extension study 
(93,225). Anamorelin, an oral and specific ghrelin receptor agonist, was given 
to patients with advanced non-small cell lung cancer and cachexia. Lean body 
mass increased in patients taking Anamorelin compared with placebo in all 
trials, as did body weight and anorexia-cachexia related symptoms. However, 
the trials were unable to demonstrate differences in handgrip strength as the 
functional co-primary endpoint. Food intake was not recorded, and it is 
therefore unclear as to whether an increase in appetite and nutritional status 
led to the observed changes in body mass. Besides anamorelin, the other 
novel Ghrelin agent macimorelin (NCT01614990) is currently under 
investigation, the results of which are expected in 2020 (226). 
 
Other emerging anabolic agents are the selective androgen receptor 
modulators (SARMs). These drugs, most notably Enobosarm which was 
investigated in the POWER 1 and 2 trials are a new class of non-steroidal 
(227,228). SARMs are unique in their ability to increase muscle mass without 
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anabolic side effects. The POWER trials were randomised, double-blinded, 
placebo-controlled trials in patients with advanced lung cancer who had at 
least 2% weight loss in the previous 2 months. They both involved 3mg of 
Enobosarm or placebo daily at the start of chemotherapy (Platinum + Taxane 
in POWER 1 and Platinum + Non-Taxane in POWER 2). Unpublished results 
have shown a significant increase in lean body mass (LBM) but no increase in 
mean stair climb power (228).  
 
Previous therapies for muscle wasting in cancer have focused on improving 
appetite, reducing inflammation and modifying muscle protein anabolism and 
catabolism. No single agent has yet been shown to be able to do this, 
highlighting the need for an integrated approach. This has led to the 
development of the MENAC trials (multimodal-exercise, nutrition and anti-
inflammatory medication for cachexia) for palliative lung and pancreatic cancer 
patients (229,230). The pre-MENAC trial showed that a multimodal 
intervention in cachexia may improve weight, leading to the phase III MENAC 
trial [NCT01419145] (231). It consists of non-steroidal anti-inflammatories, 
eicosapentaenoic acid, a physical exercise programme using resistance and 
aerobic training, as well as dietary counselling and oral nutritional supplements 





Figure 14 Targets for previously trialled cachexia drugs Drugs are highlighted in orange boxes alongside their targets 
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Figure 15 Notable previously trialled drugs for cachexia 
and the stage of cachexia they target [adapted from (232)]




Selective Androgen Receptor Modulator 
NSCLC before first line chemotherapy 




Increase in LBM but not in stair climb 
power 
Anamorelin: 
Ghrelin receptor agonist 
Humanised monoclonal antibody 
Unresectable stage III to IV NSCLC 
Weight loss >5% in previous 6 months 
Prognosis >4 months 
Increase in LBM no increase in hand grip 
strength 
MABp1: 
Anti-IL 1a antibody 
Humanised monoclonal antibody 
Metastatic colorectal cancer 
Weight loss >5% in previous 6 months 
Increases in LBM and symptom relief seen 
Bimagrumab: 
ActRII receptor antagonist 
NSCLC or stage III to IV pancreatic cancer 
Weight loss >5% in last 3 to 6 months 
Prognosis >4 months 





Multimodal therapy (exercise, nutrition 
and anti-inflammatories) 
Palliative lung and pancreatic cancer 
Increase in weight seen in pre-MENAC 
trial 
MENAC trial still ongoing 
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To date no clinical trials have been considered wholly successful in the 
treatment or prevention of cancer cachexia. This is in part due to difficulties in 
assessing cachexia diagnosis but also due to a lack of clear consensus on 
how to measure primary end points of change in LBM and physical activity. 
Recent trials have used various outcome measures including stair climbing, 
hand grip strength, 6-minute walk test and the timed up and go, and a 
consensus needs to be made on which is the most appropriate choice to inform 
future trial design 
 
This introductory overview has highlighted that muscle wasting in cancer is 
multifactorial and complex. It is underpinned by hypercatabolism, a net loss of 
energy, and systemic inflammation. Although its effects are most devastating 
later in the disease process, molecular changes are likely to begin very early 
on. Previous therapeutic targets have been promising in preclinical models but 
have not been fully efficacious in clinical trials. The availability of both 
promising animal and clinical studies do, however, highlight that treatments 
need to be targeted and supported by multi-modal approaches. Research 
needs to focus on the link between pre-clinical and clinical models to unpick 
the mechanisms involved and develop standardised methods and outcomes 







1.12 Research questions 
 
The introductory chapter has attempted to provide an overview of cancer 
cachexia with a particular focus on recently discovered mediators which may 
lend themselves as future therapeutic targets. In particular, adipose wasting 
and tissue cross-talk may have important undiscovered effects on patient 
outcomes. There still remains difficulty in assessing patients due to the lack of 
a cachexia-related biomarker and increasing rates of obesity since the 
consensus definition was introduced. Therefore, this thesis is targeted at 
evaluation of patient body composition and signalling pathways within 
cachectic human plasma, muscle and fat. A number of studies have been 
undertaken with the main questions being asked summarised below: 
1. Is it possible to use one single screening tool to assess cachexia, 
sarcopenia and malnutrition? If so is it able to distinguish between the 
three conditions? 
2. What is the relationship between CT derived measures of body 
composition and age and sex in patients with oesophago-gastric 
cancer? 
3. Are abnormalities in the neuromuscular junction responsible for the 
muscle wasting observed in cancer cachexia?  
4. What are the transcriptomic differences in visceral and subcutaneous 
adipose depots in patients with cancer cachexia and healthy controls? 
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5. Are we able to identify potential plasma biomarkers of cancer cachexia 

























2.0 General Methods 
This next section describes methods that were common to all studies included 
in this thesis. It details patient recruitment, anthropometric measures, body 
composition analysis and tissue sampling. Functional and QoL assessment 
was also performed as part of a wider biobank collection and as such is briefly 
described, however this data was not utilised in the studies that made up this 
thesis. 
 
2.1 Participant groups 
Patient data were drawn from three sources. An existing and continuing 
biobank (created through a funded collaboration with Novartis) which contains 
>250 samples of rectus muscle, subcutaneous and visceral fat, urine and 
plasma from robustly phenotyped patients, a previous CRUK biomarker study, 
and the prospectively collected tissue for the neuromuscular junction study. 
 
1. Muscle wasting in cancer study: An ongoing study of healthy controls, 
vascular and cancer patients at the Royal Infirmary of Edinburgh (RIE). 
Patients underwent CT, functional assessment, QoL assessment, 
blood, fat, urine and muscle sampling at the time of their operations  
2. CRUK cancer biomarker study: A previous study of patients with UGI 
cancer at the RIE who underwent functional assessment, MRI 
quadriceps, CT scanning, blood, urine and muscle sampling. (n=121 
patients with cancer) 
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3. NMJ study: An ongoing study at the RIE assessing the NMJ involving 
UGI cancer and vascular patients. Patients underwent CT, functional 
assessment, QoL assessment, blood and muscle sampling at the time 
of their operations  
 
2.2 Participant recruitment 
2.2.1 Cancer patient recruitment 
All cancer patients who were prospectively recruited attended the Surgical 
Department of the RIE. Staging was carried out according to the American 
Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer 
(UICC) systems. Ethical approval for the study was obtained from the South 
East Scotland Research Ethics Committee, co-sponsored by the University of 
Edinburgh and National Health Service (NHS) Lothian Health Board (IRAS ID 
190214). In accordance with the Helsinki Declaration, all patients provided 
written and informed consent prior to surgery. Patients who were suitable to 
undergo potentially curative surgery were identified at the regional UGI cancer 
multi-disciplinary team meetings (process summarised in figure 16). They were 
approached at their routine pre-operative clinic appointment and patient 
information sheets were given (appendix 1). QoL (appendix 2) and the timed-
up-and-go (TUG) and blood tests were performed at this appointment.  
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Figure 16 Cancer patient recruitment process 
Patients with a suspected or confirmed diagnosis of UGI cancer were referred 
to the central MDT meeting (comprising surgeons, radiologists, pathologists, 
nurse specialists, physicians, oncologists, and dieticians). A consensus 
decision on treatment was then made. Patients included in this thesis were 
recruited from the curative surgery cohort. Abbreviations: MDT, multi-
disciplinary team; UGI, upper gastrointestinal 
Referral to UGI cancer service 











2.2.2 Control patient recruitment 
Patients undergoing elective surgery for aortic aneurysmal or occlusive 
disease were approached once admitted to the vascular unit the day prior to 
their planned surgery. Vascular patients were chosen as they were all 
undergoing laparotomy meaning tissue was easily accessible. They also form 
an interesting group of patients who often have low muscularity despite not 
suffering from cancer. Healthy patients who were undergoing laparoscopic 
surgery for live renal transplant donation were approached at their routine pre-
operative assessment appointment. Baseline blood tests were taken routinely. 
Written informed consent was obtained. QoL and TUG test were performed at 
the same meeting.  
 
2.3 Anthropometric measurements 
2.3.1 Height, weight and weight changes 
Body weight was measured with patients lightly clothed using a beam scale 
(Seca, UK). Height was measured using a standard wall mounted measure. 
Weight change was calculated as the percentage difference between stable 
pre-morbid weight (self-reported by the patient) and the weight at assessment. 
There is evidence that self-reported weight is reliable, with height and weight 
measurements performed by physicians and nurses being shown to have a 




2.3.2 Body mass index (BMI) 
BMI was calculated according to the formula: 
BMI (kg/m2) = weight (kg)/height (m)2 
 
2.4 Muscle mass measurement 
2.4.1 CT scan identification and location 
Patients routine diagnostic and staging CT were analysed for muscle mass 
assessment. Recent CTs performed at the RIE were easily identified from the 
electronic clinical record (TrakCare, InterSystems Corporation, Cambridge 
Massachusetts). CTs could then be found on the PACS (Picture Archiving and 
Communications System) electronic x-ray viewing system. Scans performed 
at peripheral hospitals could be located on the national PACS archive. 
 
2.4.2 Slice selection and preparation 
Cross sectional images were located at the level of the third lumbar vertebra 
(L3) on abdominal CT. L3 was identified by locating the lowest thoracic 
vertebra (the lowest vertebral body with ribs) and counting vertebra in a caudal 
direction. The slice with both transverse processes visible was taken as the 
first slice. Cross sectional images were saved in the DICOM format.  
2.4.3 Tissue segmentation 
Muscle cross sectional area (CSA) was measured with SliceOmatic V4.3 
software (Tomovision, Canada) and the Alberta protocol from the ABACS 
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software (Vorioni, Canada) according to a previously established protocol. 
Tissue segmentation was performed using Hounsfield unit ranges -29 to +150 
for muscle, -190 to -30 for subcutaneous adipose tissue, -190 to -30 for 
intramuscular adipose tissue, -150 to -50 for visceral adipose tissue. Each 
tissue type was manually drawn out if required and abdominal viscera 
excluded. Muscle groups included were Quadratus lumborum, Erector spinae, 
Psoas major and minor, Internal and External abdominal oblique, Transversus 
and Rectus Abdominus. The software outputted data as a CSA in cm2 for each 
tissue which was then converted into the skeletal muscle index (SMI) as 
described. below. An example of the CT analysis undertaken is shown in figure 
17. 
 
SMI was calculated as the ratio of lumbar skeletal muscle area to height and 
was defined according to Martin et al: SMI <43cm2/m2 for men with a BMI <25, 
<53 for men with a BMI ³ 25 and <41cm2/m2 for women (27). Subcutaneous 
and visceral adipose tissue was indexed for height (SATI and VATI). Low SATI 
was defined as <50cm2/m2 in males and <42cm2/m2 in females. Low VATI was 
defined as <52.9cm2/m2 in males and <51.5cm2/m2 in females (234). Total 
adipose tissue index (TATI) was defined as the sum of VATI + SATI. High TATI 
was considered to be ³107.7cm2/m2 in men and ³102.2cm2/m2 in women 
(223). Intramuscular fat was described in terms of cross-sectional area (CSA). 
Sarcopenic obesity was defined as sarcopenia in the presence of BMI ≥30 








Figure 17 Cross sectional CT image  
 
Image take at L3 showing demarcation of skeletal muscle and adipose tissue 
using Slice-o-matic and ABACS software. 
 
Light blue – subcutaneous fat 
Red – muscle 
Green – intramuscular fat 







2.5 Functional measures  
2.5.1 Sit to Stand times (STS)  
STS times were measured by a single observer using a digital stopwatch. The 
patient began seated with their arms by their side and feet in front of the chair. 
Once instructed that the test had begun, they were to rise from the chair. The 
test stopped when they were in the upright position. The STS test is associated 
with coefficient of variation for repeated tests of between 6.8% (healthy 
volunteers) and 14% (elderly) (235). 
 
2.5.2 Timed up and go (TUG)  
TUG was measured in conjunction with the STS test, and was timed by one 
observer using a digital stopwatch. The participant undertook the STS test and 
then were instructed to walk at their normal pace for three meters and then 
return to the chair and sit down again. The TUG test is recognised as a reliable 
and reproducible test with an inter-rater reliability intra-class correlation 
coefficient (ICC) of .99 and an intra-rater ICC of .98 (236). 
 
2.6 Quality of life assessment 
2.6.1 Karnofsky performance score (KPS) 




2.6.2 European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) 
EORTC QLQ C-30 was assessed in all patients and results analysed using 




















Figure 18 Data and samples collected for each patient 
Each patient underwent pre-operative functional and QoL assessment as well 
as having blood taken for inflammatory markers. Plasma was sampled at the 
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2.7 Tissue sampling 
2.7.1 Muscle wasting in cancer study 
All biopsies were taken at the start of open or laparoscopic abdominal surgery 
during the initial incision.  
Muscle: Approximately 1cm2 biopsies of rectus abdominus were taken using 
sharp dissection. Samples were cleaned of fat/blood/fibrous tissue, placed in 
a tube (NUNC Cryotubes, Sigma-Aldrich Co. LLC) snap frozen, and stored at 
−80°C. Three sections of the muscle were treated with optical cutting 
temperature (OCT) and lowered into 5mls of cooled isopentane solvent 
(−190°C) prior to storage at −80°C. Specific details of muscle taken for the 
NMJ study are described in the corresponding chapter. 
 
Fat: Approximately 1cm2 biopsy of subcutaneous fat was taken from all 
patients. Visceral omentum was sampled from cancer and vascular patients 
and perinephric fat from controls. Omental fat was sampled at the beginning 
of the operation whereas perinephric fat was sampled once the donor kidney 
had been removed. Samples were snap frozen in liquid nitrogen and stored at 
-80°C. 
 
Urine: Urine was taken from the patient at the time of general anaesthesia 
following an overnight fast. It was collected in a sterile container, divided into 
2 ml aliquots, and snap frozen in liquid nitrogen, prior to storage at -80oC 
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Plasma samples: Venous blood samples were taken using 2 x 9ml serum 
Monovette tubes and 1x EDTA tube (Sarstedt,Num̈brecht, Germany). 
Samples were centrifuged at 4°C at 15 000 x g for 15 mins. Plasma was 
removed with a pasteur pipette and divided into 2ml aliquots. These were 
frozen at -80°C prior to processing. 
 
2.7.2 Blood measures 
All pre-operative samples were processed by the Department of Clinical 
Chemistry, RIE (fully accredited by Clinical Pathology Accreditation Ltd, UK) 
CRP was measured by enzyme linked immunosorbent assay (ELISA) (Ely, 
UK). 
 
Further detailed methods pertaining to each study are described in more detail 
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3.1 Overview of chapter  
The first chapter in this thesis focusses on the ability to screen for cachexia. 
Malnutrition and sarcopenia also present with unintentional weight loss and so 
the ability to pick out the underlying condition would aid in targeting patients 
for selection into clinical trials as well as instigating appropriate treatments. 
 
3.1.1 Objectives 
To systematically review validated screening tools for cachexia, sarcopenia 
and malnutrition in adults and, if a combined tool is absent, make suggestions 
for the generation of a novel screening tool. 
 
3.1.2 Methods 
A systematic search was performed in Ovid MEDLINE, EMBASE, CINAHL 
(Cumulative index to Nursing and Allied Health Literature) and Web of 
Science. Two reviewers performed data extraction independently. Each tool 
was judged for validity against a reference method. Psychometric evaluation 
was performed as was appraisal of the tools ability to assess the patient 
against consensus definitions.  
 
3.1.3 Results 
Thirty-eight studies described 22 validated screening tools.  The Cachexia 
score (CASCO) was the only validated screening tool for cachexia; performing 
well against the consensus definition. Two tools assessed sarcopenia (the 
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Short Portable Sarcopenia Measure [SPSM] and the SARC-F); scoring well 
against the 1998 Baumgartner definition. The SPSM required large amounts 
of equipment and the SARC-F had a low sensitivity. Nineteen tools screened 
for malnutrition. The 3 minute nutrition score (3 MinNS) scored best meeting 
consensus definition criteria (ESPEN) and also having sensitivities and 
specificities >80%. No tool contained all the currently accepted components to 
screen for all three conditions. Only three tools were measured against cross-
sectional imaging, a clinical tool that is gaining wider interest in body 
composition analysis.  
 
3.1.4 Conclusion 
No one validated screening tool can be implemented for the simultaneous 
assessment of cachexia, sarcopenia and malnutrition. The development of a 
tool that encompasses consensus definition criteria and directs clinicians 
towards the underlying diagnosis would be optimal to target treatment and 
improve outcomes. Proposed is a tool that incorporates a stepwise 
assessment of nutritional status; oral intake; disease status; age; muscle 








Unintentional weight loss (UWL) as a form of nutritional depletion is commonly 
seen in ageing, cancer and many chronic diseases. As discussed in the 
introductory section the main subtypes can be categorised into three primary 
syndromes: cachexia, age-related sarcopenia and malnutrition; however, it is 
not clear whether existing screening tools are able to distinguish between 
these three conditions. This is due in part to the complex overlap between 
them. Loss of muscle mass is a key feature in both cachexia and sarcopenia 
but patients with sarcopenia are not necessarily cachectic. As we have seen 
there are many definitions for each condition, with nutritional depletion playing 
a part in each, therefore making it difficult to separate them out 
(28,174,237,238). These conditions are also often not noticed in their earlier 
phases but do become apparent following a critical event or development of 
disability (239).  
 
More than 70 nutritional screening tools for use in hospitals have been 
developed to facilitate easy screening or assessment of a patient’s nutritional 
status or to predict poor clinical outcomes related to UWL. Despite increasing 
research, there appears to be a lack of a practical and implementable clinical 
screening tool to support diagnosis (240). In the general community, the 
European Society for Clinical Nutrition and Metabolism (ESPEN) endorses the 
use of Malnutrition Screening Tool (MUST) (240,241), and Nutritional Risk 
Screening (NRS-2002) (242) and the Mini Nutritional Assessment – Short 
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Form (MNA-SF) for the elderly (243,244). Some tools claim to have been 
developed to screen in specific target groups however, there are currently no 
disease specific recommendations. There is no international consensus on a 
single ‘best tool’ to identify all three syndromes across populations. The use of 
different tools in different studies makes drawing any conclusions about their 
comparison and meta-analyses difficult.  
 
Current diagnostic methods for sarcopenia and cachexia include the 
measurement of total body potassium and water, assessment of body 
anthropometry using either body mass index (BMI) or estimated weight loss, 
or by direct assessment of muscle and fat mass using dual-energy X-Ray 
absorptiometry (DXA), bioelectrical impedance analysis (BIA), CT or MRI 
scanning. Whilst the latter two radiographic modalities are accurate, they are 
impractical, expensive and some expose the patient to ionizing radiation. This 
diagnostic approach to detect the presence of sarcopenia is time consuming, 
expensive and requires highly specialised equipment (245). Therefore, a 
screening tool that is implementable in a larger population that allows for early 
detection is important. This approach would highlight the potential for further 
assessment with early biomarkers, thus allowing prophylactic intervention in 
malnutrition and driving further research in sarcopenia and cachexia. 
 
This chapter aims to systematically review validated screening tools for the 
general adult population to enable clinicians to distinguish between the three 
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syndromes. The specific strengths and limitations of each tool were assessed, 
as was the appropriateness of the validation population. Through 
psychometric evaluation and assessment of the tools against the agreed 
consensus definitions, we also investigated if any one single tool could be used 
for the simultaneous assessment of all three.  
3.3 Methods 
Methods for conducting systematic reviews of the effectiveness of 
interventions have been well described. In accordance with PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (246) 
guidelines we applied the principles to systematically reviewing validated 
screening tools used in the assessment of cachexia, sarcopenia and 
malnutrition. 
3.3.1 Literature review 
A systematic search was performed on 7th August 2018 in Ovid MEDLINE 
(1946-2017), EMBASE (1974-2017), CINAHL (Cumulative index to Nursing 
and Allied Health Literature) and Web of Science. Relevant articles were 
identified by title and abstract. Reference lists of review articles were also hand 
searched. Double data extraction was performed by two reviewers 
independently to ensure consistency. Any disagreements were settled by a 
third reviewer.  
 
 143 
The basic search strategy was “Sarcopenia” OR “Cachexia” OR “Malnutrition” 
AND “screening” AND “validation study” using MeSH terms and keywords 
appropriate to each database. No language restriction was imposed. The 
search was designed to be broad to ensure all validated tools were identified. 
There were no disease specific or language limits. 
3.3.2 Inclusion and exclusion criteria 
Studies were included if they had developed a screening tool which had been 
validated for the screening of either cachexia, sarcopenia or malnutrition in 
adults (Table 3). Disease specific tools were included. Papers were excluded 
if the tools had not been validated or if they assessed malnutrition in children 
or obesity in adults. Studies which described modified versions of pre-existing 
tools were also excluded as this was out with the scope of this review. It was 
intended that studies that included less than 25 patients should be excluded 
as they were unlikely to yield robust, generalisable psychometric results, 







Types of participants 
Adults (>18 years) undergoing 
routine screening for cachexia, 
sarcopenia, or malnutrition 
 
Includes patients with advanced 
cancer, end stage cardiac, renal and 
liver disease 
Types of tools 
Validated, quantitative 
measurements of cachexia, 
sarcopenia or malnutrition 
 
Tools developed for clinical or 
research purposes. Completed by 






Construct validity, including 












Demonstration of at least 2 
criteria: 
Breadth of scope of tool; to what 
extent does it appear to capture the 
relevant aspects of unintentional 
weight loss; are there gaps? 
How well the tool relates to other 
measures of the same construct; 
lack of correlation with dissimilar or 
unrelated constructs or variables 
How consistent an individual’s 
scores are over a defined time-
period presuming weight stays 
constant 
How closely related are the different 
items in the tool? 
Ability to detect clinically meaningful 
change for individuals 
For a tool comprising several items, 
a way of grouping them into factors 
which may tap into a particular 
construct 
A shortened version of a scale, 
concurrent validity with the longer 
version which has been validated 
Table 3 Systematic review Inclusion criteria 
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3.3.3 Assessment of Validity 
Studies had to have evaluation of at least two of the following psychometric 
characteristics: 
• Content validity 
• Construct validity e.g. including convergent validity, discriminant validity 
• Test-retest reliability 
• Internal consistency 
• Responsiveness 
• Factor analysis 
• Criterion validity 
Primary criteria used to evaluate the tools were construct validity and 
responsiveness. 
3.3.4 Criterion and construct validity, reference method  
Studying the validity of a tool usually compares to a gold standard. Although 
many research groups are now using cross sectional imaging to investigate 
UWL there is currently the absence of a perfect gold standard. Studies used 
different reference methods to validate their tools e.g. DXA and assessment 
by a health professional. The tools SGA and MNA are the tools currently 
recognised as the industry standard and were therefore considered valid 
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references (238,240). The term criterion validity was used for these 
comparisons.  
Less valid reference methods including the use of other screening tools and 
blood tests for example albumin which can be influenced by other factors 
including inflammation and acute disease were included as many research 
groups vary in their opinion on the optimal reference method (247). These 
comparisons were termed construct validity. 
3.3.5 Predictive validity  
Predictive validity was assessed as the ability of the tool to predict the 
probability of a better or worse clinical outcome due to nutritional risk. 
3.3.6 Diagnostic criteria 
Tools were also assessed for their ability to identify the risk of cachexia, 
sarcopenia or malnutrition by comparison of their components against the 







Syndrome Diagnostic criteria 
Cachexia 
Weight loss greater than 5%, or weight loss greater than 
2% in individuals already showing depletion according to 
current bodyweight and height (body-mass index [BMI] 
<20 kg/m2) or skeletal muscle mass (sarcopenia) (28) 
Sarcopenia Loss of function – 6-minute walk < 400m OR gait speed 
<1.0m/s  
Muscle mass – low appendicular lean mass/height (2 
standard deviations below the mean diagnostic on DXA) 
(174,237) 
Malnutrition Protein/energy deficiency - risk indicated by low BMI 
<18.5 kg/m2 OR weight loss >10% (indefinite time)/5% 
over last 3 months AND BMI <20 (if <70 years)/ <22 (if>70 
years) or FFMI < 15 and 17 kg/m2 in men and women 
respectively (238) 
 
Table 4 Summary of proposed diagnostic criteria for identification of 
cachexia, sarcopenia and malnutrition 
FFMI (Fat-free mass index) 
 
3.3.7 Assessment of bias 
Assessment of bias was made using a form of the Newcastle-Ottawa scale 
adapted for cross-sectional studies (248). Each study was scored out of 10 
and a study with a score of <5 was considered to be at high risk of bias. Full 
details of the scoring used can be found in the appendix. 
3.3.8 Secondary criteria  
Secondary criteria included face validity, development and content validity, 
factor analysis, test-retest reliability, internal consistency, respondent and 
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administrative burden (the time and effort required to complete the tool). These 
are also summarised in table 3. Data were extracted concerning the study 
participants, the tool used and psychometric evaluations (Inclusion criteria 
Table 3). Assessment of sensitivity and specificity was made. A value >80% 
was considered good, 60-80% fair and <60% poor. Agreement was also 
assessed as: 0.9-1 = excellent, 0.80-.90 = good, 0.60-0.80 = fair and <0.60 = 
poor. 
3.4 Results  
3.4.1 Principal findings 
Thirty-eight studies were included which described the validation of 22 
screening tools. The majority of papers were excluded as they described un-













Figure 19 PRISMA flow diagram to show source of studies included in 
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qualitative synthesis 
(n = 38) 
Records identified through 






















Additional records identified 
through other sources 
(n = 8) 
Duplicates removed 
(n = 1361) 
Records screened 
(n = 3430) 
Records excluded as title 
and abstract not suitable 
(n = 3350) 
 
Full-text articles assessed 
for eligibility  
(n = 80) 
Full-text articles excluded 
as tools not validated 
(n = 42) 
 
Number of screening tools 
included 
(n = 22) 
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The Cachexia score (CASCO) was the only screening tool for cachexia that 
had been validated. It performed well against diagnostic criteria (28), but 
sensitivities and specificities were not recorded. Only two tools assessed 
sarcopenia (the Short Portable Sarcopenia Measure [SPSM] and the SARC-
F) and scored well against the agreed definition (Baumgartner 1998). 
However, the SPSM required a large amount of equipment and the SARC-F 
had a very low sensitivity. Both were validated for use in the outpatient setting. 
Nineteen tools screened for malnutrition. The 3 minute nutrition score (3 
MinNS) proved to be the best, scoring well against the consensus definition 
(ESPEN) as well as having sensitivities and specificities >80%. There was no 
one validated tool which adequately screened for all three conditions. A critical 














Table 5 Critical appraisal of tools to measure unintentional weight loss 
 
 Author Tool Description Validation population Validation 
reference 
Strengths Limitations 
















A questionnaire regarding ability to carry a heavy load, 
walking, rising from a chair, climbing stairs and falls 
frequency 
 
Portable measure that combines estimates of muscle 
quantity and function into a single scale 
 
 
























No assessment of 
muscle mass, not 




muscle mass not 
measured  
Cachexia Argiles et al, 2017 (251) CASCO 
 
Score to classify cachectic patients into three different 
groups. Includes five components: body weight loss & 
composition, inflammation/metabolic 
disturbances/immunosuppression, physical performance, 
anorexia and quality of life 








not include questions 
on disease state 
Malnutrition Weekes et al, 2004 (252) 
 
 



































Tool based on four nutritional parameters (weight, height, 
recent unintentional weight loss and appetite) 
 
Score based on UWL, unintentional eating loss and being 









Evaluates nutrition using albumin, cholesterol and 




Acute medical and elderly care 
wards (n=100) 
 




















































Percentage weight loss 
not quantified 
 
Low importance given 




Assessed on admission 





depending on disease 
state, only done on 




Guerra et al, 2017 (256) 
 
 











Ferguson et al, 1999 (259) 
Isenring et al, 2006 (260) 
Neelemaat et al, 2011 
(261) 
Nursal et al, 2005 (262) 
Young et al, 2013 (263) 
Wu et al, 2012 (264) 
Bhuachalla et al, 2018 
(265) 




Kim et al, 2011 (267) 
 
 
Boleo-Tome et al, 2012 
(268) 
Leistra et al, 2013 (269) 
Sharma et al, 2017 (270) 
Neelemaat et al, 2011 
(261) 
Kyle et al, 2006 (271) 
Young et al, 2013 (263) 
Almedia et al, 2012 (272) 










































Screening tool based on ESPEN criteria for diagnosis 
malnutrition 
 
Modified nutritional risk index for geriatric patients (based 





Two-tiered tool – first is a simple pre-screen aiming to 

















Tool based on intake change, weight loss, ECOG 
performance status and BMI 
 
Five step tool including BMI, unplanned weight loss and 










Medical and surgical inpatients 
(n=632) 
 











Medical and surgical inpatients 
(n=408) 
Oncology outpatients (n=51) 
Acute hospitalised (n=193) 
Medical and surgical inpatients 
(n=2211) 
Elderly medical inpatients (n=134) 
Elderly inpatients (n=157) 
Oncology patients (n=725) 




Oncology inpatients (n=1057) 
 
 
Oncology inpatients (n=450) 
Medical and surgical outpatients 
(n=2236) 
Acute medical inpatients (n=132) 
Elderly inpatients (n=198) 
Medical and surgical (n=995) 
Medical inpatients (n=134) 
Surgical inpatients (n=300) 
Medical and surgical (n=400) 





























































































Ease of completing 

















Designed to be 
performed by 
dieticians, not nurses 
 
Does not pick up 
patients with normal 
BMI who are 
malnourished, UWL 











Prasad et al, 2012 (274) 
Faramarzi et al, 2013 (275) 





Neelemaat et al, 2011 
(261) 
Kyle et al, 2006 (271) 
Young et al, 2013 (263) 
Almedia et al, 2012 (272) 
Bauer et al, 2005 (276) 
Velasco et al, 2011 (273) 
 
Soederhamn et al, 2002 
(277) 
Duerksen et al, 2000 (278) 
Cooper et al, 2002 (279) 






Kruizenga et al, 2005 (281) 
Leistra et al, 2013 (269) 
Harada et al, 2017 (282) 
Neelemaat et al, 2011 
(261) 















































Derived from serum albumin concentration and ratio of 
usual to present weight 
 
 
Tool containing nutritional components of the MUST along 






Three-point ordinal scale with 15 items assessing weight 

















26 questions related to eating and drinking difficulties, 










Peritoneal dialysis patients (n=283) 
Colorectal cancer (n=52) 
Oncology patients (n=725) 
 
Elderly inpatients (n=198) 
Medical and surgical (n=995) 
Elderly medical patients (n=134) 
Surgical inpatients (n=300) 
Acute geriatrics ward (n=121) 
Medical and surgical (n=400) 
 








Acute elderly care and elderly rehab 
(n=95) 
End stage renal disease (n=76) 







Medical, surgical and oncological 
inpatients (n=291) 
Medical and surgical outpatients 
(n=2236) 
Oncology outpatients undergoing 
chemotherapy (n=300) 
Medical and surgical inpatients 
(n=2211) 



















































































Relies on previous 
weight – limited use 
with changes in fluid 
status 
Ease of completing 















than in non-elderly, 
unable to predict 
severe malnutrition in 
ESRD, requires 
experienced operator 
















































Tool which assesses eight criteria including appetite, 
weight loss and level of spinal cord injury 
 
 
Nine questions assessing malnutrition risk/symptoms 




Questionnaire based on diagnostic criteria for malnutrition 
and muscle wastage 


















































scales to measure 
paralysed patients 
 
Patients picked up for 









SPSM (Short Portable Sarcopenia Measure), CASCO (Cachexia Score), BAPEN (British Association for Parenteral and Enteral Nutrition, BNST (British Nutrition 
Screening Tool), CNST (Canadian Nutrition Screening Tool), CONUT (Controlling Nutritional Status), EDC (ESPEN Diagnostic Criteria for Malnutrition), GNRI (Geriatric 
Nutrition Risk Index), INSYST (Imperial Nutritional Screening System), MST (Malnutrition Screening Tool), MSTC (Malnutrition Screening Tool for Cancer), NRI 
(Nutritional Risk Index), NRS-2002 (Nutritional Risk Screening), NUFFE (Nutritional Form For the Elderly), SGA (Subjective Global Assessment), SNAQ (Short 





3.4.2 Tools with evidence of validity, reliability and acceptability 
The available validity, reliability and acceptability data are summarised in 
tables 6 and 8.  Table 7 assesses how well each tool encompasses the criteria 
in the chosen definitions. Assessment of bias is shown in table 9. 
 
3.4.3 Sarcopenia 
In total two tools were found that were validated for the assessment of 
sarcopenia (SPSM and SARC-F). Three other tools assessed muscle function 
but no other tools made an assessment of muscle strength, mass or wasting. 
Both tools which were validated for the assessment of sarcopenia were done 
so in the community setting. They agreed with the SCWD diagnostic criteria 
but the SARC-F showed variation in agreement against the three consensus 
definitions it was validated against (EWGSOP, IWGS criteria and the Asian 
working group for sarcopenia). The SARC-F had good specificity (94.2-99.1%) 
but poor sensitivity (3.8-9.9% dependent on sex) and also showed good 
agreement (0.78-0.90). Values for the SPSM were not assessed.  
 
3.4.4 Cachexia 
Only one tool had been validated for the screening of cachexia – the CASCO. 
Overall six tools quantified weight loss within a specified time frame, with a 
further three quantifying it within an unspecified time frame. Sixteen tools 
characterised weight loss as unintentional. Only seven tools asked about the 
presence of underlying disease and only the CASCO took into account the 
 156 
presence of raised inflammatory markers and quality of life. Sensitivities and 
specificities were not recorded for the CASCO but it scored well in the 
assessment of its validity with it being able to quantitatively classify stages of 
cachexia. Its ability to predict patient’s outcome was not assessed. 
 
3.4.5 Malnutrition 
Nineteen screening tools were found to be validated for the assessment of 
malnutrition. However, only twelve of these incorporated a question about 
dietary intake or decline. Six measured percentage weight loss over time and 
13 assessed BMI. In particular those tools which had high sensitivities and 
specificities (MSTC and SNST) did not encompass all parts of the agreed 
definition: The SNST did not assess BMI and the MSTC made no assessment 
of quantifying weight loss within a specified time frame. The 3 MinNS was the 
tool which incorporated the consensus definition criteria and also had high 












Table 6 Psychometric evaluation of tools to measure unintentional weight loss 
u = tool assessed for and found to be valid   X = tool assessed for and found not to be valid - = tool not assessed for/not enough information provided 
 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7 Domains assessed by tools to measure relevant parameters required to identify risks of malnutrition, 
sarcopenia and cachexia 
  Patient reported weight loss BMI & FFM 
measurements 
Nutritional intake Assessment of 
muscle mass 
and function 





















































































































Cachexia CASCO X ü 
 
X X ü 
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Table 8 Sensitivity, specificity, predictive values, and reproducibility of 




Sensitivity Specificity PPV NPV Agreement 
Woo et al, 2014  
 





























Argiles et al, 2017  CASCO - - - - - 
Weekes et al, 2004  
 
Mirmiram et al, 
2011  
 
Laporte et al, 2015  
 
Ignacio et al, 2005  
 
Guerra et al, 2017  
 
Abd-El-Gawad et 
al, 2014  
 
Tammam et al, 
2009  
 
Kim et al, 2011  
Ferguson et al, 
1999  
Isenring et al, 2006  
Neelemaat et al, 
2011  
Nursal et al, 2005  
Young et al, 2013  
Wu et al, 2012  
Bhuachalla et al, 
2018  
Leipold et al, 2018  
 
Kim et al, 2011  
 
Boleotome et al, 
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Sharma et al, 2017  
Neelemaat et al, 
2011  
Kyle et al, 2006  
Young et al, 2013  
Almedia et al, 
2012  
Velasco et al, 2011   
Bhuachalla et al, 
2018  
Prasad et al, 2012  
Faramarzi et al, 
2013  
Bhuachalla et al, 
2018  
 
Neelemaat et al, 
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Soederhamn et al, 
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Xia et al, 2016  
 
Duerksen et al, 
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Cooper et al, 2002  
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2014  
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Susetyowati et al, 
2014  
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1.Representativeness of the 
sample 
2. Sample size justified 
3. Response rate 
satisfactory 
4. Ascertainment of 
exposure (validated 












































































































































































































































































Comparability (max 2 stars)                                       
1.The study controls for 
disease severity 
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Outcome (max 3 stars)                                       
1. Assessment of outcome 
















































































Total (Out of 10) 7 6 5 5 6 6 6 5 6 6 6 6 4 5 4 7 4 7 5 4 4 6 6 5 6 5 4 5 5 7 7 6 4 6 6 4 5 5 






Whilst recent systematic reviews have described the results of studies 
examining malnutrition screening tools, to our knowledge this is the first review 
to examine tools that have been validated against another to assess cachexia, 
sarcopenia and malnutrition. There has only been one prior review on tools for 
cachexia, sarcopenia and malnutrition (287). This review did not include 
psychometric evaluation, did not comment on the validity of the tools, nor 
compare them to the agreed consensus definitions. Existing systematic 
reviews of malnutrition screening tools have been limited to describing tools 
that are non-disease specific and ‘quick and easy’ or have been narrative in 
nature. 
 
Thirty-eight studies describing 22 tools were identified and judged for validity 
against a reference method. In the absence of a generally recognised gold 
standard for screening, assessment by a professional, DXA, CT, MRI, 
anthropometry or the screening tools SGA and MNA were considered ‘valid’ 
reference methods by our research group (247,278–280). Although cross 
sectional imaging is now used routinely for body composition analysis, only 
three tools identified were validated against CT. The heterogeneity in 
populations, age groups, tools and reference methods was large, and 
therefore pooling of results was impossible. Most tools had only been tested 




There were too few disease-specific tools to conclude which would be superior 
for different disease processes.  
 
3.5.2 Problems with current screening tools 
For the generalised adult population, all tools showed inconsistent results 
regarding their validity. The SGA which is often considered to be the industry 
standard (288) and against which many tools are validated has not itself been 
well validated. It performed well against the diagnostic criteria but sensitivities 
and specificities were either not recorded or poor. Arguably the most well-
known tools ‘MUST’ and ‘NRS-2002’ showed a variation in results from poor 
to good (261,263,268–273,276), and consistency between groups in which the 
tools were studied was poor. The less well-known NUFFE showed good 
validity, but it has been described in only a small volume of literature and is not 
implemented widely (277). The “quick and easy” screening tools, including 
SNAQ and MST performed reasonably (sensitivities ~80%) in most studies in 
which they were used (259–264,269,281,282). Of note because these tools 
are quick, they require a further detailed assessment by a qualified health 
professional if screening is positive. They also miss approximately 20% of at 
risk patients at initial screen and therefore may be more useful in screening 
high risk patients. 
 
The tool which performed the best for malnutrition was the 3MinNS (286). It 




the correct diagnostic criteria (percentage weight loss over specified time and 
measurement of BMI) for malnutrition. It was validated in acute medical and 
surgical patients and proved quick and easy to complete. It has only been 
validated in one paper and therefore it cannot be assumed that it would 
perform as well in different patient populations. Both tools which assessed 
sarcopenia (SPSM, SARC-F) scored well against the agreed definition 
(249,250). However, the SPSM required transport of equipment and the 
SARC-F had a very low sensitivity (247,249). The CASCO was the only 
validated screening tool for cachexia (251). It performed well against 
diagnostic criteria, but sensitivities and specificities were not recorded. It has 
also only been validated in the cancer setting; more work would be needed to 
validate the tool in other cachectic populations or the general adult population.  
 
Most tools were validated in the adult hospital inpatient setting. Tools for 
sarcopenia have only been validated in healthy, community dwelling 
individuals (249,250). Length of hospital stay is diminishing worldwide and 
outpatient nutritional screening is advocated to pick up patients at risk. In this 
review, we identified eight studies in which outpatients were included. More 
studies focussing on the construct and predictive validity of tools for outpatient 
screening are warranted, especially since care is shifting to this setting. 
 
The tool which appeared to have the broadest coverage was the CASCO 




the variables required for a diagnosis of malnutrition. However, assessment of 
muscle mass or function (required for sarcopenia) is not included. One 
previous review showed that 20 screening tools appeared relevant for 
starvation, but none contained all the currently accepted components needed 
to screen for sarcopenia and cachexia risk (287). This study supports this.  
 
3.5.3 Outlook and recommendations for future tools 
A screening tool needs to be developed that encompasses the criteria to pick 
up all three possible syndromes. This concept is supported by the notion that, 
in the human being, there may be no “pure” phenotype of cachexia, as it is 
usually associated with reduced food intake (potential for malnutrition) and 
increasing age (increasing sarcopenia) (289). There is also currently a lack of 
agreement as to the diagnostic criteria of each syndrome and the relative 
importance of body composition analysis and the nature of depleted tissue 
within each definition. It was hypothesised that the overlap between 
syndromes could be illustrated as in figure 20 along with the identified best 













Figure 20 Overlap between cachexia, sarcopenia and malnutrition 
Figure demonstrates similar clinical presentation between the three conditions 
 
 
There are clearly many existing validated screening tools (at least for 
malnutrition). It is unlikely that any further novel tools will be devised without 
breakthroughs in biomarker development. We therefore suggest that the ideal 
composite tool incorporate a stepwise assessment of nutritional status; oral 










derangement. The presence of underlying disease is a key question in order 
to stratify the syndromes. Suggested components for use in creating a new 
tool are depicted in table 10. 
 
1. Quantification of weight loss 
2. Measurement of BMI 
3. Assessment of appetite/dietary intake and decline 
4. Underlying health state – is there the presence of chronic 
disease? 
5. Take into account patient’s age (i.e. >60 more likely to be 
sarcopenic) 
6. Assessment of muscle mass and function 
7. Measurement of metabolic derangement/raised CRP 
8. Gender  
 
Table 10 Suggested components for use in creating a new screening tool 
 
 
By screening for all three syndromes, it will allow for a more targeted 
intervention. Screening for cachexia, sarcopenia or malnutrition is not 
warranted unless it is accompanied by an intervening care plan. It would be 
expected that an adequate intervention would prevent any further decline in 




Most studies did not comment on intervention, which depending on the 
balance of the three syndromes may need to include varying attention to 
nutrition, exercise and measures to combat inflammation. 
 
3.5.4 Strengths, limitations and assessment of bias 
One of the strengths of this review is that it provides a complete overview of 
tools that have been validated for cachexia, sarcopenia and malnutrition. It did 
not describe reliability, repeatability or other clinical outcome measures in any 
great detail. The review used the consensus definitions of each syndrome, 
however,  many other definitions exist. There were a number of study 
limitations. There was a risk of bias when assessing each tool for their 
predictive validity. Studies may have been biased if they did not adjust for 
factors such as cancer stage or disease severity. As clinical outcome is 
affected by more than just nutritional status alone adjusting for these variables 
is important. Nutritional intervention is likely to improve outcomes for 
malnutrition but potentially not for age-related sarcopenia or established 
cachexia. Only one study discussed whether they did this. There is no agreed 
‘gold standard’ tool and therefore cross sectional imaging and the SGA and 
MNA were chosen based on the results of previous studies (247). Tools that 
were compared to potentially less valid standards were also included to allow 
a wider analysis. Full nutrition assessments were different in each study 
ranging from anthropometric to biochemical measures and full assessment by 




original papers in which there may have been varying definitions with regards 
to the subject group, syndrome or assessment undertaken. Another potential 
limitation is that modified versions of pre-existing tools were excluded. They 
were excluded as reliability and validity data would only relate to the modified 
tool and it was therefore difficult to assess improvements from the original. It 
is possible that these tools were being improved or evaluated more thoroughly. 
 
3.6 Conclusion 
This study has highlighted that many practitioners who regularly come into 
contact with patients suffering from weight loss are not able to easily screen 
between the conditions of cachexia, sarcopenia and malnutrition as there is no 
one validated tool which can be implemented for the assessment of all three 
conditions. The adaptation of existing screening tools incorporating all relevant 
criteria described in this review would be optimal for diagnosis and to direct 


























AGE AND SEX RELATED 























4.1 Overview of chapter 
The previous chapter has highlighted the difficulties in screening patients for 
cachexia. This chapter investigates the use of the current gold standard for the 
assessment of muscle mass in cancer patients. CT based cutoff values for 
determining low skeletal muscle mass are sex and BMI-specific, and have 
historically been driven by optimal stratification to predict mortality in cancer 
patients. Elderly patients may be sarcopenic at diagnosis and more patients 




The aim of the forth chapter was to investigate the age and sex-specific 
differences in skeletal muscle, visceral (VAT) and subcutaneous adipose 
tissue (SAT) in patients suitable for resection of oesophageal cancer. 
 
4.1.3 Methods 
This was a retrospective, observational, single-centre study. Medical records 
of patients who underwent neoadjuvant chemotherapy (NAC) and or 
oesophagectomy were reviewed. CSA at the third lumbar vertebrae on routine 
staging and post-chemotherapy CT were measured, and skeletal muscle, 
visceral and subcutaneous adipose tissue indexed for height. Intra-muscular 




CT. The association between age, sex, skeletal muscle and adipose 
measurements were examined.  
 
4.1.4 Results 
108 patients were included, 71 of those had undergone NAC. Failure to 
complete NAC occurred in 11 patients. Significant differences in body 
composition were seen between males and females and those above and 
below 60 years of age. Males had a higher baseline muscle and visceral 
adipose tissue mass (p=0.0123 and p=0.016) whereas females had higher 
levels of subcutaneous fat (p=0.017). Older patients and females lost 
significantly more fat following NAC (p=0.004 and p=0.008 respectively). 
Patients of all ages were found to lose muscle mass following NAC but there 
was no difference between rates of wasting by age or sex.  
 
4.1.5 Conclusion 
This is the first study to report variation in body composition in oesophageal 
cancer by age and sex. Rates of adipose wasting appear to be clinically 
significant in oesophageal cancer. Further studies are needed to define 












Several studies have used CT to evaluate outcomes in relation to low muscle 
mass in various groups e.g. cancer patients, patients undergoing surgery and 
those in intensive care. Most studies associate lower skeletal muscle mass 
with poor oncological and surgical outcomes. The majority of these studies 
demonstrate a linear relationship between skeletal muscle index and outcome, 
and very few have created cutoff points in order to distinguish between “low” 
and “normal” skeletal muscle mass. It is becoming increasingly apparent that 
cut points that were set for use in cancer patients cannot be applied to other 
groups and to older patients who may be sarcopenic by definition at diagnosis. 
Interpretation of muscle parameters is also made difficult since reference 
values in a healthy population are lacking.  
 
The body composition of contemporary cancer patients is highly variable with 
respect to the features of muscle and fat mass as well as the distribution of fat 
in abdominal and subcutaneous regions. The WHO identifies more than 600 
million adults as obese (BMI >30 kg/m2) meaning that BMI no longer provides 
an adequate assessment of body composition (210).  
 
Low subcutaneous adipose tissue index (SATI) has been independently 
associated with increased mortality in gastrointestinal and respiratory cancer 
patients. In the presence of sarcopenia however, the longest survival was 




highlighted sarcopenic obese patients to have particularly bad outcomes. The 
concept and impact of sarcopenic obesity therefore requires further 
investigation.  
 
Patients do not also necessarily lose or gain muscle and fat in equal measures. 
Muscle and adipose tissue parameters are likely to be associated with age, 
sex, BMI and ethnicity and these characteristics should be taken into account 
when interpreting body composition. In order to better quantify the severity of 
muscle and adipose tissue loss, in the elderly in particular requires scoring 
systems or reproducible cutoff values for differing age groups. With this in mind 
this chapter aims to investigate the age and sex related differences in body 
composition in patients suitable for potentially curative resection of 
oesophageal cancer.  
 
4.3 Methods 
This was a retrospective, observational single centre study. All data was 
acquired as part of routine clinical practice.  
 
4.3.1 Study population 
Medical records of individuals undergoing potentially curative resection for 
oesophageal malignancy were retrieved. These were all patients who had 
been recruited to previous cachexia studies and had undergone rectus muscle 




staging CT. Patients with locally advanced disease who had a WHO 
performance status 0-2 had preoperative chemotherapy [Epirubicin, Cisplatin 
and Capecitabine (ECX) or Epirubicin, Cisplatin and Fluorouracil (ECF) or 
Cisplatin and Fluorouracil (Cis5FU)]. For those patients who underwent pre-
operative chemotherapy a post-chemotherapy staging scan was also required.  
 
4.3.2 CT scan analysis 
CT analysis was performed as previously described. Cachexia was defined as 
>2% weight loss over the preceeding six months and low muscularity on CT. 
 
Due to variation in the interval between CT images acquired before and after 
chemotherapy (88 ± 31 days), change (Δ) in parameters of body composition 
that were observed between the diagnostic and post-chemotherapy CT 
assessment are expressed as Δ/100days. 
 
To determine the rate of either skeletal muscle or total adipose tissue loss 
during chemotherapy, patients were divided into four groups: (i) stable (gain or 
no loss); (ii) minimal rate of loss (iii) moderate rate of loss, or: (iv) severe rate 
of loss. Minimal rate of loss in muscle mass was defined by a loss of no greater 
than 6cm2 Δ/100days of CSA. Moderate rate of loss was defined as loss of 
between -6cm2 to -18cm2 Δ/100days, whilst severe rate of loss was considered 
in skeletal muscle CSA decreased by more than 18cm2 Δ/100days. In 




of no greater than 16cm2 Δ/100days of CSA. Moderate rate of loss was defined 
as loss of between -16cm2 to -70cm2 Δ/100days, whilst severe rate of loss was 
considered in total adipose tissue CSA decreased by more than 70cm2 
Δ/100days (290).  
 
4.3.3 Outcome measures 
The primary outcome measure of this study was variation in parameters of 
body composition (intra-muscular fat, skeletal muscle, visceral and 
subcutaneous adipose cross-sectional areas, SMI, SATI and VATI) by age and 
sex. Secondary outcomes were change in body composition following 
neoadjuvant chemotherapy (NAC). 
 
4.3.4 Statistical analysis 
Data were exported to Microsoft Excel (Microsoft Office, Washington, USA). 
Statistical analysis was performed using SPSS (version 24.0, IBM Corp., 
Armonk, USA). Patients were analysed based on age and sex. For staging 
scan data all patients were analysed by decade of life. For patients who 
underwent chemotherapy patients were divided into two age groups (<60 
years or 60 years and over). Dependent on their distribution, continuous 
variables are presented as either mean (standard deviation) or median 
(interquartile range, IQR). Comparison of continuous variables was performed 
using the Independent-Samples T test or Mann-Whitney U test respectively. 




groups was performed by one-way analysis of variance or the Kruskal-Wallis 
test. Categorical variables were compared using the chi-squared or Fisher’s 




4.4.1 Patient characteristics 
One hundred and eight patients (84 males and 24 females) were included. 
Baseline patient characteristics are presented in table 11. Patients were 
predominantly diagnosed with adenocarcinoma (81.65%) of the lower 
oesophagus or gastroesophageal junction. As all patients were deemed 
suitable for potentially curative surgery; none had metastatic disease. There 
were no differences between weight, BMI and percentage weight loss at 
diagnosis between age groups. Staging BMI, a marker of nutritional status 
often used in the outpatient setting was found to correlate poorly with muscle 












 Age group (years) 
<49 50-59 60-69 70-79 80-89 P 
Value 
N 5 26 38 34 5 N/A 






































Type of cancer 
(ACC:SCC:Other) 
5:0:0 21:4:1 31:7:0 27:6:1 5:0:0 N/A 
Cancer location 
(UO:LO:GOJ) 
0:4:1 2:17:7 2:29:7 1:27:6 0:4:1 N/A 
 
Table 11  Staging patient demographic details 
 
Data are Mean (SD) 
 
ACC – adenocarcinoma, SCC – squamous cell carcinoma, UO – upper 








R2=0.2072     R2 = 0.4437 
 
R2 = 0.2699 
 
Figure 21 Variation in muscularity and adiposity on staging CT scan in 
patients suitable for potentially curative resection of oesophageal cancer 
(N=108).  
 

























































4.4.2 Variation in staging body composition parameters 
 
None of the patients under 50 years were sarcopenic at diagnosis, this 
increased to 80% in the >80 years group with those in the middle displaying a 
similar prevalence (42, 40 and 58% for the age 50-59, 60-69 and 70-79 year 
groups respectively). Although not significant staging SMI was the lowest in 
the 80-89 years age group [43.13 (3.54) compared with 55.29 cm2/m2 (10.52) 
in the <50 group, p=0.207]. The oldest patients also had the lowest VATI and 
SATI on staging scan [30.50 (12.85) p=0.005 and 35.92 cm2/m2 (15.39) 
p=0.132 respectively]. IMAT CSA was significantly different between age 
groups (p=0.003). Staging TATI and total adipose CSA also differed by age 
(p=0.030 and p=0.016). This is summarised in table 12 and figure 22. 
 
Again none of the patients under 50 met the diagnostic criteria for cachexia 
(>2% weight loss and low muscularity on CT), but this increased to 40% in 
those over 80 years. Staging SMI and muscle CSA was lower in cachectic 
patients but there were no differences in any measures of adipose tissue at 
diagnosis between those who were cachectic and non-cachectic by consensus 
definition (2% weight loss and low muscularity). Sarcopenic obesity was 








 Age group (years) 





























































































































Table 12  Variation in staging body composition parameters by age 
Mean (SD) *Denotes significant result 
SMI measured in cm2/m2 







Figure 22 Staging indices on CT scan by decade of life 
 
Staging SMI decreases with age. IMAT increases with age. Staging levels of 
SATI, VATI and TATI are variable by decade. SATI and TATI increases until 
the age of 69 then appears to decrease. Staging VATI appears to increase by 
decade but is lowest in those aged over 80. 
 














Women weighed significantly less at diagnosis (74 vs 83kg, p=0.029). There 
was no difference in BMI or weight loss at presentation between sexes 
(p=0.489 and p=0.658). There was a significant difference between staging 
muscle CSA and SMI with males displaying higher muscle mass (P<0.001, 
p=0.012). Females had a higher SAT CSA and SATI (290.65 vs 180.98 cm2 
and 109.11 vs 58.83 cm2/m2, p=0.015 and p=0.003) and males had a higher 
VAT CSA and VATI (204.61 vs 123.11 cm2, p<0.001 and p=0.007). This data 























83.22 (16.36) 74 (17.81) 0.029* 
Staging BMI 
(kg/m2) 
27.00 (5.36) 27.98 (6.22) 0.489 
% weight loss 4.21 (5.37) 4.83 (6.16) 0.658 
Staging SMI 49.29 (9.49) 44.40 (7.61) 0.012* 
Staging SATI 58.83 (31.38) 109.11 (73.90) 0.003* 
Staging VATI 66.67 (34.74) 46.31 (29.81) 0.007* 
Staging TATI 125.20 (56.19) 155.41 (88.30) 0.124 
Staging IMAT 
CSA 
12.15 (7.70) 9.69 (4.32) 0.055 
Staging muscle 
CSA 
151.42 (28.78) 117.52 (24.95) <0.001* 
Staging SAT 
CSA 
180.98 (97.21) 290.65 (200.07) 0.015* 
Staging VAT 
CSA 
204.61 (104.98) 123.11 (81.06) <0.001* 
Staging total 
adipose CSA 
397.45 (173.26) 422.64 (242.82) 0.638 
Table 13 Variation in staging body composition parameters by sex  
SMI measured in cm2/m2 CSA measured in cm2 
 







Figure 23 Staging indices on CT scan by sex 
 
Males have higher staging SMI, IMAT and VATI whereas females have 
higher SATI and TATI 
 












4.4.3 Variation in body composition parameters following 
chemotherapy 
 
Seventy-one of the patients included in the study had NAC and thus an 
available second CT. No one aged over 79 was given NAC. There were 21 
patients aged under 60 years and 50 patients aged 60-79 years. There were 
no differences in weight, BMI or percentage weight loss at diagnosis between 
age groups or sex. Sarcopenia at staging was more prevalent in those aged 
over 60 years (42% compared with 33%). Rates of low subcutaneous fat mass 
were the same between groups (33% each) with those under 60 having a 
higher prevalence of low visceral adipose tissue mass (62% vs 30%) (figure 
24). Pathology was predominantly adenocarcinoma of the lower oesophagus. 
This data is summarized in tables 14,15 and 16 and figure 25. 
 
Figure 24 Prevalence of low muscle and adipose indices on staging scan 
in those patients undergoing neoadjuvant chemotherapy  



























Chart to show prevalence of low muscle and 
adipose indices on staging scan




 Age group (years) 
<60 years 60 years and 
over 
P Value 
N 21 50 N/A 
Male:Female 17:4 39:11 N/A 
Staging weight 
(kg) 
79.24 (15.89) 81.63 (16.92) 0.57 
Staging BMI 26.10 (5.11) 27.41 (5.79) 0.35 
% weight loss 4.78 (5.35) 5.35 (6.21) 0.70 
Cancer type 
ACC:SCC 
18:3 40:10 N/A 
Cancer site 
UO:LO:GOJ 
5:10:6 1:43:6 N/A 
 













 Age (Years) 
<60 60 and over P Value 
Staging muscle 
CSA 
154.55 (35.71) 145.19 (28.64) 0.295 
Staging SAT 
CSA 
180.91 (117.07) 228.60 (157.44) 0.166 
Staging VAT 
CSA 
138.91 (89.99) 205.84 (103.21) 0.012* 
Staging IMAT 
CSA 
8.97 (4.35) 12.56 (7.36) 0.013* 
Staging total fat 
CSA 
328.79 447.00 0.024* 
Staging SMI 50.86 (10.63) 48.71 (9.00) 0.420 
Staging SATI 60.39 (40.85) 77.20 (58.58) 0.173 
Staging VATI 45.58 (29.61) 68.13 (33.23) 0.007* 
Staging TATI 105.97 (65.78) 145.33 (66.81) 0.028* 
 
Table 15 staging CT data for patients undergoing neoadjuvant 
chemotherapy by age 
 
SMI measured in cm2/m2 









Figure 25 CT staging data by age in patients undergoing neoadjuvant 
chemotherapy 
 
Older patients have lower SMI and higher adipose tissue indices 
 











 Sex  
Male Female P Value 
N 56 15 N/A 
Weight 76.24 (24.67) 73.88 (24.95) 0.748 
BMI 26.69 (5.26) 28.28 (6.78) 0.410 
% weight loss at 
diagnosis 
4.60 (5.57) 6.31 (7.05) 0.397 
Staging muscle 
CSA 
155.19 (29.08) 120.99 (21.75) <0.01* 
Staging SAT 
CSA 
184.30 (97.32) 327.21 (233.67) 0.035* 
Staging VAT 
CSA 
201.15 (101.76) 129.63 (92.65) 0.016* 
Staging IMAT 
CSA 
11.77 (7.23) 10.49 (4.86) 0.426 
Total fat CSA 397.22 (170.02) 467.33 (274.39) 0.359 
Staging SMI 50.6 (9.8) 44.8 (6.9) 0.013* 
Staging SATI 59.07 (31.05) 120.42 (87.22) 0.017* 
Staging VATI 65.15 (32.85) 47.68 (34.01) 0.089 
Staging TATI 124.07 (54.15) 169.60 (100.85) 0.111 
 
Table 16 Staging CT data for patients undergoing neoadjuvant 
chemotherapy by sex 
SMI measured in cm2/m2 






Eleven patients failed to complete all cycles and 73% did not receive any 
dietetic intervention or had no dietetic intervention noted. Mean CT interval 
























Patient characteristics Number of patients 
Chemotherapy regimens and tolerance: 
ECF – 4/3/2/1 cycles 
ECX – 4/3/2/1 cycles 
Cis5FU – 2/1 cycles 
Carboplatin & Taxal 








Dietetic intervention during NAC: 
None/not documented 

























Table 17 Details of chemotherapy regimens, nutritional supplementation 





Both age groups had a net overall loss of muscle following NAC however the 
amount of muscle lost and therefore the changes in muscle CSA and SMI were 
not significantly different (-7.71 v -13.00 cm2 and -2.67 v -4.56 cm2/m2, p=0.398 
and 0.380). Older patients (those >60 years) lost significantly more adipose 
tissue than their younger counterparts with significant changes in VAT CSA 
(7.66  v -17.75 cm2, p=0.014) and VATI (2.57 v -5.42 cm2/m2, p=0.026), SATI 
(-1.15 v -12.72 cm2/m2, p=0.035), total adipose CSA (5.95 v -45.46 cm2, 
p=0.004) and TATI (5.87 v -47.83 cm2/m2, p=0.004) seen. An overall net gain 
in adipose tissue CSA was seen in those under 60 years (table 18, figures 26 


















 Age (years)   
<60 60 and over P Value 
Change in 
muscle CSA 
-7.71 (21.07) -13.00 (29.51) 0.398 
Change in SAT 
CSA 
-7.10 (26.10) -31.78 (85.59) 0.069 
Change in VAT 
CSA 
7.66 (28.52) -17.75 (55.62) 0.014* 
Change in IMAT 
CSA 
0.30 (3.79) 2.38 (10.43) 0.222 
Total fat loss 
CSA 
5.95 (45.26) -45.46 (101.75) 0.004* 
Change in SMI -2.67 (6.89) -4.56 (10.69) 0.380 
Change in SATI -1.15 (9.16) -12.72 (35.19) 0.035* 
Change in VATI 2.57 (9.42) -5.42 (20.09) 0.026* 
Change in TATI 5.87 (45.06)) -47.83 (105.56) 0.004* 
 
 
Table 18 Change in tissue indices and area by age following 
neoadjuvant chemotherapy 
 
SMI measured in cm2/m2 






Figure 26 Change in tissue index following neoadjuvant chemotherapy 
by age 
 
Both age groups lost muscle mass. Those under 60 gained adipose tissue 
whereas those over 60 had a net loss of all types of adipose tissue 
 






Figure 27 Change in tissue area following neoadjuvant chemotherapy by 
age 
 
Both age groups lost muscle mass. Those under 60 gained adipose tissue 
whereas those over 60 had a net loss of all types of adipose tissue 
 










Following NAC both sexes lost muscle mass but this was not significantly 
different (-11.23 v – 12.24 cm2 for muscle CSA and -3.86 v -4.56 cm2/m2 for 
SMI, p=0.875 and p=0.76 respectively). Females lost significantly more 
subcutaneous adipose tissue (SATI: -3.25 v -31.90 cm2/m2, p=0.05) and had 
a higher overall total fat loss (-11.38 v -100.71 cm2 for total adipose CSA and 
-13.38 v -101.26 cm2/m2 for TATI, p=0.008 and p=0.006 respectively). This 




















 Sex P Value 
Male (n=56) Female (n=15) 
Change in SMI -3.86 (10.32) -4.56 (7.27) 0.76 
Change in SATI -3.25 (16.50) -31.90 (53.24) 0.05* 
Change in VATI -1.14 (15.37) -10.21 (24.71) 0.194 
Change in TATI -13.38 (83.39) -101.26 (105.41) 0.008* 
Change in IMAT 
CSA 
2.08 (10.00) 0.55 (3.38) 0.339 
Change in 
muscle CSA 
-11.23 (29.12) -12.24 (19.54) 0.875 
Change in SAT 
CSA 
-11.05 (47.84) -74.59 (121.87) 0.066 
Change in VAT 
CSA 
-6 (45) -27 (66) 0.263 
Total fat loss -11.38 (78.87) -100.71 (103.81) 0.006* 
 
Table 19 Change in body composition following neoadjuvant 
chemotherapy by sex 
 
SMI measured in cm2/m2 






Figure 28 Change in tissue index following neoadjuvant chemotherapy 
by sex 
 
Both sexes lost muscle mass. Females had greater losses of all types of 
adipose tissue 
 






Figure 29 Change in tissue area following neoadjuvant chemotherapy 
by sex 
 
Both sexes lost muscle mass. Females had greater losses of all types of 
adipose tissue 
 












Rates of muscle wasting did not significantly vary by age (p=0.122) whereas 




Figure 30 percentage rates of tissue wasting by age 




























Chart to show percentage rates of muscle 
wasting by age



























Chart to show percentage rates of adipose 
wasting by age





Those patients who had a more severe rate of muscle wasting also 
demonstrated a greater loss of total body fat [-86.88 cm2/m2 (123.17) in the 
severe wasting group, p=0.010]. Those patients with a severe rate of adipose 
wasting also demonstrated the largest change in SMI [-8.09 cm2/m2 (13.67) in 
the severe wasting group, p=0.026] as shown in figure 31. 
 
 




Those patients who had the most severe rate of muscle loss also had the 
largest loss of total adipose tissue. Those who did not complete chemotherapy 
had the largest loss of muscle mass (p=0.006) and gain in IMAT (p=0.001). 
Changes in fat mass between the two was not significantly different (figure 32). 
 
Figure 32 Changes in SMI and IMAT in those who did and did not 
complete chemotherapy 
Those who did not complete chemotherapy had higher loss of SMI and gain 





In this retrospective cohort study the significance of differences in adipose and 
skeletal muscle mass by age group and sex were investigated in patients with 
potentially curable oesophageal cancer. Females had a lower baseline muscle 
mass but interestingly there were no differences in baseline muscle mass by 
age.  Those who failed to complete chemotherapy showed the largest losses 
of muscle mass indicating they may be a particularly vulnerable patient group. 
Adipose depots differed in terms of baseline mass and predisposition to 
wasting. Older patients  had a higher baseline adipose mass but also 
demonstrated a greater amount of adipose wasting following chemotherapy. 
Females also showed a greater loss of subcutaneous adipose tissue in 
particular compared to males. Interestingly all patients demonstrated loss of 
muscle mass but this did not appear to be age or gender specific. To our 
knowledge this is the first study to examine the association between age, sex, 
body composition and oesophageal cancer.  
 
BMI which is frequently used as an easy method of body composition 
assessment does not differentiate between fat and fat-free mass. Despite wide 
variations between tissue areas and indices in this study, BMI was never 
shown to be different between age groups or sex. Any changes in body 
composition are therefore unlikely to be detected by clinicians and an 
understanding of the type of tissue being lost is required to associate 




subcutaneous adipose tissue distribution was found to differ between age 
groups and males and females. Patients over the age of 60 had greater loss 
of visceral, subcutaneous and total adipose tissue compared with those under 
60 who gained adipose mass following chemotherapy. Females also 
demonstrated a greater loss of subcutaneous and total adipose tissue. 
Visceral and subcutaneous depots differ in their metabolic activity with visceral 
adipose being shown to produce more inflammatory cytokines and adipokines 
therefore contributing to the inflammatory state found in cachexia (291). 
Subcutaneous adipose is a large producer of leptin which may confer benefits 
associated with insulin sensitivity, glucose and lipid metabolism (292). The 
impact of these differences in patients with cancer remain relatively unexplored 
but they highlight the need to evaluate cancer mortality not just on the basis of 
muscle wasting or total adiposity. 
 
Animal models have shown that fat loss occurs prior to muscle loss. Mice who 
were injected with lung carcinoma or melanoma cells showed fat loss occurred 
prior to muscle loss at early stages of tumour growth and that the rate of 
wasting was greater than that of muscle (159). Patient based studies have 
shown losses of subcutaneous and visceral fat following chemotherapy in 
colorectal and lung cancer and a further study in pancreatic cancer also 
indicated that the severity of wasting rather than the amount of visceral 
adipose tissue lost was a better indicator of survival (293). These patients also 




The rate of adipose tissue change was also much greater than that of muscle. 
The only other study undertaken in oesophagogastric patients demonstrated 
that patients with locally advanced cancers lost on average 6% fat mass 
following NAC (193). Little is known in general about the effects of chemo or 
radiotherapy which may induce alterations in body composition. Potential 
differences in fat loss however, have not been consistently demonstrated due 
to variations in the type of scans used in various studies (e.g. CT/DEXA) as 
well as differences in tumour type and stage (resectable or palliative). Studies 
also differ in the way they report fat mass – either by CSA or indexed for height. 
This study used both to allow for maximal comparison with others. Regression 
equations have also not yet been developed for adipose tissue in cancer 
however visceral adipose CSA at L3 has been shown to correlate with total 
body visceral adipose tissue volume in healthy controls (294).  
 
This was an observational study of changes in body composition and as such 
was not powered to detect differences in clinical outcomes. Patients in this 
study were chosen as they had been previously recruited to cachexia studies 
and had undergone muscle biopsy. They were therefore felt to be 
representative of the target population thus eliminating the risk of selection 
bias. There were large differences in numbers between age groups but this 
represents “real life” clinical practice. The risk of being diagnosed with 
oesophageal cancer is less in those under 50 and those over 80 are less likely 




identify the effects of changes in body composition following chemotherapy on 
surgical outcomes. It is also important to note that the association between 
changes in tissue mass and chemotherapy does not necessarily imply 
causality.   
 
4.6 Conclusion 
Alterations in fat mass between age groups and sexes appear to be 
significantly different. Little is known about the prognostic significance of these 
depots in large populations and it therefore requires investigation throughout 
cancer disease progression. Due to the role of adipose tissue in controlling 
aspects of metabolism further identification of mediators and mechanisms of 
fat loss in cancer would be helpful to identify those who would benefit from 









































5.1 Chapter overview 
 
The forth chapter has highlighted the importance of muscle wasting by 
showing that all patients with cachexia regardless of age or sex demonstrate 
loss of muscle mass. This fifth chapter moves on to investigate a possible 
mechanism of muscle loss involving the neuromuscular junction (NMJ). 
Despite sharing pathophysiological features with a number of other 
neuromuscular wasting conditions, the mechanisms underlying cachexia 
remain poorly understood. Studies using animal models have suggested that 
pathological targeting of the NMJ may play a key role in the pathogenesis of 
cachexia, but this has yet to be investigated in human patients.  
 
5.1.1 Objectives 
To determine if the NMJ plays a role in muscle wasting in cancer. 
 
5.1.2 Methods 
High-resolution morphological analyses were undertaken on NMJs in samples 
of rectus abdominis muscle obtained from patients undergoing surgery for 
gastrointestinal cancer and compared with control cases (N=30 individuals; 
n=1165 NMJs). Cancer patients included those with both cachexia (according 






5.1.3 Results  
Despite low SMI and a significant degree of muscle fibre atrophy noted in 
patients with cachexia, compared to weight stable cancer and control patients, 
NMJ morphology was fully conserved, with no significant differences observed 
in any of the major pre- and post-synaptic variables measured (including axon 
diameter, nerve terminal area and complexity, motor endplate area and 
fragmentation, and percentage overlap between pre- and post-synaptic 
structures). 
 
5.1.4 Conclusion  
NMJs remain structurally intact during cancer and cachexia, suggesting that 
denervation of skeletal muscle is not a major driver of disease pathogenesis. 
The absence of NMJ pathology in human cancer is in contrast to observations 
noted in animal models, and supports the hypothesis that intrinsic changes 
within skeletal muscle, independent of any changes in motor neurons, 














At present, the consensus definition of cancer cachexia confirms loss of 
skeletal muscle as a key feature of the condition (28). Cancer cachexia is 
largely mediated by pro-inflammatory cytokines and tumour associated 
mediators, which results in the activation of catabolic pathways in skeletal 
muscle (295). In this regard, cancer cachexia shares many of the muscle-
specific and systemic inflammatory pathways common to the muscular 
dystrophies (49,296,297).  
 
Although the majority of cachexia research to date has focused on muscle 
abnormalities as the major locus of pathophysiology, many lines of evidence 
have implicate NMJs a critical and early mediator of neuromuscular 
dysfunction and breakdown, as denervation represents a common, key 
hallmark of several, related muscle wasting conditions and neuromuscular 
diseases (298–301). For example, NMJ pathology is considered to represent 
an early and key driver of neuromuscular defects in age-related sarcopenia 
(302–304), driven at least in part by an age related loss of lower motor neurons 
and motor axons (305). As cachexia and sarcopenia share similar molecular 
mechanisms (306) and as cachexia is considered to be a multifactorial 
syndrome that includes components of both age-related sarcopenia and bed 
rest/reduced physical activity (289), the NMJ has similarly been implicated in 
the pathogenesis of cachexia. Moreover, the identification of displaced 




has previously been used to suggest the presence of denervation (50). 
Furthermore, a member of the UPP pathway (MuRF1) that is pivotal to muscle 
wasting in tumour-bearing mice (and other murine models of muscle wasting) 
has been shown to be critical to the maintenance of NMJs (307). Additionally, 
recent mouse studies of mTOR signalling, a key regulator of protein synthesis 
that is suppressed by inflammatory mediators in cancer cachexia (308,309) 
have shown that muscle specific-deletion of mTOR or Raptor results in muscle 
fibrillation or NMJ fragmentation.  
 
The role of the muscle-nervous system interface in human cachexia is 
therefore of particular importance to both basic and clinical scientists, and 
relevant to both our understanding of disease pathophysiology and the 
development of effective treatments. Previous studies in patients with heart 
failure and cardiac cachexia have shown good correlation between body 
composition and levels of C-terminal fragment of agrin, a proteoglycan 
important for forming NMJs (310). Similarly, cancer cachexia has been the 
subject of co-culture/informatics projects (311) and ongoing patient studies 
(see ClinicalTrials.gov identifier NCT03477721 “NUMANCAN study). 
Nevertheless, experimental evidence supporting a direct role for NMJs in 
human cachexia is highly reliant on studies of animal models. However, recent 
data have revealed striking and unexpected differences between the cellular 




organisms (e.g. mice (46)), suggesting that findings from animal models may 
not be directly applicable to human patients.  
 
The present study builds upon my collaborators recent work establishing a 
robust protocol to facilitate sampling and high-resolution, quantitative 
morphological analyses of NMJs from human patients undergoing surgery. 
These protocols have been adapted to facilitate a comprehensive analysis of 
the NMJ in cancer cachexia patients. Findings reveal that, in stark contrast to 
predictions from animal models, NMJs remain structurally intact and 
conserved during cancer and cachexia, suggesting that denervation of skeletal 
muscle is not a major driver of disease pathogenesis. 
 
5.3 Methods 
5.3.1 Patient recruitment 
Patients with a confirmed diagnosis of gastrointestinal cancer (oesophageal, 
gastric or colonic) suitable for surgical resection with curative intent were 
recruited from the regional multi-disciplinary team meeting (n = 20; Table 20) 
and comprised patients with both weight stable disease (n = 10) and cancer 
cachexia (n = 10) based on consensus definition. Suitable age-matched 
control patients undergoing a range of elective abdominal procedures (e.g. 
repair of aortic aneurysm or donor nephrectomy) were also approached prior 




ability to give consent. Exclusion criteria for the control cohort included 
previous history of malignancy.  
 
5.3.2 Body composition analysis 
SMI was calculated from routine staging CT performed prior to surgical 
intervention as previously described. Those patients who underwent NAC (n=5 
in the cachectic group and n=3 in the weight stable group) had their post 
chemotherapy re-staging scan analysed. SMI cut‐offs for low SMI were 
obtained from previously published reference data. Cachexia was defined 
according to standard consensus (>2% weight loss and low muscularity;) as 
this was the only definition, which has been shown to be associated with 
histological muscle wasting in previous studies (312). 
 
5.3.3 Tissue sampling 
Tissue sampling was performed under general anaesthesia at the start of the 
surgical procedure. All samples were obtained approximately 4 to 6 weeks 
following the cessation of chemotherapy. Biopsies of rectus abdominis (RA) 
muscle were obtained following initial opening of the abdomen. Rectus 
abdominis has an ‘in-series’ architecture, with motor endplate bands located 
throughout its length (figures 33 and 34) (313). To ensure successful sampling, 
a longitudinal strip of muscle lying between two contiguous tendinous 




Samples were immediately fixed in 4% paraformaldehyde (PFA) for 






Figure 33 Anatomical distribution of rectus abdominus muscles 





Figure 34 Differences between superficial and deep rectus 













5.3.4 Tissue processing and NMJ immunohistochemistry 
Teased muscle fibre preparations were immunohistochemically labelled for 
NMJ analysis. In order to visualise key pre-synaptic proteins (the synaptic 
vesicle protein SV2 and the neurofilament protein 2H3), with post-synaptic 
acetylcholine receptors (AChRs) labelled using rhodamine-conjugated alpha-
bungarotoxin. Optimal labelling was achieved with incubation in primary 
antibodies for 3 nights and secondary antibodies for 1 night. Samples were 
whole-mounted in Mowiol and stored at -20oC prior to imaging. 
 
5.3.5 Antibodies 
Primary antibodies: mouse monoclonal SV2 and 2H3 (1:50; Developmental 
Studies Hybridoma Bank, University of Iowa). Secondary antibodies: 
AlexaFluor-488-conjugated donkey anti-mouse IgG antibody (1:200; A21202, 
Life Technologies). Rhodamine-conjugated alpha-bungarotoxin (2 ug/mL; 
BTIU00012, VWR International). 
 
5.3.6 Confocal imaging and NMJ-morph analysis 
Confocal images of individual en face NMJs and their pre-terminal axons were 
acquired on a Zeiss LSM 710 or Nikon A1R confocal laser-scanning 
microscope, using standardised imaging approaches (46,314). In addition, 
individual muscle fibre diameter measurements were obtained on an Olympus 
IX71 microscope and Hamamatsu C4742-95 camera with Openlab 




standardised workflow (‘NMJ-morph’), as previously described. NMJ-morph 
data output generates 21 separate morphological descriptors for each NMJ 
(see table 21), including pre- and post-synaptic variables (e.g. nerve terminal 
area, motor endplate area, etc.), derived variables (e.g. nerve terminal 
complexity, motor endplate fragmentation, etc.) and related nerve and muscle 
measurements (including motor axon diameter and muscle fibre diameter). As 
per NMJ-morph guidelines, a total of 40 NMJs were analysed for each 
individual patient/muscle sample (n = 18), where possible, giving a complete 
dataset of 697 NMJs. Parameters assessed by NMJ morph are summarised 
















Figure 35 Parameters assessed by NMJ Morph. Stepwise process of analysis shown 




 Figure 36 Summary of methods used in NMJ 
analysis Tissue is sampled and fixed. It is then 
microdissected and IHC undertaken. NMJs are 
then imaged and analysed by NMJ morph 
IHC/IF were performed in collaboration with the University of Edinburgh Anatomy Department. Confocal imaging and 




5.3.7 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 Software. 
Results are expressed as mean (± standard error of mean [SEM]). Group 
comparison of normally distributed data (based on D’Agostino-Pearson test, P 
> 0.05) was performed by one-way analysis of variance (ANOVA) and Tukey’s 
post hoc test; non-parametric data was analysed by Kruskal-Wallis test and 
Dunn’s post hoc test. 
 
5.4 Results  
To investigate the role of the NMJ in cancer cachexia, a comprehensive 
morphometric analysis of the NMJ in samples of rectus abdominis muscle 
obtained from patients undergoing surgery for gastrointestinal cancer was 
performed. This case series included 10 patients with cancer cachexia, 10 
weight stable cancer patients and 10 controls. Patient demographic data is 
shown in Table 20. Mean ages were 64 years in the control group, 66 years in 
the weight stable group and 70 years in the cachexia group. Cachectic patients 
demonstrated significantly lower SMI by CT criteria compared with weight 
stable patients (Table 20). Cachectic patients with low SMI also demonstrated 
a trend towards lower subcutaneous adiposity and higher visceral adiposity 
compared with weight stable cancer patients. These two body composition 
phenomena are associated with worsened outcomes in cancer patients 




patients in the weight stable cancer group exhibited a small degree of weight 


























Table 20 NMJ Patient demographic data  Data are mean ± SEM
Patient Group 
(n = 10)
Ctrl Weight Stable Cachexia























F (2, 27) = 0.3887 0.682 -1.90 -4.10 -2.20
BMI
28.68 ± 1.32
(min 20.0, max 36.2)
27.00 ± 1.78




F (2, 27) = 1.096 0.349 1.69 3.00 1.31
% weight loss
0 % ± 0 %
(min 0 %, max 0 %)
0.89 % ± 0.5 %
(min 0 %, max 4.38 %)
7.99 % ± 1.65 %
(min 2.70 %, max 19.1 %) 22.71 < 0.0001 **** -3.400 % -16.10 % **** -12.70 % **
SMI
52.0 ± 2.08
(min 38.5, max 59.6)
56.9 ± 4.0




12.98 0.0015 ** -2.100 11.10 * 13.20 **
VATI
64.4 ± 9.85
(min 15.8, max 111.6)
53.0 ± 16.6




F (2, 27) = 0.644 0.5329 11.39 -9.342 -20.73
SATI
67.3 ± 14.0
(min 2.58, max 153.2)
60.3 ± 11.3
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 226 
To confirm/validate the patient groupings based on the clinical and radiological 
guidelines (% weight loss and SMI, respectively) muscle fibre diameters in 
rectus abdominis from the three groups were assessed. Mean muscle fibre 
diameter was found to be significantly reduced (by almost 20%) in the 
cachectic patients compared with both controls and those with weight stable 
disease (p < 0.0001; Figure 37). These observations are in keeping with 
previously published data showing marked muscle fibre atrophy in cachexia 



























Figure 37 Atrophy of skeletal muscle fibres in cancer cachexia 
 
Upper panel shows a box and whisker plot of muscle fibre diameters (MFD) in 
control (n = 10 patients), weight stable (n =10) and cachectic (n = 10) patients. 
Bottom panels are representative micrographs of single, teased muscle fibres 
from control (left), weight stable (middle) and cachectic (right) patients. Scale 
bar = 50μm. Cachectic patients had significantly reduced muscle fibre 
diameters compared with weight stable and control cases. Each group is the 
pooled data from ~40 measurements of muscle fibre diameter in each of 10 
patients (control n = 388, weight stable n = 362, cachexia n = 400 muscle fibres 
in total). The box contains the mean (+) and median (line) muscle fibre 
diameters for the group and encloses the central 90% of the data; the whiskers 
represent the SEM; outlying data points are shown beyond the whiskers. One-
way ANOVA paired with a Tukey’s post-hoc test (****P < 0.0001). 
 
Muscle fibre measurements were performed by Dr Ross Jones, 




Given that muscle fibre pathology/atrophy would be predicted to result from 
and/or lead to NMJ instability based on findings from animal studies, an initial 
qualitative assessment of NMJs across the three human patient groups was 
performed. Despite the presence of muscle fibre atrophy in the cachectic 
patients, NMJ morphology was indistinguishable from that observed in weight 
stable and control patients (Figure 38). NMJs of all three cohorts were noted 
to display the typical ‘nummular’ morphology characteristic of human NMJs, 
and despite the predicted heterogeneity in form across the complete pool of 
NMJs (Figure 39), there was no evidence of gross pathological changes or 


















Figure 38 Conservation of NMJ morphology in cancer cachexia 
 
Confocal micrographs of representative human NMJs from rectus abdominis in the 
three patient groups. Despite the heterogeneity in size and shape of individual NMJs, 
overall morphology was remarkably conserved across the three groups, with no 
evidence of NMJ pathology in either the cachexia or weight stable groups compared 
with controls. Axon and nerve terminals in green (2H3/SV2) and AChRs of the motor 






Figure 39 Structural integrity of the NMJ in cancer cachexia 
 
Morphometric analysis using NMJ-morph did not reveal any significant differences in 
NMJ architecture between the three groups, with NMJ morphology being conserved 
in both cachexia and weight stable disease. Data presented as a pair of charts 
(scatterplot, above; box & whisker plot, below) for key NMJ variables, including 
measurements of pre- and post-synaptic architecture and axon diameter. Scatterplots 
depict the ~40 individual NMJs (data points) for the 10 patients (1 to 10) in each group; 
the mean NMJ value is given by the red line; the observed heterogeneity is a normal 
feature of human NMJ morphology. Box and whisker plots constructed using the 
mean patient data in each group (10 patients; control NMJs n = 387, weight stable 
NMJs n = 386, cachexia NMJs n = 392). The box contains the mean (+) and median 
(line) values for each NMJ variable and encloses the central 90% of the data; the 
whiskers represent the SEM. One-way ANOVA paired with a Tukey’s post-hoc test 






Although initial qualitative observations suggested an absence of gross 
pathology at the NMJ, it is possible that more subtle changes in NMJ 
morphology could have still been present in the cachectic patients. A 
comprehensive NMJ-morph analysis of all patient NMJs was therefore 
undertaken (Table 21). NMJs from rectus abdominis were initially compared 
with an existing database of human NMJs from several lower limb muscles 
(including extensor digitorum longus, peroneus longus, peroneus brevis and 
soleus to determine their likeness (or otherwise) to established human NMJ 
morphology in other muscle groups. NMJ-morph analysis revealed 
comparable NMJ morphology in rectus abdominis and the four lower limb 


























F (DFn, DFd) or
Kruskal Wallis statistic P
Mean Difference








1) Nerve Terminal Area (μm2) 76.64 ± 6.89 76.62 ± 12.11 74.99 ± 10.01 F (2, 27) = 0.009 0.9909 0.011 1.646 1.635
2) Nerve Terminal Perimeter (μm) 143.62 ± 10.12 138.88 ± 14.25 134.93 ± 11.66 F (2, 27) = 0.128 0.88 4.741 8.682 3.941
3) Number of Terminal Branches 38.19 ± 3.47 36.88 ± 2.32 37.33 ± 2.50 0.008 0.9961 -0.300 0.000 0.300
4) Number of Branch Points 17.66 ± 3.26 17.12 ± 1.84 17.68 ± 1.93 F (2, 27) = 0.017 0.9831 0.540 -0.020 -0.559
5) Total Length of Branches (μm) 64.55 ± 6.33 62.14 ± 7.13 60.07 ± 5.98 F (2, 27) = 0.119 0.888 2.414 4.486 2.072
post-synaptic
6) AChR Area (μm2) 130.03 ± 9.69 128.97 ± 17.62 124.75 ± 15.01 F (2, 27) = 0.037 0.9635 1.061 5.287 4.225
7) AChR Perimeter (μm) 150.90 ± 9.47 154.14 ± 14.61 153.77 ± 18.95 F (2, 27) = 0.014 0.9859 -3.238 -2.868 0.371
8) Endplate Area (μm2) 240.77 ± 21.01 235.29 ± 32.27 221.51 ± 29.81 F (2, 27) = 0.125 0.8833 5.483 19.27 13.79
9) Endplate Perimeter (μm) 77.82 ± 4.27 78.32 ± 6.54 77.29 ± 6.68 F (2, 27) = 0.007 0.9926 -0.497 0.528 1.025
10) Endplate Diameter (μm) 27.29 ± 1.32 28.79 ± 2.44 27.96 ± 2.25 F (2, 27) = 0.133 0.876 -1.502 -0.678 0.824
11) Number of AChR Clusters 4.16 ± 0.29 4.20 ± 0.41 4.29 ± 0.45 F (2, 27) = 0.031 0.9694 -0.049 -0.136 -0.086
derived variables
pre-synaptic
12) Average Length of Branches (μm) 1.91 ± 0.11 1.82 ± 0.15 1.79 ± 0.10 F (2, 27) = 0.29 0.7506 0.098 0.126 0.027
13) Complexity 4.35 ± 0.15 4.34 ± 0.11 4.37 ± 0.12 F (2, 27) = 0.007 0.993 0.009 -0.012 -0.021
post-synaptic
14) Average Area of AChR Clusters (μm2) 42.29 ± 4.64 39.19 ± 4.05 38.49 ± 2.53 F (2, 27) = 0.278 0.7598 3.107 3.804 0.697
15) Fragmentation 0.65 ± 0.03 0.63 ± 0.04 0.63 ± 0.03 F (2, 27) = 0.107 0.8994 0.015 0.021 0.006
16) Compactness (%) 56.14 ± 1.33 56.88 ± 1.61 58.95 ± 1.11 F (2, 27) = 1.142 0.3341 -0.740 -2.812 -2.071
17) Overlap (%) 55.83 ± 5.11 65.90 ± 5.89 64.98 ± 5.23 F (2, 27) = 1.054 0.3624 -10.07 -9.148 0.919
18) Area of Synaptic Contact (μm2) 71.18 ± 7.59 81.81 ± 10.98 74.51 ± 4.41 F (2, 27) = 0.448 0.6433 -10.63 -3.332 7.295
associated nerve & muscle variables
19) Axon Diameter (μm) 1.15 ± 0.05 1.06 ± 0.08 1.06 ± 0.05 2.07 0.355 5.550 3.750 -1.800
20) Muscle Fibre Diameter 78.8 ± 1.00 79.8 ± 1.24 69.5 ± 0.97 53.66 < 0.0001 -4.311 148.5 **** 152.8 ****
21) Number of Axonal Inputs 1.08 ± 0.03 1.10 ± 0.03 1.11 ± 0.04 0.188 0.910 -1.6 -1.25 0.35
Table 21 NMJ Morph data. The mean values +/- SEM are listed for each patient group, representing the mean of the entire analysed 
NMJ data set. Statistical significance from a one-way ANOVA paired with a Tukey’s post-hoc test. Statistical significance of average 







Figure 40 Comparative anatomy of rectus abdominis (RA), extensor 
digitorum longus (EDL), peroneus brevis (PB), peroneus longus (PL) 
and soleus (S) in humans 
 
No major differences between the muscles were observed between lower limb 
muscles extensor digitorum longus (EDL, n = 10 patients), peroneus brevis 
(PB, n = 10 patients), peroneus longus (PL, n = 10 patients), soleus (S, n = 10 
patients) and rectus abdominis (RA, n = 10 patients). The lower limb data of 
10 patients from the previously published data set in Jones et al 2017 was 
chosen due to its completeness of pre- and post-synaptic parameters. 
Representative confocal images depicting the homogeneity in NMJ 
morphology across five different muscles. Heterogeneity in NMJ size is 
present in all five muscles. SV2/2H3 = synaptic vesicle 2 and neurofilament 
(presynapse, green); α-BTX = α-bungarotoxin (acetylecholine receptors, red). 






Quantitative NMJ-morph analyses confirmed that there were no significant 
differences in any aspect of NMJ morphology in the rectus abdominis across 
the three patient groups. Crucially, there was no evidence of denervation 
(given by % overlap between the nerve terminals and motor endplate). The 
identification of displaced mononuclei in cachectic patients and C26 tumour 
bearing mice have previously been used to suggest the presence of 
denervation (50). However, detailed analyses of the NMJ confirmed that 
denervation is not a major feature of pathogenesis in cachectic patients.  
 
Similarly, there was no evidence for increased NMJ fragmentation (breaking 
up of the motor endplate into discrete AChR islands) in either of the cancer 
groups compared with the control cases, a classical feature of NMJ pathology 
found in animal models of neurodegeneration (298–301). Animal models of 
cardiac cachexia have demonstrated disaggregation of AChRs in the soleus 
muscle of rats where heart failure was induced with monocrotaline (51). Again, 
detailed analyses of the NMJ confirmed that fragmentation of the NMJ is not a 
major feature of pathogenesis in cachectic patients.  
 
Alongside analyses of denervation and NMJ fragmentation, NMJ-morph 
analysis confirmed no statistically-significant changes in any of the other 
morphological variables investigated (Figure 39; Table 21); similar axon 
diameters (~1um) were observed across all 3 groups with no evidence of 








The complex pathogenesis involved in cachexia is not yet fully understood with 
theories about the involvement of the NMJ to date being largely based on 
animal models of sarcopenia (317–321). Since the consensus definition of 
cachexia focuses on the importance of muscle wasting, the NMJ could 
conceivably contribute through impaired transmission efficiency and impaired 
stability leading to denervation. Many morphological and electrophysiological 
changes have been observed at the NMJ in ageing animals including 
fragmentation, denervation, polyinnervation and axon sprouting. However 
whether these changes contribute to the pathogenesis of sarcopenia or 
cachexia still remains up for debate. In the present study the human NMJ was 
found to display a remarkable degree of structural stability in both cachectic 
and weight stable cancer patients, with no evidence of denervation or 
remodelling that has been demonstrated previously in animal models. These 
findings provide fundamental new insights into the role of the NMJ in cancer 
and cancer cachexia. 
 
A well-studied and major morphological change of the rodent NMJ is that of 




endplate into discrete AChR islands). It is thought to coincide with muscle 
weakness and has the potential to be reversed by exercise (298). However, 
some studies have shown that neuromuscular transmission is increased in 
ageing mice due to the increase in quantal content (322,323). Aging human 
NMJs have been associated with an increase in axon diameter and area of 
nerve terminal which has previously been shown to be associated with quantal 
content (314). Similar axon diameters (» 1µm) were observed across all 3 
groups (with no evidence of axonal swelling or neurofilament accumulation) in 
this study implying no increase in quantal content. A study of human NMJs has 
also shown no evidence of fragmentation into the 10th decade of life suggesting 
that age related fragmentation is limited to rodents (46). It is important to note 
however that although older patients were used in this study muscle mass and 
force was not measured. Animal models of cardiac cachexia have 
demonstrated disaggregation of nAChRs in the soleus muscle of rats induced 
with heart failure by monocrotaline. Aggregates of nAChRs were distributed as 
continuous branches that were elongated, smooth and fluorescent forming 
continuous channels along the muscle fibre and presented a spot or island 
pattern (51). This suggested that the NMJs had undergone potential 
fragmentation and remodelling. Investigation of nAChR subunit gene 
expression showed upregulation of the alpha1 and epsilon subunits of nicotinic 
AChR in the heart failure group (51). The present study disagrees with these 




patient groups. This again may be a feature of cachexia that is limited to animal 
models.  
Post mortem studies along with animal models have shown that sarcopenic 
loss of muscle fibres is linked to a loss of motor neurons associated with low 
muscle volume and contractility (321,324). In previous studies fast twitch fibres 
have demonstrated a greater reduction than slow twitch fibres in a sex-specific 
fashion (318). Rectus abdominis consists predominantly of type I (slow-
oxidative) and 2A (fast oxidative-glycolytic) fibres (325), whereas type 2B (fast-
glycolytic) fibres have been shown to be more susceptible to atrophy 
(326,327). Previous studies in rodents have shown correlations between fibre 
type switching and muscle atrophy in wasting diseases (318) and it is 
conceivable that the present observations may be confounded by such factors. 
Roles for displaced mononuclei in cachectic patients and C26 tumour bearing 
mice have been also been highlighted as a sign of denervation. Non-peripheral 
myonuclei have been observed upon denervation in the absence of molecular 
markers of muscle regeneration e.g. embryonic or fetal myosin. The number 
of nuclear clusters were also upregulated in cachexia alongside levels of 
neural cell adhesion molecule (NCAM); a marker of denervation suggesting 
this may be a underlying process in cachexia pathogenesis (50). Crucially in 
this study there was no evidence of denervation as evidenced by the 





Autophagy plays an important role in the regulation of the agrin-MuSK-Lrp4 
signalling axis in stabilising the NMJ. Several animal models and studies of 
human gene expression have demonstrated that activity dependent regulation 
of autophagy and the agrin-MuSK-Lrp4 signalling axis are of great importance 
in stabilising the NMJ (328,329). Based on these insights, agrin-derived 
fragments are currently being evaluated as biomarkers for age-related muscle 
wasting. Investigation of levels of C-terminal Agrin (a marker of muscle wasting 
caused by degeneration of NMJs) in patients with heart failure were elevated 
in the majority of patients who had DEXA proven muscle wasting suggesting 
a link between NMJ degeneration and cachexia (310). Remodelling of the NMJ 
is thought to precede sarcopenia and be due to a loss of proteins including 
lamin-a4, b2 or integrin-a3 (317). Altered expression of Lamin-a4 in particular 
has been noted in wild type NMJs prior to an age related decline in 
transmission (330,331). Lamin-a4 knock out mice have shown altered 
measures of NMJ transmission but no change in muscle wasting suggesting a 
role for loss of function only (330). Proteomic profiling in humans has revealed 
distinct distribution of active zone proteins (46) but functional measurements 




It should be noted that the cachectic patients recruited into the current study 




both low CT muscularity together with weight loss. They were found to have a 
significantly reduced mean muscle fibre diameter consistent with previous 
studies (312). This definition was deliberately chosen, rather than weight loss 
alone, to ensure the presence of histological wasting. However, this study only 
enrolled patients who were eligible for curative surgery. It is not possible, 
therefore, to draw conclusions concerning a possible role for the NMJ in the 
development of refractory cachexia or active muscle wasting.  
 
The groups recruited were not sex matched as this was an exploratory study 
and not designed to detect differences in sexual dimorphism. This may explain 
the higher muscle fibre diameter seen in the control group as they contained 
only male patients. There was still however a significant difference between 
the weight stable and cachectic groups which both contained female patients.  
 
All patients received intravenous atracurium besilate during anaesthesia, 
which competitively displaces acetylcholine from its receptor sites. Its half-life 
is 17-21 minutes, but whether it has longer-lasting effects on the form or 
function of the NMJ is not known (332). Importantly, therefore, samples from 
the current study were compared with lower limb samples from patients who 
had received spinal anaesthesia only. No differences were observed between 
these groups, suggesting that the choice of anaesthetic was unlikely to have 
had any significant impact on the morphological variables of the NMJ 




It is also important to note that the majority of patients in this study may have 
had some degree of age related sarcopenia that may co-exist with cancer 
specific loss of muscle and that the diagnostic criteria may not necessarily 
separate one from the other. The study only captured patients who were 
eligible for curative surgery and therefore it cannot be said if the NMJ plays a 
role in the development of refractory cachexia or active muscle wasting. The 
control patients used were a mixture of patients undergoing aortic aneurysm 
repair and donor nephrectomy. Whilst the aortic patients do not necessarily 
represent a completely healthy cohort, they do represent a group that are free 
of cancer. Previous CT based muscularity studies have highlighted varying 
measures of muscularity between different patient groups and therefore 




In summary, the NMJ retains full structural stability in both cachectic and 
weight stable cancer patients. This suggests that denervation of skeletal 
muscle is not a major driver of disease pathogenesis. The absence of NMJ 
pathology in human cancer is in contrast to observations noted in animal 
models, and supports the hypothesis that intrinsic changes within skeletal 
muscle, independent of any changes in motor neurons, represent the primary 




cancer cachexia, promotion of muscle hypertrophy using neural stimulation 





































ADIPOSE DEPOT GENE 















6.1 Chapter overview 
The fifth chapter focussed on understanding a possible mechanism of muscle 
wasting. The second forth however, had highlighted the need to better 
understand differences in adipose depot wasting. During cachexia, different 
adipose depots demonstrate differential wasting rates. Studies from animal 
models have suggested adipose tissue may be a key driver of muscle wasting 
through fat-muscle crosstalk but human studies in this area are lacking.  
6.1.1 Objectives 
This chapter aimed to perform global gene expression profiling of visceral 
(VAT) and subcutaneous (SAT) adipose tissue from weight stable and 
cachectic cancer patients and healthy controls. 
6.1.2 Methods 
Cachexia was defined as >2% weight loss plus low CT-muscularity. Biopsies of 
SAT and VAT were taken from patients undergoing resection for oesophago-
gastric cancer, and healthy controls (donor nephrectomy) (n=16 and 8 
respectively). RNA was isolated and reverse transcribed. cDNA was hybridised 
to the Affymetrix Clariom S Microarray and data was analysed using 
R/Bioconductor. Differential expression of genes was assessed using empirical 
Bayes and moderated-t-statistic approaches. Category enrichment analysis 
was used with a tissue-specific background to examine the biological context 




validated by qPCR. ELISA for Intelectin-1 was performed on VAT samples for 
the corresponding patients. The current cohort plus 12 additional patients from 
each group also had plasma Intelectin-1 ELISA carried out. 
 
6.1.3 Results 
In VAT versus SAT comparisons there were 2101, 1722 and 1659 significantly 
regulated genes in the cachectic, weight stable and control groups respectively. 
There were 2200 significantly regulated genes from VAT in cachectic patients 
compared to controls and 1253 significantly regulated genes from VAT in 
weight stable cancer patients compared to controls. The gene showing the 
largest difference in expression was Intelectin-1 (Omentin-1) (FDR corrected 
p=0.0001); a novel adipocytokine associated with weight loss in other groups. 
Genes involving inflammation were enriched in cancer and control VAT versus 
SAT though different groups of genes contributed. Energy metabolism and fat 
browning genesets were downregulated in cancer VAT as were key fat 
browning genes (e.g. UCP1).  
 
6.1.4 Conclusion 
SAT and VAT have unique gene expression signatures. VAT is metabolically 
active in cancer, and maybe a target for therapeutic manipulation. VAT may 
play a fundamental role in cachexia, but the downregulation of energy 
metabolism genes implies a limited role for fat browning in human cachectic 





Although the consensus definition of cancer cachexia (28)  emphasises loss 
of lean tissue (particularly skeletal muscle) as a key identifier in the diagnosis 
of the condition, the loss of adipose tissue in cancer cachexia is increasingly 
thought to play an important role (335). A better understanding of the 
physiological effects of cancer on adipose tissue would open new therapeutic 
avenues for treatment  resulting in improved outcomes.  
 
In cancer, the loss of adipose tissue is driven by lipolysis (338) rather than 
adipocyte apoptosis or necrosis. Mediators of lipolysis in cancer cachexia are 
largely unknown. In the past, increased mRNA expression of zinc-α2-
glycoprotein (ZAG), a proposed lipid mobilising factor, was identified in fat 
samples from cachectic patients; however, serum ZAG levels were unchanged 
from controls (339,340). Microarray analysis has revealed that changes in the 
transcriptome of subcutaneous fat in cachexia are opposite to those seen in 
obesity, underlining the importance of lipolysis (108). Visceral adipose tissue 
is thought to be lost more rapidly than subcutaneous adipose tissue during 
cachexia, suggesting differential adipose depot-dependent responses to the 
wasting process though this has not been consistently demonstrated in 
humans (341). Bioinformatic analysis of mRNA expression in visceral 
(omental) and subcutaneous adipose depots in non-cachectic, obese 
endometrial cancer patients demonstrated nineteen shared biological 




the fat depots (342). Recently, focus has concentrated on the concept of “fat-
muscle crosstalk” in cancer cachexia (335). Notably, genetic ablation of 
lipolytic pathways in adipocytes protects against muscle mass loss in animal 
models of cancer cachexia (159). Inhibition of lipolysis through genetic ablation 
of adipose triglyceride lipase (Atgl) or hormone sensitive lipase (HSL) was 
shown to reduce muscle wasting (159). These data support the loss of visceral 
fat driven by lipolytic mechanisms as an early event in cancer cachexia with a 
potential effect on skeletal muscle.  
 
Global gene expression profiling is an effective method to examine regulatory 
pathways in patho-physiological contexts (343). In previous studies, 
microarray analysis of skeletal muscle biopsies taken at the time of resectional 
surgery for UGI cancer revealed an 83-gene signature that was able to identify 
patients with >5% weight loss (344). In further studies, a transcriptomic 
comparison of sequential muscle biopsies (at surgery and 8 months post-
surgery) from UGI cancer patients revealed 1,868 regulated genes associated 
with cancer and weight loss (345). Contrary to expectation, the vast majority 
(94%) of genes were downregulated. Category analysis of the differentially 
expressed genes showed that both anabolic and catabolic process gene 
expression was suppressed in cancer. Furthermore, there was a lack of 
substantive overlap with transcriptomic signatures from endurance training, 




included lipid oxidation, fatty acid metabolism, and peroxisome pathways, 
implying a role for fat-muscle crosstalk in cancer cachexia (346). 
In the current study the global transcriptome of VAT and SAT depots in 
patients with confirmed cachexia was examined according to the diagnostic 
consensus definition  (>2% weight loss and low muscularity on CT; n=8) 
compared with weight stable cancer patients (n=8), as well as healthy controls 
undergoing donor nephrectomy (n=8). These data provide the first 
examination of global gene expression in these two fat depots in cancer 




6.3.1 Patient recruitment 
UGI cancer and donor nephrectomy patients were recruited as previously 
described. Subcutaneous and visceral adipose tissue biopsies were taken 
from all patients as well as fasting venous blood samples. CT body 
composition analysis was performed. Patients were divided into three groups: 
cancer cachexia (CC), weight stable cancer (CWS) and control (Ctrl). Cancer 
patients were defined as being cachectic based on the consensus definition 
(>2% weight loss and low CT muscularity). Patient demographics are 
described in terms of median (interquartile range). Kruskal Wallis test was 




6.3.2 RNA extraction of fat 
6.3.2.1 Cutting of fat 
Fat that had been stored at -80oC was placed in dry ice and transferred to a 
piece of aluminium foil for cutting. A surgical blade and forceps were used to 
cut the fat into the desired sections. The forceps and blades were cleansed in 
vircon after each sample was taken to remove macroscopically visible tissue. 
Samples that had not been thawed were placed back in their storage tube and 
into the -80oC freezer thereafter. 
 
Approximately 0.5cm of frozen fat was excised from the original biopsy sample 
and homogenised with 500μl of TRIzol. This step was performed as quickly as 
possible to ensure the tissue did not thaw. The lysate was centrifuged at full 
speed for three minutes and the supernatant removed by pipetting. It was then 
transferred to a new microcentrifuge tube. One volume of 70% ethanol was 
added to the cleared lysate and mixed immediately by pipetting. 700μl of the 
sample was transferred to an RNeasy spin column placed in a 2ml collection 
tube. This was centrifuged for 15s at >8000 x g (>10,000 rpm) and the flow-
through was discarded. 700μl Buffer RW1 was added to the RNeasy spin 
column and centrifuged for 15 seconds at > 8000 x g (>10,000 rpm) to wash 
the spin column membrane. The flow-through was discarded. 500μl of Buffer 
RPE was added to the RNeasy spin column and centrifuged for 15 seconds at 
>8000 x g (>10,000 rpm) to wash the spin column membrane. Ethanol was 




500μl of Buffer RPE was added to the RNeasy spin column and centrifuged 
for 2 minutes at >8000 x g (>10,000 rpm) to wash the spin column membrane. 
The RNeasy spin column was placed in a new 2 ml collection tube and the old 
collection tube containing the flow-through was discarded. This was 
centrifuged at full speed for one minute. The RNeasy spin column was placed 
in a new 1.5ml collection tube. 30μl of RNase-free water was directly added to 
the spin column membrane and centrifuged for one minute at >8000 x g 
(>10,000 rpm) to elute the RNA. The quality of the RNA was then tested on a 
nanodrop. 
 
6.3.2.2 Preparation of RNA with poly-A controls and synthesis of first 
strand cDNA 
2 μl of serially diluted Poly-A RNA control was added to 100ng of RNA. 
Nuclease free water was added as required to make the total volume 5 μl. On 
ice the first strand master mix was prepared. The volume required for one 
reaction was 4 μl of first strand buffer and 1 μl of first strand enzyme. 5 μl of 
master mix was added to 5 μl of total RNA/Poly-A control mixture. This was 
incubated for 60 minutes at 25oC, then for 60 minutes at 42oC in a thermal 
cycler using the “first strand cDNA synthesis” program. 
 
6.3.2.3 Synthesis of second strand cDNA 
On ice the second strand master mix was prepared. The volume required for 




enzyme. 20 μl of second strand master mix was added to each (10 μl) first 
strand cDNA sample. This was incubated for 60 minutes at 16oC, then for 10 
minutes at 65oC in a thermal cycler using the “second strand cDNA synthesis” 
program. 
 
6.3.3.4 Synthesis of cRNA by in vitro transcription 
The second strand cDNA samples were transferred to room temperature whilst 
the IVT master mix was prepared. The IVT master mix was also prepared at 
room temperature. The volume for one reaction was 24 μl of IVT buffer and 6 
μl of IVT enzyme, giving a total volume of 30 μl per reaction. 30 μl of IVT 
master mix was transferred to each (30 μl) of second strand cDNA sample. 
The IVT reaction was incubated for 16 hours at 40oC in a thermal cycler using 
the “in vitro transcription cRNA synthesis” program. 
 
6.3.3.5 Purification of cRNA 
Nuclease-free water was preheated to 65oC. Purification beads were mixed 
before use at room temperature. 80% ethanol wash solution was prepared. 
The purification beads container was mixed to resuspend the magnetic 
particles. 100 μl of the magnetic beads were added to each (60 μl) cRNA 
sample. These were mixed by pipetting up and down and transferred to a well 
of a U-bottom plate. They were further mixed by pipetting up and down and 
the incubated at room temperature for 10 minutes. The plate was moved to a 




magnetic stand the supernatant was carefully aspirated and discarded without 
disturbing the magnetic beads. 200 μl of 80% ethanol was solution was added 
to each well and incubated for 30 seconds. The ethanol was then slowly 
aspirated without disturbing the magnetic beads. This wash was repeated a 
total of 3 times. The final wash solution was completely removed. The 
magnetic beads were air dryed on the magnetic stand for 5 minutes until no 
liquid was visible. The plate was removed from the magnetic stand. 27 μl of 
the preheated (65oC) nuclease-free water was added to each sample and 
incubated for 1 minute. This was mixed well by pipetting up and down 10 times. 
The plate was moved to the magnetic stand for approximately 5 minutes to 
capture the magnetic beads. The supernatant which contains the eluted cRNA 
to a nuclease free tube. The purified cRNA was placed on ice and the cRNA 
yield was assessed using a NanoDrop. 
 
6.3.3.6 Synthesis of 2nd cycle ss-cDNA 
On ice 15 μg of cRNA was prepared in a volume of 24 μl nuclease free water. 
4 μl of 2nd cycle primers were added to each (24 μl) cRNA sample. This was 
incubated at 70oC for 5 minutes, 25oC for 5 minutes and 4oC for 2 minutes in 
a thermal cycler using the “2nd cycle primers cRNA annealing” program. The 
cRNA/2nd cycle primers were then placed on ice and the 2nd cycle ss-cDNA 
master mix was prepared. This included 8 μl of 2nd cycle ss-cDNA buffer and 
4 μl of 2nd cycle ss-cDNA enzyme giving a total volume of 12 μl for one 




cRNA/2nd-cycle primers sample. This was incubated for 10 minutes at 25oC, 
90 minutes at 42oC and then 10 minutes at 70oC in a thermal cycler using the 
“2nd cycle ss-cDNA synthesis” program. 
 
6.3.3.7 Hydrolysing RNA using RNase H 
On ice 4 μl of RNase H was added to each (40 μl) 2nd cycle ss-cDNA sample. 
This was mixed thoroughly, followed by a quick spin. This was incubated at 
37oC for 45 minutes in a thermal cycler using the “RNA hydrolysis” program. 
The hydrolysed 2nd cycle ss-cDNA samples were placed on ice and 11 μl of 
nuclease free water was added to each (44 μl) hydrolysed 2nd cycle ss-cDNA 
sample. This was mixed thoroughly and immediately frozen at -20oC. 
 
6.3.3.8 Purification of 2nd cycle ss-cDNA 
Nuclease free water was pre-heated to 65oC. Fresh dilutions of 80% ethanol 
were prepared. The purification bead container was mixed to resuspend the 
magnetic particles. 100 μl of the magnetic beads were added to each (55 μl) 
hydrolysed ss-cDNA sample. These were mixed by pipetting up and down, and 
transferred to a well of a U-bottom plate. 150 μl of 100% ethanol were added 
to each sample. These were mixed well by pipetting up and down 10 times 
and incubated for 20 minutes. The plate was moved to a magnetic stand and 
incubated for 5 minutes to capture the magnetic beads. The supernatant was 
carefully aspirated and discarded without disturbing the beads. Whilst still on 




and incubated for 30 seconds. The ethanol was slowly aspirated and discarded 
without disturbing the magnetic beads. This was repeated for a total of 3 
washes. The final wash solution was completely removed and the beads were 
left to air dry on the magnetic stand for 5 minutes until no liquid was visible. 
The plate was removed from the magnetic stand. 30 μl of the preheated (65oC) 
nuclease free water was added to each sample and incubated for 1 minute. 
Samples were mixed well by pipetting up and down 10 times. The plate was 
moved to the magnetic stand for 5 minutes to capture the magnetic beads. The 
supernatant which contained the eluted ss-cDNA was transferred to a 
nuclease free tube. The purified ss-cDNA was placed on ice and the yield was 
quantified using a NanoDrop. 
 
6.3.3.9 Fragmentation and labelling of ss-cDNA 
On ice 5.5μg of ss-cDNA was prepared in a volume of 31.2μl with nuclease 
free water. On ice the fragmentation and labelling master mix was prepared. 
This contained 10μl of nuclease free water, 4.8 μl 10X cDNA fragmentation 
buffer, 1μl of UDG, 10 U/μl and 1μl of APE 1, 1000U/μl giving a total volume 
of 16.8μl for each reaction. 16.8μl of the fragmentation master mix was added 
to each (31.2μl) 5.5μg ss-cDNA sample. This was incubated for 60 minutes at 
37oC, then 2 minutes at 93oC in a thermal cycler using the “fragmentation” 
program. On ice 45μl of the fragmented ss-cDNA was added to an individual 
well. The labelling master mix was prepared on ice. This contained 12μl of 5X 




a total volume of 15μl for each reaction. 15μl of the labelling master mix was 
added to each (45μl) fragmented ss-cDNA sample. This was incubated for 60 
minutes at 37oC, then for 10 minutes at 70oC in a thermal cycler using the 
“labelling” program. 
 
6.3.3.10 WT cartridge array hybridization 
The 20X hybridisation controls were heated for 5 minutes at 65oC in a thermal 
cycler using the “hybridisation control” program. The hybridisation master mix 
was prepared at room temperature.  
 
The hybridisation master mix was added to individual tubes containing the 
biotin labelled ss-cDNA sample to prepare the hybridisation cocktail.  
 
The hybridisation cocktail was incubated at 5 minutes for 95oC, then 5 minutes 
at 45oC in a thermal cycler using the “hybridisation cocktail” program. 80μl was 
loaded onto the array and hybridised with rotation at 60 rpm for 16 hours at 










Figure 41 Loading of hybridisation cocktail onto arrays 
Vent septa were opened and the hybridisation cocktail was pipetted into the 
load septa. Care was taken not to have any visible air bubbles in the arrays. 
 
 
6.3.3.11 Wash and staining 
Arrays were removed from the oven and the hybridisation mix extracted on ice. 
Each array was completely filled with wash buffer at room temperature. Vials 
containing 600 μl of stain cocktails 1 and 2 and 800 μl of array holding buffer 

























Figure 42 Fluidics  
protocol
Sample holder 









After washing and staining images were captured and cel files generated using 
the GeneChip Scanner 3000 (Thermofisher UK). The cel files can be accessed 
at the Gene Expression Omnibus using the ID GSE131835. A summary of this 


























Figure 43 Summary of transcriptomic analysis methods 
Nucleic acid 
Sample amplification and 
labelling 
Labelled sample injected 
into microarray 
Probe array hybridisation Probe arrays washed and 
stained 













Total RNA was extracted and cDNA was prepared as described above. First 
strand cDNA synthesis was carried out using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, cat no. 4368814) with 500ng total RNA 
input for each reaction. Quantitative PCR (qPCR) was carried out using 
Luminaris Hi Green Low ROX qPCR Master Mix (Thermofisher UK, Cat no. 
K0974) 5ul, 0.3ul forward and reverse primer at 10uM each and 3.4ul ddH2O. 
Primers were selected from the Primer Bank resource (347) except for ACTB 
and GAPDH. These latter primers were designed to span exons using the 
Primer-BLAST resource (348). Primer sequences are detailed in table 22. We 
selected primers to cover genes involved in inflammation (ACVR2A1, IL6, 
IL18), adipogenesis (LEPR, STAT5A, PDCD4), adipose browning (UCP1, 
PPARGC1A, PRDM16) as well as genes which demonstrated a substantial 
fold change by microarray data (ITLN1, ALOX15, PPARA). We also profiled 5 
genes to use as reference values in PCR data normalisation as recommended 
by the MIQE guidelines (349). PCR reactions were carried out on the 
Lightcycler 480 Instrument with the following protocol; 50oC, 2mins, 95oC 
10mins and 40 cycles of 95oC 15s and 60oC 60s before a final melting curve 
step using triplicate reactions per sample in 384 well plates. Analysis of qPCR 
data was carried out using the NormqPCR package in R/Bioconductor (350). 
The genorm method (351) was used to identify the four most stable control 
genes from ACTB, GAPDH, YWHAZ, POLR2A and PSMB2 and the geometric 
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Table 22 Primer sequences used in qPCR validation 
Gene Category Forward primer Reverse primer Primer Bank ID 
ACVR2A Inflammation GTTTGCCGTCTTTCTTATCTCCT GTCACCATAACACGGTTCAACA 65508448c1 
IL6 Inflammation ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG 224831235c1 
IL18 Inflammation TCTTCATTGACCAAGGAAATCGG TCCGGGGTGCATTATCTCTAC 342349317c1 
LEPR Adipogenesis ACCTCTGGTTCCCCAAAAAGG TTGGCACAGGCACAAGACAT 310923190c1 
STAT5A Adipogenesis GCAGAGTCCGTGACAGAGG CCACAGGTAGGGACAGAGTCT 221316717c1 
PDCD4 Adipogenesis GCAAAAAGGCGACTAAGGAAAAA TAAGGGCGTCACTCCCACT 313760536c1 
UCP1 Browning CAATCACCGCTGTGGTAAAAAC GTAGAGGCCGATCCTGAGAGA 194733736c2 
PPARGC1A Browning TCTGAGTCTGTATGGAGTGACAT CCAAGTCGTTCACATCTAGTTCA 116284374c1 
PRDM16 Browning CGAGGCCCCTGTCTACATTC GCTCCCATCCGAAGTCTGTC 289547570c1 
ITLN1 Microarray  AGTGTTGGACTGACAACGGC TACATCCGGTGACCCTCATTC 31542985c2 
ALOX15 Microarray  TGGAAGGACGGGTTAATTCTGA GCGAAACCTCAAAGTCAACTCT 40316936c2 
PPARA Microarray  TTCGCAATCCATCGGCGAG CCACAGGATAAGTCACCGAGG 61744436c2 
ACTB Reference AATGTGGCCGAGGACTTTGATTGC AGGATGGCAAGGGACTTCCTGTAA NA 
POLR2A Reference CCTGAGGGTGACGAGGATCT GTGCTTCCATTCCGCATACAG 306482654c2 
PSMB2 Reference ATCCTCGACCGATACTACACAC GAACACTGAAGGTTGGCAGAT 315139005c1 
YWHAZ Reference TGTAGGAGCCCGTAGGTCATC GTGAAGCATTGGGGATCAAGA 208973243c2 




Intelectin-1 concentration was assessed in the VAT and plasma using enzyme-
linked immunosorbent assay (ELISA) (Amsbio EH0564); sensitivity 
<46.875pg/ml; reference range: 78.125-5000pg/ml). A further 36 patients were 
recruited to increase the total of plasma samples to 20 for each group. Pre-
experiment dilution testing was performed on one plasma sample from each 
group. Based on standard curves produced, a medium target protein 
concentration was chosen (5000-50000pg/ml) 1:10 dilution. Reagents were 
prepared according to manufacturers instructions (Amsbio). Plates were 
washed twice with wash buffer before samples were added. Intra and 
interassay coefficients of variation were <8% and <10% respectively.  
 
0.1ml of 500pg/ml,2500pg/ml, 1250pg/ml, 625pg/ml, 312.5pg/ml, 156.25pg/ml, 
78.125pg/ml, standard solutions were aliquoted into the standard wells. 0.1 ml 
of Sample / Standard dilution buffer was added into the control (zero) well. 
0.1ml of sample was added into the test sample wells. The plate was sealed 
with a cover and incubated at 37 °C for 90 min. The cover was removed and 
the plate content discarded making sure the wells did not completely dry at 
any time. 0.1 ml of Biotin-detection antibody working solution was added into 
the above wells (standard, test sample & zero wells). The solution was added 
at the bottom of each well without touching the side wall. The plate was sealed 
with a cover and incubated at 37°C for 60 min. The cover was removed, and 
the plate washed 3 times with Wash buffer. 0.1 ml of SABC working solution 




was added into each well, the plate covered and incubated at 37°C for 30 min. 
The cover was removed and the plate washed 5 times with Wash buffer, each 
time the wash buffer was left in the wells for 1-2 min. 90 μl of TMB substrate 
was added into each well, the plate covered and incubated at 37°C in the dark 
for 15 minutes. Shades of blue can be seen in the first 3-4 wells (with most 
concentrated ITLN1 standard solutions), the other wells show no obvious 
color. 50 μl of Stop solution was added into each well and mixed thoroughly. 
The color changes into yellow immediately. The O.D. absorbance was read at 
450 nm in a microplate reader immediately after adding the stop solution.  
The standard curve was plotted as the relative O.D.450 of each standard 
solution (Y) vs. the respective concentration of the standard solution (X). The 
ITLN1 concentration of the samples was then interpolated from the standard 
curve.  
 
Tissue ELISA was carried out on homogenised VAT tissue. Adipose tissue was 
homogenised in RIPA buffer with added protease inhibitors (ThermoFisher, 
UK). Tissue aliquots were added to 1.5ml PowerBead tubes with 1.4mm 
ceramic beads (Qiagen cat no 13113) and shaken at 5000rpm for 20s with 10s 
rest on ice 3 times using the MagNALyser instrument (Roche, UK). The 
homogenate was centrifuged at 5000rpm for 15minutes at 4oC and the aqueous 
phase beneath the lipid cake and above the cell pellet was removed to a 
separate tube. Aliquots were diluted 1:20 in PBS and protein content quantified 
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using the Qubit 4 Protein Assay (ThermoFisher). The same ELISA kit was used 
for VAT and plasma (Amsbio EH0564). 
 
6.3.5 Statistical analysis 
Microarray were analysed using R/Bioconductor using an updated chip 
definition file (CDF) from the Brainarray resource (352) based on Ensembl 
gene definitions (ENSG version 22). Raw microarray data were normalised 
and filtered using the SCAN-UPC method (353). Expression intensity and UPC 
filters were set at 0 and 0.5 respectively. Use of these filters suggested 49% 
of the genes with probes on the microarray CDF were not expressed in 
adipose tissue. This is in line with my collaborators previous experience using 
GeneChip microarrays. Filtering also improved the clustering of samples by 
principle components analysis (PCA). Changes in differential expression were 
examined using empirical Bayes and a moderated t statistic implemented in 
the limma package (354) with subject identifier as a blocking factor in linear 
modelling to account for the repeated measures structure (see section Additive 
Models and Blocking in the limma manual). Category enrichment analysis was 
carried out using the camera algorithm (355) and the Broad Institute curated 
Hallmark Genesets collection (356). A FDR <5% was taken to indicate 
significant enrichment of a category. 
 
The qPCR data were analysed using the R/Bioconductor NormqPCR package 
(350). The expression data was modelled with a mixed effects linear model 
Assistance with statistical analysis was given by Dr Iain 
Gallagher, University of Stirling 
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using the lme4 R package (357) with subject group, fat depot and the 
interaction between these as fixed factors and subject identifier as a random 
factor to account for pairing. Post-hoc testing of interaction or main effects was 
carried out using the emmeans (358) package. 
 
ITLN1 concentrations were calculated from raw ELISA data in R using the nCal 
package (359). After subtraction of blank values as recommended by the kit 
manufacturer a 5-PL model was fit to the data and concentrations back 
calculated. Statistical analysis was carried out on log transformed data. Tissue 
ELISA data were analysed using a linear model with log ITLN1 concentration 
modelled by group. For the plasma ELISA data the log ITLN1 concentrations 
from assays 1 & 2 were combined and modelled with a mixed effects model 
using the lme4 package (357) with assay as a random factor. Post hoc testing 
was carried out using the emmeans package (358). 
 
6.4 Results 
6.4.1 Patient characteristics 
Twenty-four patients were included in the study with 8 subjects in each of the 
control, CWS and CC groups. Patient demographics and anthropometric 
details are shown in table 23. Median weight loss was 12.5% in the cachectic 
group (IQR  6.87-15.5, p<0.001). Control patients were younger (median 51 
years compared to 60 in the CWS group and 70 in the CC group, p=0.002). 
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Skeletal muscle index was significantly different between the groups (p=0.002) 
































Group (n=8) Control Cachexia Weight stable P 
value 
Male:Female 4:4 5:3 6:2 / 
Age (years) 51 (48-55) 70 (64-77) 60 (57-64) 0.002 
BMI (kg/m2) 25.5 (23.75-28.25) 24 (20.25-29.25) 31.5 (23-40) 0.227 
%weight loss 0 12.5 (6.87-15.5) 0 <0.001 
SMI cm2/m2 48.30 (11.05-43.06) 39.99 (38.24-41.13) 55.52 (48.40-64.22) 0.002 
VATI cm2/m2 20.97 (11.05-43.06) 23.3 (5.82-38.76) 55.52 (48.40-64.22) 0.196 
SATI cm2/m2 50.32 (29.46-63.43) 50.75 (20.15-98.77) 70.35 (34.04-120.67) 0.605 
VAT CSA cm2 61.27 (29.77-122.65) 68.97 (18.16-102.12) 179.18 (80.43-251.94) 0.018 
SAT CSA cm2 159.29 (129.72-211.40) 154.10 (60.44-271.01) 214.42 (117.01-297.11) 0.013 
 
 
Table 23  Demographic and selected clinical data for adipose study subjects 
 




6.4.2 Microarray analysis 
Filtering the microarray data as recommended by the SCAN-UPC authors 
(353) led to the identification of 8679 probesets (approximately 49%) as 
unlikely to be expressed in adipose tissue. These were removed from the data 
set prior to further analysis to improve statistical power. Principle components 
analysis indicated a substantive difference in visceral versus subcutaneous 
transcriptome profiles in the presence of cancer (Figure 44) so we first 
examined mRNA expression differences between the subcutaneous and 
visceral depots within each group using a 5% false discovery rate (FDR) cut 






















Figure 44 Adipose PCA analysis. Scatterplots showing separation of adipose depot and group samples by principle 
components analysis before (A) and after (B) removal of non/low expressed genes using the Universal exPression 
Code (UPC) (Piccolo, 2013) generated filter. Ctrl – healthy control, CWS – cancer weight stable, CC – cancer 
cachexia.
A B Pre UPC probeset 
filter












In the CC group 2101 probesets were significantly regulated between the fat 
depots with fold changes ranging from 8-fold upregulated to 2-fold 
downregulated. In the CWS group 1722 probesets were significantly regulated 
with fold changes ranging from 9-fold upregulated to 2.5-fold downregulated. 
In the control group 1659 probesets were differentially regulated with fold 
changes from 4.6-fold upregulated to 2.3-fold downregulated. These data 
indicate that SAT and VAT depots have substantial mRNA expression 
differences. In addition the number of differentially expressed probesets is 
higher in the cancer groups and highest in the CC group (table 24). Comparing 
VAT between the groups found 2200 (10-fold up to 2.3-fold down) and 1253 
(9-fold up to 2.3-fold down) probesets regulated between CC, CWS and control 
respectively. No probesets met the statistical cut off for significance in VAT 






















 No. Regulated genes 
(FDR < 5%) 
VAT v SAT in Group 
Comparison 
 
CWL VAT v SAT 2101 
CWS VAT v SAT 1722 
Control VAT v SAT 1659 
VAT Between Group 
Comparisons 
 
CWL v Control 2200 
CWS v Control 1253 
CWL v CWS 01 
SAT Between Group 
Comparisons 
 
CWL v Control 02 
CWS v Control 03 
CWL v CWS 04 
 
 
Table 24  Regulated genes between groups. Number of genes regulated 
in the microarray data with FDR < 5% in each within and between group 
comparison. 
 
1 – lowest adjusted p-value = 0.7; 2 – lowest adjusted p-value = 0.1; 3 – 
lowest adjusted p-value = 1; 4 – lowest adjusted p-value = 0.5. 
 
 
Intelectin-1 was the most upregulated gene with a 10-fold increase in CC 
versus control and a 9-fold increase in CWS versus control (Figure 45). 
Intelectin-2 was also significantly increased across these comparisons. SAT 
demonstrated no significant differences in any comparison. These data 
demonstrate that whilst the transcriptional profile of SAT is not sensitive to the 
presence of cancer or cancer cachexia in our cohort there are substantial 


















Figure 45 Intelectin-1 mRNA expression values (log2 transformed) from the microarray data. Ctrl = healthy controls, CWS = cancer 
weight stable, CC = cancer cachexia. a = significantly different from paired subcutaneous values; b = significantly different from control 
visceral values. 
a,b a,b 
Ctrl CWS CC 
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6.4.3 Geneset Enrichment Analysis 
The Broad Institute Hallmark curated genesets collection (356) was used to 
examine the data for geneset enrichment. Firstly, differences between fat 
depots in each group were assessed. Seven genesets were significantly 
enriched in the CC group – Adipogenesis (FDR 2x10-9), Fatty acid metabolism 
(FD 0.004), Myogenesis (FDR 0.008), Hedgehog Signalling (0.044) and 
Oxidative Phosphorylation (0.047) were downregulated and Inflammatory 
response (FDR 0.036) and Allograft Rejection (FDR 0.043) were upregulated 
– in VAT compared to SAT. Two genesets were regulated in the CWS group 
– Adipogenesis (FDR 1x10-6) and Fatty acid metabolism (FDR 0.044) – both 
downregulated in VAT compared to SAT. There were 23 genesets regulated 
in the control group. Only Adipogenesis and Fatty Acid metabolism were 
enriched in all three VAT versus SAT comparisons. In cancer these genesets 
were downregulated whilst in the control group they were upregulated. The 
Inflammatory Response and Oxidative Phosphorylation genesets were 
common only between CC and control VAT versus SAT comparisons. The 
Inflammatory response category was increased in expression in both cancer 
cachexia and control VAT compared to SAT but different genes drove the 
enrichment signal in each group (Figure 46). The oxidative Phosphorylation 
genesets was downregulated in CC and upregulated in controls in VAT versus 
SAT. These data suggest a downregulation in genes related to growth of 
adipose tissue in cancer irrespective of weight loss whilst (compared to SAT) 


















Figure 46 Heatmap of genes in Hallmark Inflammatory Response geneset. Data is subcutaneous and visceral adipose tissue of 
healthy control (Ctrl), cancer weight stable (CWS) and cachectic cancer (CC) patients. The purple boxes delineate inflammatory 
genes differentially contributing to geneset enrichment in cancer cachexia and controls. The cancer weight stable group 
demonstrate a similar signal to the cancer cachexia group but the geneset as a whole did not meet statistical significance for 








Next, category enrichment in VAT between the groups was examined. In 
cachexia compared to control there were 14 categories enriched. Notably 
Oxidative phosphorylation (FDR 1.2x10-16), Adipogenesis (FDR 1.2x10-16) and 
Fatty acid metabolism (3.3x10-9) were downregulated in CC compared to 
control. There were five categories enriched in the CWS group compared to 
control. MYC Targets (FDR 0.038) and Allograft rejection (FDR 0.046) were 
upregulated in the presence of cancer whilst Adipogenesis (FDR 0.038), 
Xenobiotic metabolism (FDR 0.046) and Hedgehog signalling (FDR 0.038) 
were downregulated in the presence of cancer. Whilst no individual mRNA met 
the statistical thresholds for significance in CC versus CWS VAT (see above) 
five genesets were significantly enriched – MYC targets (FDR 0.038) and 
Allograft rejection (FDR 0.046) were co-ordinately increased in CC whilst 
Adipogenesis (FDR 0.038), Hedgehog signalling (FDR 0.038) and Xenobiotic 
Metabolism (FDR 0.046) were co-ordinately downregulated. Given the 
observation of a downregulated energy metabolism signature in the VAT of 
cancer patients the Gene Ontology category Brown Fat Cell Differentiation 
(GO:0045444) was specifically examined and found to be downregulated in  
visceral adipose tissue in cachexia (p = 5.4x10-6 ) and in weight stable cancer 
(p = 2x10-7 ) compared to control. These data suggest that there is a 
downregulation of mRNA related to adipose expansion and energy 
use/generation in the VAT of cancer patients and that this is a stronger 
signature in CC patients. There was no evidence of brown fat cell 
differentiation in this cohort of CC patients. 
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QPCR was used to examine selected genes including those detected as 
regulated in the microarray data and the biological processes of fat browning, 
inflammation and adipogenesis. 
 
6.4.4 Microarray candidates 
ALOX15 demonstrated a significant group x depot interaction effect (p=0.005) 
with increased expression in VAT in the cancer groups compared to control 
(CC p=0.018 and CWS p=0.025 respectively). There was no difference 
between in ALOX15 expression in VAT between the cancer groups (p=0.9). 
ALOX15 was also increased in VAT compared to SAT in the cancer groups 
(weight stable p=0.04, cachectic p=0.0046) but not in the control group 
(p=0.9). ALOX15 was not differentially expressed in SAT depots between 
groups. These results are in agreement with the array results. There was a 
significant group x depot interaction effect for ITLN1 (p=0.0006). ITLN1 was 
significantly increased in the VAT of the cancer groups (CC p=0.0001, CWS 
p=0.02) compared to VAT in the control group but was not different between 
the cancer groups (p=0.5). ITLN1 expression was also significantly greater in 
VAT compared to SAT in the cancer groups (CC p=0.0004, CWS p=0.03) with 
no difference in the control group (p=0.9). There were no significant 
differences in ITLN1 in SAT between any groups. PPARA2 also demonstrated 
a group x depot interaction (p=0.004). However multiple testing was unable to 
detect specific differences. Inspection of the qPCR data suggests lower 
expression in the VAT of the cancer groups. The direction of change in the 
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qPCR data for the cancer groups was the same as seen in the microarray. The 
difference  PPARA2 expression between the VAT and SAT depot in the control 
group was significant (p=0.03).  
 
6.4.5 Genes involved in fat browning 
There were no differences in UCP1 expression in terms of either an interaction 
(group x depot) or main effects. This is in agreement with the microarray 
results. PPARGC1A demonstrated a main effect of depot (p=0.003) with VAT 
showing higher expression than SAT. Post-hoc testing revealed that 
PPARGC1A was significantly upregulated in the VAT compared to SAT in the 
control group only (p=0.01). The direction of change for PPARGC1A in other 
comparisons was the same as seen in the microarray data but not statistically 
significant after multiple testing correction. There were no significant 
differences in PRDM16 expression in terms of interactions or main effects.  
 
6.4.6 Inflammation 
There were no significant differences in ACVR2A1 expression in terms of 
interactions or main effects but the direction of changes seen in the qPCR data 
agreed with the microarray data. There were no significant differences in IL6 
expression in terms of interactions or main effects. IL6 was significantly 
downregulated in CC compared to control VAT in the microarray data. The 
direction of change was the same in the qPCR data driven by few patients 
(Figure 47) and not statistically significant. IL18 demonstrated a significant 
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group x depot interaction effect (p = 0.0009) with increased expression in the 
VAT of both cancer groups compared to control (CWS p=0.02, CC p=0.0001). 
Expression of IL18 was also increased in the VAT compared to the SAT in the 






































































































































































































































































































































































































































































































































































































































Figure 47 Data from qPCR of selected genes. Categories of genes validated by qPCR were - significantly different in microarray data 
(ALOX15, ITLN1, PPARA2), involved in browning (PPARGC1A, PRDM16, UCP1), inflammation related (ACVR2A1, IL6, IL18), involved in 
adipogenesis (LEPR, STAT5A, PDCD4). * = significant group x depot interaction; † = no significant interaction but significant difference between 
same depot in control group. See main text for full reporting of statistically significant differences. Ctrl = healthy controls, CWS = cancer weight 











Ctrl C S CC Ctrl C S CC Ctrl C S CC 
Ctrl CWS CC Ctrl CWS CC Ctrl CWS CC 
Ctrl CWS CC Ctrl C S CC Ctrl CWS CC 




LEPR demonstrated a significant group x depot interaction effect (p=0.03) with 
post-hoc testing revealing decreased expression in the VAT in the CC 
compared to control group (p=0.04). LEPR was also increased in control VAT 
compared to SAT (p=0.02). STAT5A did not demonstrate any significant 
interaction or main effects although the effect of fat depot was borderline 
significant (p=0.06) with specific differences undetectable by post-hoc testing. 
PDCD4 did not demonstrate any significant interaction or main effects. 
 
6.4.8 ELISA results 
VAT ITLN1 concentrations are shown in figure 48. Linear modelling of log 
ITLN1 concentration by group showed a significant effect of group (p=0.04). 
There was a significant difference between the CC and control groups (mean 
ITLN1 concentrations 43.6ng/ml and 20.5ng/ml respectively, p=0.014) but no 
statistically significant difference between CWS (mean ITLN1 concentration 







































Figure 48 Intelectin-1 tissue ELISA.  Intelectin-1 visceral adipose tissue protein concentration (ng/ml) as measured by ELISA across the 
control (Ctrl), cancer weight stable (CWS) and cancer cachexia (CC) groups. * = significant effect of group; †  = significantly different from 
control group.  
* 
†  
Ctrl CWS CC 
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Patients demographics of those included in the plasma ELISA study are 
summarised in table 25. 
 




Male:Female 14:6 14:6 14:6 / 
Age (years) 49 (11) 69 (10) 64 (9) <0.001 
BMI (kg/m2) 25.66 (2.81) 25.06 (4.85) 29.93 (7.79) 0.187 
%weight loss 0 11.60 (6.58) 0.26 (0.71) <0.001 
SMI (cm2/m2) 50.69 (7.55) 41.54 (4.82) 55.92 (12.48) <0.001 
VATI (cm2/m2) 26.23 (20.04) 41.50 (36.65) 111.90 
(215.25) 
0.008 




Table 25 Details of patients included in the plasma ITLN1 ELISA 
 
Data are mean (SD). 
 
 Plasma ITLN1 concentrations are shown in figure 49. Mixed effects linear 
modelling with group as a fixed effect and assay run as a random effect was 
used to model log ITLN1 concentrations. There was a significant effect of 
group (p=0.028). Post-hoc testing using Tukey’s correction demonstrated a 
significant difference in plasma ITLN1 concentrations between the cachectic 
and cancer weight stable groups (mean ITLN1 concentrations 2.6ng/ml and 
1.9ng/ml respectively, p = 0.02). There was no significant difference between 





































Figure 49 Plasma Intelectin-1 ELISA.  Intelectin-1 plasma protein concentration (ng/ml) as measured by ELISA across the control (Ctrl), 
cancer weight stable (CWS) and cancer cachexia (CC) groups. * = significant effect of group; ‡  = significantly different from Ca group.  
* 
‡  




Different mechanisms have been previously proposed to account for the 
changes in adipose tissue seen in cachexia. In CC, human and animal studies 
have shown increased rates of lipid mobilisation and loss of adipose tissue 
before any demonstrable changes in loss of muscle mass (360). An increased 
rate of adipose tissue loss has also been associated with worsening prognosis 
in cancer patients highlighting the importance of gaining a greater 
understanding of the mechanisms involved. To the best of our knowledge, this 
is the first study to examine both SAT and VAT depots in CC patients. This 
study has shown that SAT and VAT have unique gene expression signatures 
and VAT has an altered gene expression signature in cancer. It found 
increased expression of Intelectin-1 and Intelectin-2 in particular suggesting 
these adipokines may play a role in adipose changes in response to cancer. 
Intelectin-1 may be a target for therapeutic manipulation. 
 
The gene which showed the largest difference in expression was ITLN1; a 34 
kDa novel adipokine. Expression of ITLN2 was also high but not as great as 
ITLN1 and so ITLN1 formed the focus of this study. ITLN1 is preferentially 
produced by stromovascular cells in VAT(361) but has also been identified in 
human epicardial fat cells, mesothelial cells, airway goblet cells and cells lining 
the gut and ovaries (362). A series of studies have linked raised levels of ITLN1 
to various cancers (265,363–369). ITLN1 has been suggested to promote 






(phosphatidylinositol-3 kinase downstream effector) signalling pathways (370). 
The role of ITLN1 in CC however, has not been well characterised. 
Randomised control trials have shown that weight loss significantly increases 
plasma ITLN1 concentration (371) whereas hyper-insulinaemic induction in 
healthy individuals reduces ITLN1 plasma concentration (372). Decreased 
levels of ITLN1 have been associated with obesity in patients with ovarian 
cancer (372) and levels of ITLN1 measured before patients were diagnosed 
with colorectal cancer have been confined to non-obese individuals suggesting 
it has a role in weight loss (373).  
 
The microarray results confirmed that expression of ITLN1 was higher in VAT 
in cancer although not confined to CC patients. Plasma levels of Itln1 were 
significantly increased in CC compared to CWS groups but showed no 
difference with controls suggesting it possibly has a role in cancer induced 
weight loss. However as in the previous studies, this study found that plasma 
Itln1 differences were driven by a few individuals with high levels. The 
combination of low study numbers and high interindividual variability in plasma 
ITLN1 likely limited the power to detect an effect across all groups here. The 
significant increase in intelectin seen in the VAT ELISA of cachectic patients 
suggests a possible role in the pathogenesis of cachexia. There was a clear 
increasing gradient from controls through CWS to CC in VAT Itln1 level. This 
was not reflected in the plasma Itln1 protein levels. These results are similar 






pattern of increased tissue protein levels but no change in circulating levels 
could be explained by cells outside adipose tissue contributing to circulating 
protein. Alternatively there could be a predominantly paracrine role for adipose 
tissue secreted protein which is not released into the circulation. 
 
There was no evidence of increased browning in white adipose tissue in this 
cohort. Previously increased thermogenic activity of brown and beige adipose 
tissue has been shown to contribute to the increased energy expenditure and 
weight loss in rodent models of cachexia (374–376). White adipose tissue 
browning is associated with increased expression of uncoupling protein 1 
(UCP1), which uncouples mitochondrial respiration toward thermogenesis 
instead of ATP synthesis, leading to increased lipid mobilization and energy 
expenditure (377). Whilst browning of white fat depots contributes to futile 
energy cycling in cachexia in animal models the importance of this is uncertain 
(378,379). Genes involved in fat browning in the present study were not 
upregulated suggesting browning has a limited role in the pathogenesis of 
cachexia in patients and highlights the importance of patient based research.  
 
Cachexia is thought to be a chronic inflammatory state and changes in 
inflammatory mediators in adipocytes may be capable of inducing changes in 
adipose tissue homeostasis (380). Several studies have shown adipose tissue 
to be the target of several pro-cachectic factors as well as adipose tissue itself 






of studies assessing inflammation in cachexia have examined inflammatory 
markers from a systemic point of view rather than a tissue specific one with 
IL6 in particular frequently found to be raised in the plasma of CC patients 
(134). IL6 was downregulated in adipose tissue in CC suggesting a possible 
homeostatic response. Specific adipose tissue inflammation is important to 
consider as it may be an event very early on in the cachectic process prior to 
any systemic effects being demonstrated.  
 
Adipogenesis is the process by which preadipocytes differentiate into mature 
adipocytes able to store triglycerides and secrete adipokines. Some studies 
have shown that adipogenic genes are downregulated in animal epididymal 
and retroperitoneal fat in cachexia (383,386). Co-culture studies have 
demonstrated inhibition of pre-adipocyte maturation in the presence of tumour 
cells which was associated with increased inflammatory cytokines (387). 
Changes in adipogenesis are likely to precede the clinical signs of fat wasting 
and tissue inflammation. It is possible therefore that factors such as increased 
infiltration of macrophages and production of inflammatory cytokines silence 




The current study confers similar limitations to other microarray studies most 






valuable as it provides testable hypotheses to be taken forward. Another 
limitation of this study was the availability of omental and perinephric adipose 
tissue in the cancer and control, groups respectively. Differences in these two 
depots are not well defined. In rodents there are possible depot specific 
differences in innervation but this has not been documented in humans (388). 
A very small study in humans has suggested blood flow in omental fat may be 
higher than in perinephric fat though the difference was not significant (389). 
This may potentially the affect the removal of lipolytic products and the rates 
of lipolysis. The patients studied were predominantly male and we are 
therefore unable to draw conclusions about sex specific differences. There 
was no longitudinal follow up of patients and so it is unclear whether the 
patients in the CWS group went on to develop cachexia and therefore may 
have been pre-cachectic at the time of biopsy. We also excluded patients in 
the control and CWS groups who were sarcopenic on CT. In doing so we have 
assumed that a reduction in SMI in the cachectic group was due to disease. 
Given that these patients have a median age of 70 it is possible that they were 
sarcopenic prior to the start of the disease process. 
 
6.6 Conclusion 
This exploratory analysis confirms differential gene expression in adipose 
depots in patients with cancer with and without cachexia and highlights the 
importance of VAT in cancer. VAT may have a fundamental role in cachexia, 






browning in cachectic patients as suggested in pre-clinical models. Future 
mechanistic studies are important to evaluate the effects of VAT in cachexia 



























































































7.1 Chapter overview 
The previous chapters have investigated methods of screening for cachexia 
along with providing an insight into potential pathophysiological methods of 
muscle and adipose wasting. The final chapter aims to tie these together and 
identify easily measurables markers of tissue wasting in the plasma of 
cachectic patients. Diagnosis as discussed is difficult and relies upon 
predominantly objective measures including weight loss, which often lags 
behind disease progression. The ability to diagnose cachexia early would lead 
to new avenues for treatment and improvement in prognosis. The 'omics' 
technologies allow us to study the end points of many biological processes. 




This chapter aimed to perform liquid chromatography mass spectrometry 




Eighteen patients undergoing potentially curative surgery for UGI cancer were 
recruited. Fasting plasma samples were taken at the time of induction of 






spectrometry (LC/MS) analysis was undertaken. Data extraction for each of 
the samples was carried out by MZMine software. Metabolites obtained were 
evaluated manually and the quality of the peaks and retention times matched 
with standard metabolite mixtures. Univariate and multivariate analyses were 
performed using SIMCA-P 14.1 software. 
 
7.1.3 Results 
LC/MS analysis showed two distinct profiles, which clearly separated the 
patients into two groups (n=9 and 8 in each group) dependent on weight loss 
(greater or less than 5%). Overall 40 metabolites were associated with 
cachexia, 6 of those being highly discriminative of weight loss namely Lyso PC 
18.2, L-Proline, Hexadecanoic acid, Octadecanoic acid, Phenylalanine and 
LysoPC 16:1.  
 
7.1.4 Conclusion 
This study gives biological validation to the consensus definition and provides 











As cachexia can develop progressively through various stages, from pre‐
cachexia to cachexia to refractory cachexia, early screening and staging is 
particularly important to prevent or delay its onset (28). An improved approach 
for detecting the evolution of muscle and or fat wasting would help target early 
intervention and treatment.  
 
Recent progress in high-throughput analytical technologies and bioinformatics 
now permits simultaneous analysis of hundreds of compounds constituting the 
metabolome (390). Metabolomic analyses give complex fingerprints that 
appear to be characteristic of a given metabolic phenotype or diet. There have 
been very few previous studies attempting to quantify metabolites associated 
with cachexia. Those that have attempted to do so identified metabolites that 
are possibly discriminative of cachexia indicating there maybe scope for 
metabolomics based studies to identify biomarkers of cachexia (391–395). 
 
Building upon the theory that metabolites produced from tissue breakdown are 
likely to be found in plasma and could potentially be a sensitive indicator of 
tissue wasting this study investigated whether metabolites associated with 
cachexia could be detected from the plasma of cancer patients. Urine 
proteomics have been previously used as a measure of degradation products 
in the circulating fraction allowing discrimination between weight losing and 






choice for this study, since as previously shown several end products of 
muscle catabolism (e.g. creatinine and methylhistidine) can be easily 
measured here (397).  
7.3 Methods  
7.3.1 Participants 
Patients with UGI cancer were recruited as previously described. CT body 
composition analysis was performed and fasting plasma samples were 
obtained at induction of anaesthesia approximately four to six weeks after the 
cessation of any neoadjuvant chemotherapy. Samples were stored locally at -
80°C until transported to the metabolomic facility (Strathclyde Institute of 
Pharmacy and Biomedical sciences) in cool bags at -30°C.  
7.3.2 Chemicals and Solvents 
HPLC grade Acetonitrile (ACN) was purchased from Fisher Scientific 
(Loughborough, UK) and HPLC grade water was produced by a Direct-Q3 
UltrapureWater System (Millipore, Watford, UK). AnalaR-grade formic acid 
(98%) was obtained from BDH-Merck (Poole, UK). Authentic stock standard 
metabolites (Sigma-Aldrich, Poole, U.K.) were prepared as previously 
described and diluted four times with ACN before LC-MS analysis. Ammonium 
acetate was purchased from Sigma-Aldrich (Poole, UK). 
 
LC/MS Metabolomic analysis was performed by Dr Dave Watson 






7.3.3 Sample preparation 
Exactly 200 µL of the sample was mixed with 800 µL ACN containing 10 µg/ml 
of 2 13C glycine (Sigma-Aldrich, Poole, U.K.) as an internal standard to ensure 
retention time stability, and then centrifuged for 10 min before transferring into 
a vial with an insert. The pooled sample was prepared by pipetting 50 µL from 
each of the 18 samples and then mixing them together before diluting 0.2 ml 
of the pooled sample with 0.8 ml ACN containing 5 µg/mL of 2 13C glycine 
internal standard and centrifuging. Additionally, the prepared mixtures of 
authentic standard metabolites containing 10 µg/mL of 2 13C glycine as internal 
standard were run.  
7.3.4 LC-MS conditions  
Liquid chromatographic separation was carried out on an Accela HPLC system 
interfaced to an Exactive Orbitrap mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) using both a ZIC-pHILIC column (150 × 4.6 mm, 
5 µm, HiChrom, Reading UK). The column was eluted with a mobile phase 
consisting of 20 mM ammonium carbonate in HPLC-grade water (solvent A) 
and ACN (solvent B), at a flow rate of 0.3 mL/min. The elution gradient was an 
A:B ratio of 20:80 at 0 min, 80:20 at 30 min, 92:8 at 35 min and finally 20:80 at 
45 min. The nitrogen sheath and auxiliary gas flow rates were maintained at 
50 and 17 arbitrary units. The electrospray ionisation (ESI) interface was 
operated in both positive and negative modes. The spray voltage was 4.5 kV 






temperature was 275°C. Full scan data were obtained in the mass-to-charge 
ratio (m/z) range of 75 to 1200 for both ionisation modes on the LC-MS system 
fully calibrated according to manufacturer’s guidelines. The resulting data were 
acquired using the XCalibur 2.1.0 software package (Thermo Fisher Scientific, 
Bremen, Germany).  
7.3.5 Data extraction and analysis 
Data extraction for each of the samples was carried out by MZMatch software. 
The extracted ions, with their corresponding m/z values and retention times, 
were pasted into an Excel macro of the most common metabolites prepared 
in–house to facilitate identification. The lists of the metabolites obtained from 
these searches were then carefully evaluated manually by considering the 
quality of their peaks and their retention time match with the standard 
metabolite mixtures run in the same sequence. All metabolites were within 3 
ppm of their exact masses. The list of metabolites was refined by removing all 
metabolites with RSD >20% in the pooled samples leaving a list of 318 
metabolites. Statistical analyses were performed using both univariate with 
Microsoft Excel and multivariate approaches using SIMCA-P software version 
14.1 (Umetrics, Umea, Sweden). The 318 metabolites were modelled to give 
a PCA plot and then supervised analysis based on OPLS was carried out 
refining the list of metabolites by eliminating the less important variables to 
give a model with the lowest possible number of variables. These data will be 







Plasma samples were analysed from UGI cancer patients (n = 18) taken from 
a cross-sectional cohort of UGI cancer patients who were recruited to two 
previously-published studies of muscle transcriptomics (n = 65 pre-surgical 
rectus abdominis biopsies, and n = 12 pre- and post-surgical resection muscle 
biopsies) (345,346). In these previous studies, quantitative significance 
analysis of microarrays produced an 83-gene signature that was able to 
identify patients with >5% weight loss, while this molecular profile was 
unrelated to markers of systemic inflammation. Comparison with healthy 
control muscle revealed that despite differences in the muscle transcriptome 
at baseline (941 genes regulated), the muscle of patients at post-surgical 
resection follow-up was similar to control muscle (two genes regulated). 
Baseline, pre-surgical plasma samples were available for 18 of these patients. 
Therefore, for the present study, there were 9 nine patients who had 
experienced ≥5% weight loss in the previous 6 months (≥5%WL group), and 9 
nine patients with <5% weight loss (weight stable group: WS). Cancer 
cachexia had been primarily defined as ≥5% weight loss in order to identify 
patients who would have experienced dynamic wasting and thus be more likely 
to have identifiable markers and metabolic signatures. If the patients were 
analysed as two separate groups according to these weight loss criteria, the 
mean percentage weight loss in the ≥5% WL group was 14.39% compared 






group. There was no significant difference in age, BMI, SMI, SATI or VATI 
between the groups. However, patients in the ≥5% WL group did demonstrate 
higher CRP levels compared with WS patients. These body composition and 
systemic inflammatory phenomena are all associated with worsened 
outcomes in cancer patients (193,315,398), confirming the ≥5% WL patients 
as a high-risk group. Two patients in the WS group had >2% weight loss and 
low SMI [according to Martin criteria (27) on the CT]. Patients had a mixture of 
UGI cancers predominantly those of the oesophagus and pancreas (Table 26). 
On the overall metabolomic analysis, a total of 40 metabolites were 
significantly associated with ≥5% weight loss according to univariate analysis 
using a T test. The metabolites with the highest fold change were L-
phenylalanine and various species of LysoPE, LysoPA and LysoPC. These 














 Group 1  
<5% weight loss 
(n=9)  
Group 2  
≥5% weight loss 
(n=8) 
P Values 
Male: Female 8:1 4:4 N/A 
Age (years) 61 (4.65) 66 (10.53) 0.167 
% weight loss 2.13 (1.35) 14.39 (6.56) 0.001* 
SMI (cm2/m2) 41.93 (16.78) 45.82 (7.72) 0.536 
SATI (cm2/m2) 46.25 (20.38) 58.43 (33.86) 0.379 
VATI (cm2/m2) 57.57 (55.28) 42.10 (33.48) 0.506 
BMI (kg2/m2) 24.93 (4.42) 26.29 (4.64) 0.534 
CRP (mg/l) 17.88 (27.06) 32.56 (50.44) 0.453 
Cancer type Pancreatic – 1 
Oesophageal – 6 
Gastric - 2 
Pancreatic – 6 
Oesophageal – 2 




Table 26 Metabolomic Patient details 
 
All data are mean (standard deviation) 
*Denotes significant result 
 
 
Figure 50 shows the principal components analysis (PCA-X) of all 18 samples 
and 3 quality control (QC) samples which indicate the instrument stability was 
good for the duration of the run. PCA-X, an unsupervised model in SIMCA-P, 
produces a natural scatter of the samples based on their characteristic 






according to the threshold defined above for cachexia as being > 5% weight 
loss.  
 
Supervised models enable identification of metabolites that have the most 
significant contribution to a given clustering pattern. In SIMCA, supervised 
analysis can be carried out using orthogonal partial least squares discriminant 
analysis (OPLS-DA) or orthogonal partial least squares (OPLS) models. An 
OPLSDA model was not very successful in classifying the samples without 
omitting several. AN OPLS model based on six metabolites (Table 27) was 
successfully produced for all but one of the one of the cachectic samples. This 
sample was omitted from the OPLS model since it clustered with the weight 
stable samples. The model plotted predicted against actual weight loss and 
had a CVANOVA of 0.0014. The correlation line had an R2 value of 0.976 when 


















Figure 50 PCA-X analysis of the metabolomics footprint.18 plasma 
samples with pooled samples removed. 









Figure 51 Orthogonal partial least squares (OPLS) model. Model showing close correlation for 8 weight losing samples and 9 
weight stable samples between predicted and actual weight change  




m/z Rt  (min) Metabolite VIP value 
520.339 4.4 Lyso PC 18.2 1.82 
116.071 13.0 L-Proline 1.43 
255.233 4.3 Hexadecanoic acid 0.54 
281.249 3.8 Octadecenoic acid 0.42 
166.086 10.0 Phenylalanine 0.36 
480.344 4.4 LysoPC 16:1 0.20 
 
Table 27 The six metabolites used to produce the OPLS model (as 
shown in figure 51) 
m/z- mass to charge ratio, rt – retention time 
 
Table 28 shows the metabolites that were found to be significantly different 
between the two weight group categories. The ratio represents the intensity of 


















acids      
P 116.071 13.0 L-Proline 0.015 1.36 
P 166.086 10.0 L-Phenylalanine 0.619 0.87 
Fatty acids      
N 214.048 4.3 
sn-glycero-3-
Phosphoethanolamine 0.006 1.78 
N 255.233 4.3 Hexadecanoic acid 0.049 1.21 
N 277.217 3.9 Octadecatrienoic acid 0.010 1.60 
N 279.233 4.2 Linoleate 0.002 1.36 
N 281.249 3.8 Octadecenoic acid 0.023 1.22 
N 293.249 4.2 Nonadecadienoic acid 0.019 1.24 
N 303.233 4.1 Eicosatetraenoic acid 0.022 1.37 
N 305.249 4.2 Eicosatrienoic acid 0.054 1.50 
N 327.233 4.2 Docosahexaenoic acid 0.025 0.81 
N 329.249 4.1 Docosapentaenoic acid 0.009 1.46 
N 331.264 3.9 Docosatetraenoic acid 0.014 1.68 
P/N 380.255 5.1 Sphingenine phosphate 0.033 1.28 
Lipids      
N 214.048 4.3 Glycerophosphoethanolamine 0.006 1.78 
N 381.205 4.6 LPA 14:0 0.010 1.73 
N 393.241 4.4 LPA16:0 ether 0.048 1.37 
N 433.236 4.4 LPA 18:2 0.001 1.67 
N 435.252 4.5 LPA18:1 0.006 1.40 
N 437.267 4.2 LPA 18:0 0.028 1.23 
P/N 454.292 4.6 LPE 16:0 0.040 1.44 
N 457.235 4.3 LPA 20:4 0.001 1.62 
N 464.278 4.4 LPC 14:1 0.007 1.36 
P 468.308 4.6 LPC 14:0 0.026 1.58 
P/N 476.278 4.4 LPE 18:2 0.013 1.98 
P/N 478.292 4.4 LPE 18:1 0.013 2.02 
P/N 480.308 4.4 LPE 18:0 0.012 2.07 
N 485.267 4.3 LPA 22:4 0.007 1.96 
P/N 496.339 4.4 LPC 16:0 0.040 1.34 
N 498.262 4.3 LPE 20:5 0.053 2.13 
P/N 500.278 4.4 LPE 20:4 0.002 2.36 






N 514.294 4.3 LPC 18:4 0.005 2.28 
P/N 520.339 4.4 LPC 18:2 0.001 1.75 
P/N 524.278 4.3 LPE 22:6 0.032 1.45 
N 526.294 4.3 LPE 22:5 0.004 2.51 
N 528.31 4.3 LPE22:4 0.004 2.01 
P/N 544.338 4.3 LPC 20:4 0.014 1.81 
P/N 546.354 4.3 LPC 20:3 0.026 1.91 
P 570.356 4.2 LPC 22:5 0.009 1.89 
P 731.605 4.2 SMd18:0/18:1 0.052 1.29 
Table 28 Significant metabolites that differ between weight loss vs. 
weight stable groups ( comparing 9 weight stable and 8 weight losing 
patients) 
PE - phosphatidyl ethanolamine, PC - phosphatidyl choline, PA - 
phosphatidic acid, MZ – mass to charge ratio, rt – retention time, P – 

























Figure 52 shows a heat map showing the relative abundance of the lyso lipids 
in these plasma samples. Lyso PC18:2 is almost as abundant as lyso PC 16:0 
and is elevated by 1.75 fold. Beyond these two lysolipids the response is much 
lower but there are many more minor lipids showing similar or greater fold 
changes in the weight losing patients. 
 
m/z Rt min     Group 1 Group 2 
496.339 4.4 C24H50NO7P LysoPC 16:0   
520.339 4.4 C26H50NO7P LysoPC18:2   
544.338 4.3 C28H50NO7P LysoPC20:4   
435.252 4.5 C21H41O7P LysoPA18:1   
464.278 4.4 C22H44NO7P LysoPC 14:0   
546.354 4.3 C28H52NO7P LysoPC20:3   
437.267 4.2 C21H43O7P LysoGP 18:0   
480.344 4.4 C24H50NO6P Lyso PC 16:1   
478.292 4.4 C23H44NO7P LysoPE18:2   
570.356 4.2 C30H52NO7P LysoPC22:5   
480.308 4.4 C23H46NO7P LysoPE18:0   
454.292 4.6 C21H44NO7P LysoPE 16:0   
526.292 4.3 C27H44NO7P LysoPE22:5   
457.235 4.3 C23H39O7P LysoPG 20:4   
524.278 4.3 C27H44NO7P LysoPC18:0   
508.341 4.3 C25H52NO7P LysoPE 18:0   
504.31 4.4 C25H48NO7P LysoPE20:2   
485.267 4.3 C25H43O7P LysoPA20:4   
363.158 4.4 C16H29O7P LysoPA 16:0   
514.294 4.3 C26H46NO7P LysoPC18:4   
528.31 4.3 C27H48NO7P LysoPE22:4   
540.309 4.4 C28H48NO7P Lyso PC 20:5   
 
Figure 52 Heat map showing relative levels of lysolipids 
purple= > 30%, yellow >1% blue >0.1% 









In this study, LC-MS based metabolomics analysis was performed to reveal 
the metabolic profile of weight loss in cancer. It was able to demonstrate 
distinct profiles associated with the presence or absence of ≥5% WL. Most of 
the metabolites identified within these profiles fell within the lipid pathways. 
The clearest finding was that several long chain fatty acids and lysolipids were 
elevated in the plasma of the patients with higher weight loss. Lysolipids are 
very abundant in plasma (399) and Lyso-PC 16:0 was the most abundant 
compound by response in this set of samples; an increase of 1.34 fold between 
≥5% WL and WS patients represents a major shift in metabolic output.  
 
The OPLS model shown in Figure 51 indicates a strong association between 
weight loss and six metabolites. Two of the metabolite markers were lysolipids, 
two were amino acids, and two were fatty acids. There is a risk of overfitting 
data when the numbers of samples are small. However, in the present study, 
there was a clear indication that a small number of markers may be used to 
model the degree of weight loss with accuracy. One patient with ≥5%WL was 
removed from the analysis as this sample clustered with the WS group, but for 
this small cohort alone, six metabolites, were identified as a diagnostic test for 
cachexia (≥5%WL), making it 95% accurate. Validation of these markers will 
require larger studies, ideally with sequential assessment. The current study 






of cancer patients with weight loss. The changes in the amino acids found add 
credence to the importance of muscle wasting in cancer cachexia and indeed, 
most current research into cancer cachexia focuses on this area. However, the 
importance of lipid metabolism is re-emerging as an area of priority (335).  
 
Previously, cachexia in patients with cancer of the oesophagus and pancreas 
has been linked with high levels of plasma glycerol and free fatty acids 
(400,401). Weight-losing cancer patients have been shown to have increased 
turnover of both glycerol and fatty acids compared with cancer patients without 
weight loss (402). Some, however, have suggested that observed increases 
in lipolysis and triglyceride-fatty acid cycling in cachectic patients with 
oesophageal cancer are due to alterations in nutritional status rather than 
disease presence (403). Cachectic ovarian cancer patients have been shown 
to have increased levels of free fatty acids, monoacylglycerides and 
diglycerides in their serum and ascitic fluid (404). Whilst it is difficult to 
determine where fatty acid and lipid metabolites originate, both lysolipids and 
fatty acids are markers of lipolysis (108,405). Free fatty acids may also provide 
energy for the tumour, with the glycerol molecules released during the 
breakdown of triacylglycerides being used for gluconeogenesis by the liver 
(406,407). 
  
Previous attempts to profile metabolites associated with cachexia have yielded 






study. Metabolomics research in cachexia began in 2008 in the C26 mouse 
model (391). This was the first study to demonstrate a distinct metabolomics-
based profile associated with the onset of muscle wasting, and identified 
increased levels of very low and low density lipoprotein associated with 
aberrant glycosylation of β-Dystroglycan (β-DG, a marker of muscle wasting 
in this mouse model) (49). Human metabolomics studies in cancer cachexia 
have investigated urine and plasma from weight-losing patients. These studies 
also found large numbers of glycerophospholipids and metabolites associated 
with amino acid metabolism and were able to identify occult sarcopenia in 
patients with cancer (392,408). Recent studies have attempted to separate 
pre-cachectic, cachectic and weight stable cancer patients and healthy 
controls using serum metabolomics, and enabled identification of fifteen highly 
discriminative metabolites (394). The present study was able to discriminate 
weight-losing from weight- stable patients using only six metabolites. The only 
study to find a markedly different metabolic pattern to the present study 
analysed patients using three analytical platforms, namely gas 
chromatography mass spectrometry, capillary electrophoresis mass 
spectrometry, and LC/MS. The authors found a significant reduction in amino 
acids and glycerophospholipids associated with cachexia, a difference that 
has not previously been described in this condition, plus a high increase in 
cortisol levels (395). All bar one of these studies (392) used 5% weight loss as 
a cut off to stratify patients, in a similar fashion to the present study. Future 






dynamic assessments of tissue loss over time, e.g., using serial CT body 
composition analysis.  
 
Blood-based metabolomics is a promising method for cachexia research. 
However, as seen previously, results are often difficult to replicate due to the 
heterogeneity of the populations and study sizes. All the patients included in 
the present study were suitable for potentially curable surgical resection of 
their cancer and therefore had localized/non-metastatic disease and similar 
measures of muscle volume, indicating that the identified metabolites might be 
early markers of fat wasting preceding muscle loss. This hypothesis is 
supported by the fact that two of the patients in the WS group were “cachectic” 
according to the consensus definition, by virtue of having ≥2%WL and low SMI 
on CT, and yet, they did not group with the identified panel of six metabolites. 
This finding may be explained by a lack of dynamic wasting, and that CT-
identified sarcopenia may be the pre-cancer patient norm, rather than a 
consequence of disease.  
 
One obvious limitation of this study is the small number of samples used, 
involving differences in sex ratios and cancer types between the groups. This 
was an exploratory study involving patients without refractory cachexia and 
was not designed to identify sex- or tumour-specific differences. This study 
was limited to patients with UGI cancers and therefore, may not be applicable 
to all cancer types. Previous serum metabolomic studies in pancreatic and 






a key component of these conditions, although the exact tissue site of these 
processes is unknown (409,410). In the present study, differences in tumour 
type between patient groups are unlikely to explain the identified six-metabolite 
signature, due to the close correlation with patient weight loss. It was able to 
demonstrate distinct metabolic profiles consistent with the consensus 
cachexia definition of ≥5% weight loss. These findings support  previous 
muscle transcriptomic studies, and they give further biological validation to the 
2011 Fearon consensus definition of cancer cachexia (28) as a valid patient 
inclusion criterion in clinical trials. Furthermore, these results provide a 6-
metabolite profile for further investigation as a marker of cachexia in 
longitudinal studies, with the opportunity to explore early diagnosis and 
response to therapeutic intervention. 
 
8.6 Conclusion 
These results show that metabolomic profiles in plasma from cancer patients 
are different between patients with ≥ or <5% weight loss. Most of the 
metabolites identified within these profiles fell within the lipid pathways. 
Differences highlighted in the breakdown of lipids provide an understanding of 
the mechanisms involved in the pathogenesis of cachexia. A 6-metabolite 
signature correlated strongly with degree of patient weight loss. A better 






of datasets between studies may identify novel biomarker strategies and 






















































8.0 General Discussion 
8.1 Overview 
Cancer cachexia significantly impairs QoL and leads to poor surgical and 
oncological outcomes. This thesis set out to investigate current difficulties in 
characterising cancer cachexia as well as understand some of the currently 
underexplored pathophysiological mechanisms which underly muscle and 
adipose wasting. Each chapter has discussed the main findings for each study. 
This discussion aims to summarise the findings and place them into context 
within the overall thesis (figure 53). 
 
Chapter 3 began by investigating the ability to screen for conditions which 
present with unintentional weight loss; namely cachexia, sarcopenia and 
malnutrition. Here, the difficulties in identifying patients with cachexia first 
become apparent. A contemporary review of the literature was performed 
using search engines encompassing a wide range of medical and importantly 
nursing and allied health professional journals. Search terms were included to 
make this review as broad as possible and in doing so several thousand 
papers were initially identified.  It became apparent that many tools had been 
developed to screen for malnutrition but very few existed to identify patients 
with cachexia or sarcopenia and indeed it was not possible to identify one tool 
which is currently able to achieve screening for all three conditions. With the 
existence of so many tools already in operation it seems unlikely that the 






Therefore suggested steps were included which would allow the enhancement 
of existing tools to encompass the diagnostic criteria for cachexia. This study 
importantly highlights the difficulties in screening for cachexia in the outpatient 
setting therefore leading to difficulties in recruiting appropriate patients to 
clinical trials or allowing targeted treatment of the correct underlying condition 
which has presented with unintentional weight loss. This chapter set the scene 
for the ongoing investigations carried out in this thesis. By detailing how difficult 
it is to identify patients with cachexia more robust methods are needed to allow 
early targeting of patients. 
 
Chapter 4 therefore built on the assessment of cachexia and looked in more 
depth at radiological methods for diagnosing low muscle mass; namely CT. 
Indeed one of the main themes running throughout this thesis is the use of CT 
to quantify muscularity and adipose tissue volume. CT is a useful assessment 
of muscle mass in cancer patients as it forms part of routine care. CT does 
however, have certain limitations including exposure to radiation (81milligray 
per centimetres for a CT chest, abdomen and pelvis) and accessibility of 
measurements of muscle mass to clinicians. Factors such as patient position 
and scan quality can impact body composition assessment but when used 
correctly have been shown to provide a reliable assessment of muscle and 
adipose volumes (27). It was therefore used in most chapters to provide a 
reliable assessment of muscle mass and to divide patients into study groups 







Muscle mass may be measured by many means and broadly has been defined 
as less than 2 SD below the mean of a healthy population. It is therefore not 
necessarily applicable to all and it does not necessarily correlate with muscle 
function. This chapter therefore set out to investigate the assessment of body 
composition by age and sex in patients with oesophageal cancer. As expected 
older patients had a lower staging SMI and all patients were found to lose 
muscle mass following chemotherapy but somewhat surprisingly this did not 
differ by age. Baseline adipose tissue volume also differed by age and sex and 
older patients and females lost significantly more adipose tissue following 
chemotherapy. The type of adipose tissue lost was different by sex with males 
losing more visceral fat. The relative importance of fat wasting in cachexia is 
not well understood but this chapter has highlighted differences in adipose 
depots which require more biological investigation. 
 
The patients included in this study were chosen as they had been previously 
recruited to cachexia research within the region and had undergone muscle 
biopsy. These patients were therefore felt to be representative of the target 
population. Many studies investigating CT derived muscle wasting include 
patients of both sexes over a wide age range with a variety of cancer types. 
The ability of studies investigating CT derived body composition to generalise 
results to differing patient populations must therefore be questioned. As with 






time point at which the scan was undertaken and therefore does not provide a 
dynamic assessment of wasting. The number of patients in each group was 
very different with there being lower numbers at extremes of age. This likely 
reflects real life clinical practice but could be investigated further with a larger 
cohort. The study was also not powered to assess clinical outcomes and 
further research should investigate the association of CT derived body 
composition volumes with patient focused factors such as QoL, functional 
status and responses to treatment. 
 
Linking back to chapter 3 chapter 4 begs the question as to whether CT should 
become a routine part of the screening process for cancer patients? With the 
ease of accessibility and the advancement of body composition analysis 
techniques it could feasibly be built into routine practice in particular to identify 
those patients who may benefit from increased pre-operative prehabilitation. 
In order to do this stringent diagnostic criteria needs to be developed for all 
populations and perhaps needs to be disease as well as patient specific. Given 
that it is currently the most robust way to identify patients with low muscle mass 
it formed the basis of phenotyping patients for the following two chapters. The 
differences in age and sex seen here however, were not used as a basis for 
recruitment of the following patients. 
 
Chapter 5 was the main investigation into muscle wasting in this thesis and in 






to this had previously been derived from animal models of sarcopenia which 
had suggested that the NMJ is unstable in this condition. This chapter provided 
the not only the first characterisation of the NMJ in patients with confirmed 
cancer cachexia, it also provided the first characterisation of the NMJ in human 
disease. Findings were very different to those in rodent models showing that 
the NMJ is stable in cancer cachexia and thus it is likely to be a primary muscle 
pathology. Small numbers of patients were included in this chapter, pertaining 
to the labour intense process of NMJ characterisation in this cohort. Rectus 
muscle biopsies often yielded no NMJs meaning that many patients had to be 
recruited to obtain the numbers seen (n=60). Despite this several hundred 
NMJs were analysed for each, therefore providing a robust assessment. Some 
of the weight stable patients did however have low muscularity on CT possibly 
due to ageing that often co-exists with cancer associated muscle loss and 
current diagnostic criteria is unable to separate one from the other. A previous 
study confirmed that when this definition of 2% weight loss and low muscularity 
was used muscle fibre size, protein content and RNA/DNA content were all 
reduced therefore confirming histological muscle wasting more so than other 
definitions available (312). Groups were also not age or sex matched meaning 
that as shown in the previous chapter baseline body composition could have 
been markedly different for this reason alone. This was not undertaken due to 
the difficulty in recruiting suitable patients and obtaining NMJ’s in each sample. 







Chapter 6 returns to adipose tissue. Chapter 4 for the first time demonstrated 
that different adipose depots show different rates of wasting. This exploratory 
analysis therefore took tissue samples of these depots to investigate the first 
study of this nature in humans with cancer cachexia. It confirmed differential 
gene expression in adipose depots in patients with cancer with and without 
cachexia and highlighted the importance of visceral adipose tissue in particular. 
Intelectin-1 was identified as a novel adipokine in the visceral adipose of 
patients with cancer, having been shown to be previously linked to weight loss 
in healthy people. It was not successfully found to be raised in the plasma of 
cachectic patients limiting its role as a potential biomarker for the disease. 
Tissue ELISA levels were however raised indicating it may have an autocrine 
effect. There was also a down regulation of genes involved in energy 
metabolism in particular in fat browning suggesting it has a limited role in 
patients compared with animal models and again showing the need for future 
patient based studies. The main limitations of this chapter were in the difference 
in visceral adipose depots used (omental and perinephric fat for the cancer and 
control patients respectively). Omental fat was unable to be sampled from the 
control patients due to the nature of the operation. Future studies could look at 
sampling omentum from other control groups e.g. patients undergoing hernia 
repair to eliminate this possible reason for differences seen. The study should 
also be repeated in a much larger cohort of patients with high significance 
values in order to dampen down the signal from a large number of markers 







The final chapter of this thesis investigated the ability of metabolomics based 
analysis to identify markers of tissue wasting in the plasma of cancer patients. 
It was able to identify 6 metabolites that were highly discriminative of weight 
loss namely Lyso PC 18.2, L-Proline, Hexadecanoic acid, Octadecenoic acid, 
Phenylalanine and Lyso PC 16.1. Interestingly again this study produced more 
markers of adipose tissue wasting, in particular lipolysis-promoting activity. This 
was the only study in the thesis not to use CT based assessment of muscle 
wasting. The patients in this cohort were pre-selected as they had already been 
involved in a transcriptomic study making their categorisation into two groups 
based on CT difficult. The modelling that was performed demonstrated that 
patients were able to be identified using a different part of the consensus 
definition (>5% weight loss). It is possible that given the differences in rates of 
sarcopenia seen by age and sex in chapter 4 that these results may have been 
different depending on the way the patients were characterised from the outset.  
Interestingly fat breakdown products were seen in the plasma of patients in this 
study but itln1 was not seen in the plasma of patients in the previous study. This 
was due perhaps to large variability in individuals. The plasma was re-analysed 
in chapter 6 by weight loss categorisation of cachexia and did not appear to 
make any difference suggesting the definition of cachexia used had no impact 
on the results. This study also contained small numbers of patients but showed 
that there is the potential to use these numbers to classify patients based on 
their degree of cachexia. Validation of the metabolites seen would be required 























Characterisation of cachexia 
Cancer patient 
 
• Current screening methods 
inadequate 
• Unable to differentiate 
between conditions that 
cause UWL 
• Better tools required to 
identify patients suitable 
for entry into trials 
• CT currently gold 
standard for analysing 
body composition 
• Muscle and adipose 
wasting varies by age 
and sex 
• Should it become part 
of routine cancer care? 
Mechanisms of cachexia 
• NMJ’s are stable in 
cancer cachexia 
• No evidence of 
denervation 
• Muscle remains 




• Large differences in gene 
expression between VAT 
and SAT 
• VAT metabolically active 
in cancer 
• Intelectin-1 possible 
mediator of cachexia 
• Human adipose tissue 
behaves differently to 
rodents 
• Patients able to be separated based on % 
weight loss 
• Lipid breakdown products identified in 
plasma of cachectic patients 
Figure 53 Summary of thesis 
-Increased ability to identify 
those suitable to enter trials 
-Screening of patients 
involving CT needs to be 
patient and disease specific 
-Novel therapeutic strategies 
such as neural stimulation 
may be of use in the future 
-Possible new mediators and 
biomarkers of adipose 
wasting could monitor 




8.2 Future thoughts 
The majority of the studies included in this thesis included small patient 
numbers. In order to fully validate the findings they would need to be repeated 
on a larger scale and in patients with other types of cancer to ensure that the 
results found are not exclusive to those with UGI cancers. Whilst this thesis has 
produced some interesting results and has contributed to the body of cachexia 
knowledge, several questions remain unanswered and require further thought.  
 
This thesis has demonstrated clinical adipose wasting by CT. It has also 
analysed the mechanism for adipose wasting by transcriptomics and potentially 
identified downstream degradation products of this adipose wasting process by 
metabolomics. This linkage suggests that breakdown products of fat wasting 
do end up in the circulating compartments. Does this indicate that adipose cell 
membranes become disrupted during lipolysis and cachexia as they do in 
muscle cells (411)? Is it possible that the same degradation products could be 
found in urine thus leading to the discovery of potential non-invasive urinary 
biomarkers? The link between fat and muscle wasting may also be investigated 
by looking at relevance of myosteotosis in cachexia in more detail. Previous 
studies have shown fat deposition in muscle is increased in cachexia (161). But 
does it move from visceral or subcutaneous areas to within muscle? Which 







Should cut points for CT-derived low muscularity be more specific and include 
alterations for patients age as well as BMI? To answer this question fully the 
same study needs to be repeated on a much larger scale and with patients from 
many different ethnic backgrounds and cancer types. As well as this a baseline 
cut off needs to be derived for the normal, healthy population. It is also important 
to consider whether CT based assessment of muscle and adipose wasting 
should become part of the routine screening process for patients with cancer. 
As has been shown there is currently no way to easily differentiate between 
patients with cachexia, sarcopenia and malnutrition. The use of routine CT for 
staging cancer patients may provide an easy method of pre-operative risk 
stratification and allow the instigation of appropriate management or pre-
habilitation before major surgery in order to improve outcome. Given also that 
large variations in muscularity and adiposity were seen based on age and sex 
this may have affected outcomes in chapters 5-7. These studies were not 
controlled for either and so the morphological changes seen could well differ if 
these factors were taken into account. 
 
Whilst the morphology of the NMJ was investigated in great detail, the study 
did not comprise any assessment of proteins or function or whether the 
morphology of the NMJ changes in end stage cachexia. This could be 
investigated further by including end stage cancer patients (although the 
acquisition of muscle biopsies in this group is difficult) and by making an 







The findings from this thesis may lead on to help in the clinical management of 
cachexia. It has helped determine criteria or highlight areas in which more work 
could be done to identify those patients who are suitable to enter cachexia 
clinical trials. Notably there could be improvements made in the way patients 
are screened for inclusion either using a more adequately designed screening 
tool or through the use of serial CT assessments. Potential biomarkers 
including Intelectin-1 and those seen in the metabolomics study could be useful 
inclusion criteria in clinical trials and may aid in monitoring the response to 
treatment. The finding of stability of the NMJ means that neural stimulation may 
be a useful novel therapeutic intervention.  
 
 
8.3 Final conclusions 
 
 
 In conclusion this thesis has shown that direct measures of muscularity are 
required to assess cancer associated muscle wasting as it’s difficult to infer 
from current screening tools or anthropometric measures such as BMI. Cut 
points for use in doing so however need to be age, gender and potentially 
disease specific. The absence of NMJ pathology in patients with cancer in 
contrast to animal models demonstrated that intrinsic changes in skeletal 
muscle demonstrate the primary locus of pathology and that future trials should 
consider neural stimulation as a method of increasing muscle mass. Visceral 






importance and in particular intelectin-1 warrants further investigation through 
future mechanistic studies. Future research importantly should have a patient 
based approach as it is clear from this thesis that not all findings in animal 
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Biochemical and functional biomarkers of cachexia: 
Information for cancer patients  
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to 
others about the study if you wish. 
• Part 1 tells you the purpose of this study and what will happen to you if you 
take part. 
• Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
The purpose of this research study is to find out what causes people who have 
cancer to suffer muscle wasting, lose weight and feel tired. This wasting is a 
significant problem for patients as it causes a reduction in both quality and 
quantity of life. In order to find out what causes this problem and if there is any 
way to predict its development, we are asking patients about to undergo 
surgery for cancer if they would undergo a variety of tests before, during, and 
after their operation. These tests are mainly to measure changes in the size 
and function of the patients’ muscle and fat, and to see whether these changes 
can be predicted. In particular, we would like to take small samples of muscle, 






any biochemical changes. We aim to follow up the patients by asking for more 
blood and urine, as well as a needle test of the thigh muscle at clinic 
appointments up to 12 months after the operation. These tests are designed 
to cause the minimum of discomfort or inconvenience for anyone involved. 
 
In order to find out whether the changes we see in these tests are purely 
related to cancer, we are also asking patients who do not have cancer, but are 
having surgery for other reasons, to join the study as a control group for 
comparison. The control group will take part in the some, but not all, of the 
tests undertaken by the cancer patients.  
 
Why have I been invited? 
You have been invited because you will soon be having surgery for cancer. 
We aim to recruit 100 participants in total. Patients undergoing purely keyhole 
(laparoscopic) surgery are not being invited for technical reasons. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form by 
one of the research team. You will still be free to withdraw at any time in the 
future and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undergo certain tests before your 
operation, during your operation, and at 2-3 appointments after the operation, 
for up to 12 months. The study appointments before and after your operation 
will be timed to coincide with your normal clinic appointments. Therefore, no 
extra visits to hospital are required if you choose to take part in this study. We 
anticipate the research visits will add no more than 15 minutes to your 
appointment. However, if for any reason we are unable to coincide your study 






transport to and from the Royal Infirmary of Edinburgh’s Clinical Research 
Facility. The tests will include: 
 
• A blood test: The amount of blood taken is approximately the same as one 
teaspoonful (5ml), and it will be taken from your arm in the usual fashion. 
  
 
• A urine test: This will be performed in the usual fashion. The amount of urine 
taken is 20-30ml.  
 
• Tests of normal activity: We would like to see how much activity you do 
during a normal week. To help assess this, we may ask you to wear a small, 
light physical activity meter on your thigh, under a waterproof dressing, for a 
week at a time. This does not inconvenience most patients, and they quickly 
forget that they are wearing it. These monitors can be returned by post in a 
pre-paid envelope you will be given. 
 
• Test of functional ability (timed up-and-go and 6 minute walk): This test 
will measure your ability to get up out of a chair and walk a few metres then 
turn around and go back to your chair. It will only take a few minutes. The 6 
minute walk test measures how far you can walk in 6 minutes. This will be 
done over a measured course, and should not be tiring. It can be stopped at 
any time if necessary.  
 
• A questionnaire: This will take approximately 15 minutes to complete but 
can be taken home to do. We can provide a stamped-addressed envelope to 
post it to us if you take it home. 
 
• CT scan review: We also ask that you give us permission to review the CT 
scans that you will have had performed as part of your routine care. This review 






influence your treatment in any way. The review will be performed by a 
member of the research team. 
  
We would initially plan to carry out all of the above tests at one appointment 
prior to the date of your operation. If, after carrying them out, you found that 
these tests were acceptable to perform (as we would hope), we would ask you 
to repeat the same tests, including the blood and urine samples, at the usual 
follow-up clinic appointments after your surgery for a period of up to 12 months. 
 
If at one of the appointments after your operation you are still willing to 
participate, we would also ask that you give us permission to take a thigh 
muscle biopsy at that time. This will be performed under local anaesthetic 
injection but will otherwise be the same as the one that you had during your 
operation. This will involve a local anaesthetic injection, a small scar of 2-3 
millimetres (which will be closed with paper stitches), and may leave you with 
a bruised feeling for a day or so. We will re-confirm your permission to perform 
this test at that time. 
 
In addition to the tests described above, we will also ask permission to take 
tissue samples during your operation, whilst you are asleep (under general 
anaesthetic): 
 
• A muscle biopsy: Whilst you are asleep (under general anaesthetic) during 
your operation, small muscle samples will be removed from both your 
abdominal wall and your thigh. The abdominal muscle sample will be pea-
sized and will be taken from the incision through which your operation is being 
performed. In some cases we would also like to take a longer section of 
muscle, which will also be taken from the incision through which your operation 
is being performed. In patients who are undergoing operations for 
oesophageal cancer we will also take a small sample of muscle from your 
chest wall. This will not complicate your operation. The amount of muscle 






incision (a few millimeters long) through which a needle is introduced. This 
incision will be closed by paper stitches and will leave a small mark which will 
fade.  If you consent to have a thigh muscle biopsy in the outpatient clinic, this 
will be done under local anaesthetic.  
 
•  A fat biopsy: When you are asleep under general anaesthetic, a small piece 
of fat (again, about the size of a pea) will be taken from just under the skin and 
also from the fat layer inside of your abdomen. 
 
• Blood and urine tests:  If not taken in clinic before your operation, these 
could be taken whilst asleep under general anaesthetic. 
 
• A tumour biopsy: We will ask you permission for a sample of tumour to be 
taken from the specimen removed at your operation. This will be done after 
the tumour has been removed. 
 
• Photography: We would like to take a picture of the muscle used in the 
study. There will not be photos taken of anything else. 
 
What do I have to do? 
Apart from attendance at the appointments before your operation, and after 
you operation, no other responsibilities are required from your participation. 
We would like your permission to monitor your case for up to 5 years after your 
operation to see how things are going. 
 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 
disadvantages and risks. 
The tissue samples taken during your operation may cause a slightly increased 
risk of bleeding. This risk is very small, and the nature of the samples, together 







Regarding the thigh muscle biopsy, you may experience some mild discomfort 
and stiffness in the leg following the procedure, but this should wear off after 
a few hours. Also, approximately 1 in 200 people suffer with bruising following 
the procedure. This has been described as similar to a “dead leg” but fades in 
1-2 days. 
If you have are having a repeat thigh muscle biopsy this will be performed 
under a local anaesthetic injection. The anaesthetic agent may sting for a few 
seconds as it is being administered.  
If you have any problems after the needle test, please contact the research 
team directly using the number at the end of this sheet. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you directly, but the information we 
receive might help improve the treatment of patients with cancer and cancer-
associated weight loss. 
 
 
What happens when the research study stops? 
Following your appointment after your operation, no further appointments are 
required. However, if any of your blood, muscle,  or urine samples remain, we 
would ask your permission to store these samples (in anonymised form) in the 
University of Edinburgh so that we can consider them for use in future research 




What if relevant new information becomes available? 
If any new treatment for cancer or cancer-associated wasting becomes 
available during the time of the study, it will not be withheld from you because 
of your participation in this study should you need it. Furthermore, if you require 






(e.g. chemotherapy or radiotherapy), it will not be withheld from you because 
of your participation in this study.   
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. However, we would ask your 
permission to keep in contact with you to monitor your progress. In this way, 
any information that was collected during the time of your participation in the 
study may still be used for research purposes. Any stored blood or tissue 
samples that can still be identified as yours will be destroyed if you wish. 
If for any reason you become unable to make decisions regarding your health, 
we would stop collecting information and samples from you, and we would not 
invite you to any more appointments. We would ask to keep and use any 





What if there is a problem? 
• Complaints: If you have a concern about any aspect of this study, you 
should ask to speak with the researchers who will do their best to 
answer your question. If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. 
Details can be obtained from the hospital. 
If you wish to make a complaint about the study, please contact NHS 
Lothian: 
Patient experience team 












• Harm: In the unlikely event that something goes wrong and you are 
harmed during the research and this is due to someone’s negligence 
then you may have grounds for a legal action for compensation against 
NHS Lothian but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to 
you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the 
research will be kept strictly confidential. However, we would like to inform your 
GP of your involvement in this study but we will require your permission to do 
this. All other information about you which leaves the Royal Infirmary of 
Edinburgh will have your name and address removed so that you cannot be 
recognised from it. 
If any information comes to light during the study which may have a bearing 
on your care, we would aim to inform the team looking after you, and with your 
consent we would also inform your GP. 
Muscle, blood, fat and urine samples collected during the study may be 
transferred for the purpose of analysis to associated researchers within and 
outside the European Economic Area, including to commercial companies 
such as Novartis (a pharmaceutical company). All samples will be anonymised 
prior to sending and therefore you will not be identifiable. However, there will 
be an available link from your samples to your records so we can match any 
changes in your case (or your withdrawal) to your samples. 
 
What will happen to any samples I give? 
A portion of the blood samples will be immediately analysed by the Department 
of Biochemistry at the Royal Infirmary of Edinburgh. The remainder of the 
blood samples, along with the muscle, fat, and urine samples, will be 
transferred to the University of Edinburgh for analysis. The only individuals 






research team behind this study. The samples will be analysed in the 
University of Edinburgh by various biochemical techniques in order to measure 
the levels of certain ‘markers’ of wasting within the various tissues.  
To make sure all information remains confidential, all personal identifiers 
on your sample will be removed and replaced with a code. Your personal 
and medical history data will be stored separately and will not be 
processed. The key that links your data to the code on the sample will be 
stored in a secure location to which only authorized personnel of the 
SCHOOL of CLINICAL SCIENCES will have access. This is a “linked-
anonymised” system. Your coded samples may also be transferred for 
analysis to third parties in or outside the UK. This can include 
collaborating academic institutions or pharmaceutical companies, which 
contribute to this research project.  
 
Following all of these different analyses, if any of the samples remain, we 
would ask your permission to store these samples long-term (in anonymised 
form) in the University of Edinburgh so that we can consider them for future 
research studies (if a local Ethics Committee deems the studies appropriate). 
Professor Kenneth Fearon, Professor of Surgical Oncology, will act as 
custodian for any stored samples. The only other individuals who will have 
direct access to the stored samples will be the members of the research team 
behind the current study. 
 
Will any genetic tests be done on the samples that I give? 
We have no plans to perform genetic analysis within the remit of this current 
study. However, following this current study, we would ask your permission to 
store any remaining samples so that we may consider them for use in future 
research studies that we may carry out (if a local Ethics Committee deems the 
study appropriate). Future studies could potentially involve genetic analysis, 
but such studies are at a very early stage of planning and not yet in progress. 






implications for you and hence we would not normally feed these results back 
to you. 
 
What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and 
textbooks. Results will be made available to study participants through the 
Cancer Research UK website. You will not be identifiable in any 
report/publication or report unless you have specifically consented to release 
such information. 
 
Who is organising and funding the research? 
The research is being organised and sponsored by the University of 
Edinburgh. The research is being funded by Novartis. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by 
the South East Scotland Research Ethics Committee. NHS Lothian 
Management Approval has been obtained, and this study has also been 
reviewed by members of the scientific committee of Novartis. 
 
Contact details 
You may contact me (the main researcher) directly by telephoning 0131 242 
6520 for further information at any time. Alternatively, if you wish to discuss 
this research study with someone independent of the research team, you can 
contact Ewan Harrison in the Department of Surgery, who is acting as an 
independent advisor – contact 0131 242 3615.  
Many thanks for your time. 
 
Mr Richard Skipworth 
Consultant Surgeon 
Department of Surgery 
Royal Infirmary of Edinburgh
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1. I agree to take part in the above-titled study.  
 
2. I confirm that I have read and understand the information sheet version 3 dated 
25/09/2017 for the above study. I have had the opportunity to consider the information and ask 
questions, and I have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data collected during 
the study may be looked at by individuals from the Sponsor [University of Edinburgh and NHS 
Lothian], from the NHS organisation or other authorities, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation in the study.  
 
6. I agree to my GP being informed of any information found during the study which may 
have a bearing on my care 
 
7. I agree to the storage of anonymised samples taken during the course of this study so that 
they may be considered for use in future research studies (pending a favourable ethical opinion 
by Lothian Local Research Ethics Committee). 
 
8. I agree to the use of samples taken during the course of this study in possible future 
genetic studies (pending a favourable ethical opinion by Lothian Local Research Ethics 
Committee). (Optional. Only initial if you agree) 
 
9. I understand that my anonymised samples and anonymised data may be distributed to 
third parties such as academic institutions or pharmaceutical companies in or outside of the UK 
who participate in the project 
 
10. I understand that the results of this study may be used for future commercial development 
of products/tests/treatments and I will not benefit financially from this 
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